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ABSTRACT 
 
 
Despite continued advances in medical care, cardiovascular disease (CVD) remains the 
leading cause of death for American women [1].  Although humans and non-human primates are 
the only mammals to experience menses, rodent models are commonly used to study age-
associated cardiovascular alterations due to similar ovarian aging, low expense, and short lifetime 
to investigate cardiovascular aging.  Previous studies have found that aging in the female rodent 
is characterized by increased ventricular apoptosis, elevations in oxidative-nitrosative stress, 
ventricular remodeling, increased collagen content, mild systolic and diastolic dysfunction, and 
reduced occurrence of arrhythmias compared to males [2-7].  Similarly, age-associated alterations 
in the female rodent aorta have been shown to include increased proliferation/migration of 
vascular smooth muscle cells (VSMC) and endothelial dysfunction [8, 9]. However, no study has 
investigated the age-associated alterations in the female heart and aorta of the National Institute 
of Aging (NIA) approved Fischer 344/NNiaHSd x Brown Norway/BiNia (F344xBN) rat model.  The 
NIA has recommended the F344xBN due to its longer maximal life span, higher age for 50% 
mortality, and the fact that it exhibits a normal distribution of age-related pathologies at later 
ages [10, 11].  Here, we investigated the effects of aging on cardiovascular structure and function 
in the adult, aged, and very aged female F344xBN rats.  Compared to adult hearts, increased age 
was associated with increases in oxidative-nitrosative stress, oxidative damage, (increases in 
hydroethidine (HE) staining, 4-hydroxynonenal (4-HNE), and nitrotyrosine expression), and 
activation of the mitochondrial-mediated apoptosis pathway (increased number of terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive nuclei, increased activation 
of caspases, and Bax/Bcl-2 ratio).  Age related changes in cardiac structure consisted of an 
  xx 
 
increase in heart to body weight ratio, cardiomyocyte cross sectional area (CSA), posterior wall 
thickening, and left ventricle chamber dilatation.  Coincident with these changes in cardiac 
structure and signaling, we also found that increased age was associated with evidence of 
diastolic dysfunction, alterations in heart rhythm intervals, and alterations in connexin 43 (Cx43) 
expression.  The incidence of arrhythmias was not different with age; however, valvular 
dysfunction was increased.  In the female F344xBN aorta there was an age-associated increase of 
intima-medial thickness and activation of p44/42 MAPK.  Taken together, these results suggest 
that the female F344xBN rat may be an appropriate cardiovascular aging female rodent model in 
the absence of pathologies.  (378 words)   
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CHAPTER 1 
INTRODUCTION 
 
Cardiovascular disease is the leading cause of death in the United States. The costs 
associated with treating CVD are expected to increase to $1.48 trillion by 2030 [12].  In addition 
to the modifiable risk factors (such as lipid levels, diabetes, sedentary lifestyle, etc.) aging, in and 
by itself, is thought to be a major risk factor for the development of CVD [13] as greater than 80% 
of cardiovascular deaths occur in adults 65 years of age and older[13, 14, 15].  Cardiovascular 
aging is associated with a loss of cardiomyocytes by apoptosis, hypertrophy of remaining 
cardiomyocytes, and increases in tissue fibrosis which can lead to systolic and diastolic 
dysfunction [16-20].  These age-associated changes can lead to a decline in cardiac function 
causing the elderly heart to fail [14, 15, 21].  
It has been estimated that the costs of treating heart disease will increase 46% by 2025 
as people continue to live longer and longer [22, 23].  Although the projected increase in CVD as 
well as its impact on healthcare cost is known, the effect of sex on cardiovascular risk is not well 
understood.  Recent work has suggested that premenopausal women have a decreased risk of 
CVD compared to men of comparable age; however, this cardio-protective benefit appears to be 
lost in postmenopausal women [24, 25].  The decreased cardiovascular disease risk in 
premenopausal women may be due to age-associated sex differences in cardiac structure and 
function.  For example, in healthy aging adults, left ventricular mass and fractional shortening is 
increased in women compared to men [26-29].  Age-associated sex differences were also found 
in the incidence of different cardiovascular pathologies.  In the Framingham study, there was a 
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greater prevalence of left ventricular hypertrophy in women (69%) after 60 years of age compared 
to (15%) men.  Aged females with aortic stenosis also had better maintenance of left ventricular 
systolic function and a lower incidence of collagen structural abnormalities [26].  The short and 
long term prognosis are worse for women after myocardial infarction, however, women have 
improved survival rates following non-ischemic cardiomyopathy [16-20, 30, 31].   
The increase incidence of age-associated CVD has been attributed to the accumulation of 
free radical species known as reactive oxygen species (ROS) [32, 33].   The free radicals include 
superoxide anion (O2·−), hydroxyl radical (HO·), lipid radicals (ROO−), nitric oxide (NO), and non-
free radicals such as hydrogen peroxide (H2O2), peroxynitrite (ONOO−), and hypochlorous acid 
(HOCl).  Increased ROS levels (due to imbalance of ROS species to antioxidants) can cause 
oxidative stress that can damage cellular lipids, proteins and DNA which has been shown to lead 
to cell death [34, 35].   
Cardiovascular disease research has mostly been focused on aging male animal models.  
Although women are also at an increased risk for CVD with aging, very few experimental studies 
have determined how aging affects the female heart and aorta.  The purposes of this dissertation 
are (i.) to determine the effects of aging on F344xBN cardiac structure and function, oxidative-
nitrosative stress, and apoptosis; and (ii.) to investigate how aging may affect aortic morphology 
and protein signaling.  Age-associated alterations would suggest that this aging rodent model 
may model that seen in the aging human cardiovascular system.  
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SPECIFIC AIMS    
 Cardiovascular disease is the leading cause of death, morbidity, disability, functional 
decline, and healthcare costs in aging women [36].  It is anticipated that a better understanding 
of the role that aging plays in CVD will increase the quality of life in the aged.  The long-term goal 
of this work is to improve our understanding of the age-associated alterations in the signaling 
pathways, structure, as well as function of the aging female heart and aorta to determine if the 
female F344xBN rat is an appropriate aging model to investigate therapeutic strategies to 
attenuate or reduce age-associated female cardiovascular dysfunction.  The hypothesis of this 
dissertation is that the female F344xBN rat will exhibit age-associated alterations in 
cardiovascular structure and function.  We plan to accomplish the goals and objective of this 
study by pursuing the following three specific aims and experimental design (Figure 1.1): 
Specific Aim I:  To determine if aging in the female F344xBN rat heart is characterized by 
alterations in heart weight, apoptosis, and oxidative-nitrosative stress.  
Hypothesis:  The female F344xBN rat heart will exhibit age-associated increases in 
hypertrophy, apoptosis, and oxidative-nitrosative stress. 
 
Specific Aim II:  To determine if the heart of adult and aged female F344xBN undergo age-
associated alterations in cardiac function.  
Hypothesis:  Aging in the female F344xBN heart will be associated with increased systolic 
and diastolic dysfunction. 
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Specific Aim III:  To determine if the aorta of adult and aged female F344xBN rats undergo age-
associated alterations in morphology and signaling transduction.  
Hypothesis:  Aging in the female F344xBN aorta will be associated with increased intima-
medial thickness, increased fibrosis, and activation of mitogen activated protein kinase 
(MAPK) signaling.     
 
   FIGURE 1.1 
 
 
 
FIGURE 1.1:   EXPERIMENTAL DESIGN TO STUDY AGE-ASSOCIATED ALTERATIONS IN THE 
FEMALE F344XBN HEART AND AORTA. 
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CHAPTER 2 
REVIEW OF LITERATURE 
  
The following chapter consists of the current literature review regarding this dissertation 
study.  The areas to be covered include the following:  aging and cardiovascular disease, aging 
female cardiovascular disease, aging cardiovascular structure and function, aging cardiovascular 
oxidative stress mechanisms, aging cardiac protein signaling, aging vascular aorta, aging aortic 
structure and function, and mechanisms of signal transduction in the aging aorta. 
 
AGING AND CARDIOVASCULAR DISEASE 
 Aging is often thought of as a progressive disorder that decreases an organism's ability to 
maintain ‘normostasis’ and reproductive capacity [37].  The functional consequences of aging 
tend to be cumulative, organ-specific, as well as species-dependent.  Aging is also strongly 
correlated with a higher incidence of several diseases including cancer, diabetes, Parkinson's 
disease, Alzheimer's disease, and dementia [37].  The majority of definitions of aging are based 
on calendar age [38].  The World Health Organization has devised a classification scheme in which 
it considers senility as those 60 years of age.  Conversely, in the United States senility is typically 
defined as those greater than 65 years of age while gerontologists classify using the following 
three subgroups: younger older people (60-74 years), older people (75-85 years), and very old 
people (over 85 years) [38, 39].   
Aging is considered a major independent risk factor for cardiovascular-related morbidity 
and mortality [37, 40-42].  According to the Center for the Disease Control (CDC), 12% of adults 
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have some form of CVD including hypertension, stroke, cardiomyopathies, or heart failure [37].  
Of additional concern is the finding that the percentage of men and women presenting clinically 
evident CVD increases to 70% over the age of 75 years [38, 39].  Cardiovascular disease deaths 
over the last twenty years have been higher for women compared to men in the United States 
making CVD the number one killer of women in the Western nations [26, 43-47].  In women, 
almost 44% of total CVD deaths occurred in those above 85 years of age while 24% of total CVD 
deaths were in men over 85 years [14, 36].  Although cardiovascular risk increases with age in 
both sexes, the increase in age-associated risk is sharper in women (Figure 2.1) [45-48].   
 
FIGURE 2.1 
 
FIGURE 2.1:  PREVALENCE OF CVD IN AGING MEN AND WOMEN ACCORDING TO THE 
AMERICAN HEART ASSOCIATION (2009).   
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Differences in pathophysiology, presentation, as well as the differences in age-associated 
cardiovascular function may explain the increased risk of CVD and death in women [44, 49, 50].   
Indeed, whereas congestive heart failure in men is oftentimes due to systolic insufficiencies, 
congestive heart failure in women is often related to diastolic dysfunction [44-46, 50-53].  
Similarly, the incidences of ischemia, cardiac failure, cardiac rupture, and ventricular remodeling 
have also been shown to differ between gender with aging and often lead to worse outcomes in 
women [20, 26, 27, 54-68].       
Aging women appear to exhibit an “age window” during pre-menopause where women 
have a decreased risk of CVD compared to men of comparable age [24, 69].  This cardio-protective 
benefit appears to be lost over time as the risk of developing CVD in postmenopausal women is 
similar to that observed in men of a comparable age [25].  The reason(s) for this increase in CVD 
risk following menopause is currently unclear but may be related to changes in estrogen levels 
[70]. 
 
AGING FEMALE ANIMAL MODELS 
 In order to distinguish the physiological as well as molecular alterations that may cause 
this age-associated gender specific differences in CVD, an appropriate aging model is needed.  
Human aging research is limited due to cost, differences in lifestyle/history, and more importantly 
the time required for data collection and analysis of that particular system.  There are a number 
of different animal models that can be used to acquire information on how aging affects the 
female cardiovascular system.  The most common aging female animals studied are non-human 
primates and rodents.  Non-human primates are the closest in regards to female human aging 
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due to the fact that they undergo menstrual sloughing of the endometrial lining.  Although non-
human female primates do experience some aspects of menopause in a manner similar to women 
(irregular cycles, hormone profiles, infertility, weight gain, blood and lipid profiles), non-human 
female primates differ in that there is a short postmenopausal lifespan, differences in hormone 
secretion timing, as well as seasonal menstrual cycles [71].  The use of non-human primates as 
aging models has been limited due to ethical concerns, complicated study logistics, and cost.   
 Conversely, rodents are widely used in aging research as they exhibit a relatively short 
lifespan and are genetically quite homogenous.  Although rodents do not experience menses, 
they do experience ovarian aging.  Ovarian aging in rodents has been determined to occur over 
the span of 24 months.  In female rodents, reproductive maturity is typically reached at five 
months when there is an estrous cycle that lasts four to five days.  During reproductive maturity, 
female rats exhibit periods of persistent estrous which consists of elevated and constant levels of 
estradiol, low levels of progesterone, lack of luteinizing hormone (LH) surges, and ovulation.  
Ovarian decline occurs between six to eighteen months depending on the rodent strain.  This 
stage is characterized by low levels of estradiol and progesterone along with little or no 
developing follicles [72].  Between ten to twelve-months of age, increase in the irregularity of 
estrous cycles often occurs.  Constant estrous usually takes place at about nineteen-months of 
age and is characterized by low to medium levels of serum estradiol, estrone, testosterone, 
androstenedione, progesterone, and very low levels of 20α-hydroxyprogesterone.  In addition to 
these hormones, there is no preovulatory release of gonadotropin and prolactin.  Luteinizing 
hormone was not changed but follicle-stimulating hormone (FSH) levels were found to be 
increased in the morning.  After twenty four months, the levels of prolactin were increased in 
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aging female rats (Table 2.1).   
 
TABLE 2.1:  STAGES OF OVARIAN AGING IN LONG-EVANS FEMALE RATS AS DESCRIBED BY LU  et 
al., (1979). 
 
 
 
Comparisons between aging research in female rodent models and humans can be 
complicated due to the differences in the mechanisms of ovarian/hormone aging in women and 
its potential impact on CVD.  Although not fully understood, it is thought that the loss of the 
hormones estrogen and progesterone in aging women is due to the decrease in the ovarian 
follicular reserve [73, 74].  Conversely, aging female rats experience a persistent estrous due to a 
chronic anovulation, which consists of pseudopregnant/disestrus estrogen levels and high 
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progesterone levels from increased ovulation and the corpora lutea [73, 75].  Therefore, 
reproductive senescence in female rats consists of alterations in the hypothalamic-pituitary axis 
while reproductive senescence in women is classified as ovarian follicle depletion [73, 75].   
 
OVARIECTOMY AND THE AGING CARDIOVASCULAR SYSTEM 
 In an effort to overcome the lack of menopause in rodents, the use of transgenic models, 
pharmacological acceleration of aging, and ovariectomy procedures are often performed to 
better mimic the hormone milieu seen in aging women.  Ovariectomy is the removal of the 
ovaries, which induces a surgical menopause.  The cessation of estrogen and progesterone, as 
well as the reduced production of testosterone, occurs after a surgical menopause.  Surgical 
menopause leads to more severe and sudden symptoms compared to those observed during the 
natural menopause where ovaries produce lower levels of hormones over time.  It is thought that 
surgery-induced menopause at the time or before natural menopause increases cardiovascular 
risk in rodents [76, 77].      
Other differences have been observed in surgically-induced models of menopause 
compared to models of natural menopause.  Bilateral oophorectomy is associated with different 
hormonal alterations including changes in estrogen production, reduced levels of progesterone 
and testosterone, as well as increases in gonadotropins (LH and FSH) compared to those that 
occur in women who experience natural menopause [78, 79].  Irrespective of age, estrogen levels 
are higher in women with intact ovaries than in women after bilateral oophorectomy [77, 80, 81].  
Interestingly, both natural and surgically-induced menopausal rats exhibit increased FSH and 
decreased levels of estradiol and inhibin (A/B) [82].  Surgically-induced menopause has also been 
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shown to alter dopamine receptor affinity in the heart [82].  Other studies have found that the 
majority of women who undergo natural menopause exhibit differences in age-associated 
cardiovascular alterations when compared to those seen in surgically-induced menopausal 
women [73, 74].  It appears that the timing of the surgically-induced menopause may have an 
effect on the degree of cardiovascular alterations.  For example, the elective bilateral removal of 
the ovaries at a young age is associated with an increased risk for CVD and premature death [77].  
Ovariectomy is also associated with alterations in heart structure and function which include 
increases in cardiac interstitial space, cardiac fibrosis, heart weight, left ventricular weight, 
reduced cardiac contractility, increased evidence of oxidative stress, cardiac apoptosis, cytokine 
expression (TNF-α and IL-1β) as well as angiotensin converting enzyme (ACE) and angiotensin II 
type 1 receptor gene expression [83-87].  When estradiol treatment was given to ovariectomized 
rats, it prevented the reduction of cardiac contractility as well as the increase in apoptosis and 
cytokine expression but not elevations in oxidative stress [84, 87].  Taken together, these data 
suggest that the loss of ovarian function during aging may influence cardiovascular structure and 
function.  Due to the complexities of the aging process, more studies are needed to distinguish 
whether observed differences are due to aging alone, hormone deprivation, or some combination 
of both.  Due to the difficulties experienced using humans, aging research using rodent models 
may be an important consideration.    
 
AGING CARDIAC STRUCTURE AND FUNCTION 
Aging has been shown to impact many structural and functional aspects of the human 
heart.  Echocardiography (ECHO; a serial noninvasive technique) has demonstrated age-
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associated structural alterations including increases in left ventricular wall thickness, myocyte cell 
volume, a decrease in the number of cardiomyocytes, in addition to increases or no changes in 
the myocyte to collagen ratio [88, 89].  Age-associated changes in cardiac function include 
decreases in oxygen consumption, cardiac contractility, and ejection fraction (EF).  Systolic 
function (the ability of the ventricles to contract) is usually preserved, while diastolic dysfunction 
(ability of the ventricles to fill) is commonly seen in aging humans as evidenced by increases in 
the diastolic function parameters, isovolumic relaxation time (IVRT) and mitral valve deceleration 
time (MV decel) [22, 90-96].  Myocardial stiffness, an important factor for diastolic dysfunction, 
has been shown to increase with advancing age, which may be associated with elevations in left 
ventricular end-diastolic pressure both at rest and with exertion [97].  Changes in the early to late 
filling velocity (E/A ratio), which is used to evaluate myocardial stiffness during diastole, also 
appear to increase with age [98, 99].  In addition to contractile alterations, other data has 
suggested that the aging heart also exhibits an increased incidence of ventricular arrhythmias, 
aortic valve sclerosis, and atrial fibrillation [22, 100].    
Biochemical techniques have shown that aging is associated with the loss of 
cardiomyocytes and a compensatory hypertrophy of those myocytes that may remain [99, 101].  
Within the cardiomyocyte, the mitochondria become larger and less efficient during aging [99, 
102].  At the level of the sarcomere, aging is characterized by a prolonged contraction as well as 
relaxation due to age-associated changes in cardiac gene expression and calcium regulation [99, 
103-105].  In the extracellular matrix surrounding the cardiomyocytes, aging is associated with an 
increase in collagen, fibrosis, and lipofuscin deposition [99, 106-108].  During exercise, older 
hearts also tend to increase heart rate to a smaller degree than that seen in the younger animals 
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which may be due to decrease catecholamine sensitivity or axonal degeneration of sympathetic 
neurons innervating the atria [99, 109, 110, 111].   
 
RODENT CARDIAC STRUCTURE AND FUNCTION 
 Unlike that seen in humans, few studies have examined how aging affects cardiac 
structure and function in rodents.  Research thus far has shown conflicting results with some 
studies demonstrating few or no signs of cardiac dysfunction [94, 112-113], whereas others have 
shown that the aging rodent heart is characterized by decreases in midwall fractional shortening 
and diastolic function as indicated by increase in isovolumetric relaxation time [94, 95, 112-115].  
Age-associated changes in rodent cardiac structure include cardiomyocyte enlargement as well 
as reduced number of cardiomyocytes due to necrosis or apoptosis [13].  Other functional 
changes that have been noted include a prolongation of the action potential, increased cytosolic 
calcium transient time, increased number of L-type calcium channels, a slowed inactivation of the 
L-type current, and decreased outward potassium currents [13].   
The F344xBN rat has been recommended for age-related studies by the NIA given that this 
hybrid rat lives longer and has a lower rate of pathological conditions than other inbred rat strains 
[10-11].  Similar to that seen in aging humans, Walker and colleagues, demonstrated that aging 
in the F344xBN rats was characterized by progressive diastolic and systolic left ventricular 
chamber dilatation; mild diastolic and systolic left ventricular hypertrophy; progressive age-
associated decrements in resting left ventricular systolic function; and mild diastolic dysfunction, 
especially in very aged rats [94].  Other parameters of systolic function (ejection fraction (EF), 
fractional shortening (FS), AVmax, PVmax, MVmax, TVmax) in aged and very aged rats were not 
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statistically different from those in adult male rats, suggesting cardiac compensation may have 
taken place to obfuscate mild systolic declines.  Most left ventricular structural and functional 
parameters did not differ significantly in aged and very aged rats, which suggested that most of 
the age-related changes have occurred or are well underway in the aged rats.  In addition, the left 
ventricular hypertrophy observed in the adult rats appeared to be offset by increases in 
ventricular apoptosis and the loss of ventricular cardiomyocytes [94].   
It has been postulated that age-associated increases in left ventricle mass (LVM), 
cardiomyocyte enlargement, decreases in cardiomyocyte number, and increases in extracellular 
collagen deposition may be responsible, at least in part, for the increase in arrhythmias seen with 
aging [116-119].  The aging rodent heart has been characterized as exhibiting a prolonged action 
potential, delays in total activation time, and decreases in anisotropic conduction velocity.  In 
addition to changes in conduction velocity, aging is also characterized by the generation of 
abnormal activation patterns that vary in space and time.  The molecular mechanisms underlying 
these alterations are not well understood but some researchers have posited that they may be 
due to age-associated increases in oxidative stress and fibrosis, as well as changes in ion channel 
expression [120].  Whether the molecular mechanisms that may be responsible for the age-
associated alterations in cardiac structure and function may differ with animal gender is not well 
understood.  
 
FEMALE RODENT AGING CARDIAC STRUCTURE AND FUNCTION 
 The increased risk of CVD in women may be due to differences in the type or magnitude 
of age-associated alterations in cardiac structure and function.  Olivetti and colleagues have 
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demonstrated a small decrease in human heart weight with aging in males but not females [89, 
121] Studies have also shown differences in animal model myocyte volume and diameter [89, 
121].  Male non-human primates have also been shown to exhibit decreases in left ventricle/body 
weight, myocyte hypertrophy, and increases in the number of cells undergoing apoptosis when 
compared to that observed in their female counterparts [121].  Although a limited number of 
studies have looked at how cardiac structure and function change with age in a rodent, very few 
have directly investigated how sex may affect cardiac structure and function.  
Boluyt and colleagues investigated how aging may affect cardiac and structure in female 
Fischer 344 (F344) rats using echocardiography.  Aging female rat cardiac structural changes 
included a dilatation of the left ventricle between 13- and 22-months of age.  This dilatation was 
characterized by increases in posterior and septal wall thickness during diastole at 22- and 30-
months of age [2].  Aging in the female F344 was also associated with increases in collagen 
content and collagen cross-linking [4, 122-123].  In addition, Boluyt and colleagues demonstrated 
mild systolic dysfunction (decline in left ventricle EF, fractional shortening (FS), and velocity of 
circumferential fiber shortening) in 22-month old animals when compared to young adults and 
that these changes preceded the development of mild diastolic dysfunction [2, 124]. These 
authors suggested that this modest decline in systolic function was due, at least in part, to a shift 
in the amount of alpha and beta myosin heavy chains [2, 123]. Additional work, perhaps using 
other rodent models is needed in order to truly distinguish if these alterations are due to 
increasing age or if they are simply specific to the F344 strain.     
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ARRHYTHMIAS 
Proper cardiac function is dependent upon the precise conduction of electrical impulses 
through the heart.  The electrocardiogram (EKG), a readily performed and repeatable diagnostic 
tool, can measure and record the conduction system of the working heart in order to find 
abnormalities in cardiac conduction and to diagnose some forms of cardiovascular disease [125-
130].  The EKG records a tracing of the depolarization and repolarization of the heart that can be 
separated into specific waves and intervals (Figure 2.2). 
 
FIGURE 2.2 
 
 
 
 
 
 
 
 
 
FIGURE 2.2.  EKG TRACE ILLUSTRATING THE DIFFERENT WAVES AND INTERVALS IN A HEART 
RHYTHM.   
 
Aging is considered a risk factor for ventricular arrhythmia [100, 119].  Mirroring the 
increase in the percentage of elderly is the incidence of atrial fibrillation [130-131]. Age-
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associated increases in cardiac fibrosis as well as changes in gap junction morphology have been 
hypothesized to cause changes in cardiac conduction in addition to the incidence of arrhythmias 
and death [119, 132].  As humans age, there is an increase in the EKG abnormalities which are 
associated with increased mortality [132-133].  Men tend to experience more atrial fibrillation, 
early repolarizations, Brugada syndromes, and sudden cardiac death than women, while women 
are more likely to be at risk to develop long QT syndrome-based arrhythmias as well as 
bradycardia-induced torsades de pointes [134-135].  Although sex related differences in cardiac 
electrocardiogram parameters have been observed, electrocardiogram abnormalities seem to 
vary between studies.  In men, there is an increase in QRS duration and sinus cycle length while 
women tend to a have a higher heart rate upper limit [136-137]. 
Electrocardiogram analysis in elderly men and women have demonstrated large or 
intermediate Q waves, left axis deviation, negative T-waves, complete right bundle branch block 
as well as atrial fibrillation/flutter [138].  In aging men, the QRS complex has been found to be 
narrowed while aged women have been shown to undergo a shifting of the QRS axis to the left 
[139].  Other work has suggested that aging in men may be associated with a shortened QT 
interval, increased PR intervals, and a prolongation of the QT interval [137, 140].  Conversely, 
other research found that aging did not appear to alter EKG tracings in either men or women 
[137].   
Similar alterations in electrocardiogram parameters have also been found in aging 
rodents.  In Wistar rats, the PR and corrected QT intervals were found to increase with age [132].  
Similarly, QRS duration has also been found to be prolonged in old rats [141].  Alterations in aging 
electrocardiogram parameters have been shown to be rodent strain dependent and could only 
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be detected subsequent to heart failure at 19-months of age [142].  Very few studies have 
investigated electrocardiogram parameters in the aging female rodent.  Gonadectomy appears to 
decrease the number of arrhythmias in male but not female rats [143].  Although not fully 
understood, these differences have been attributed to higher heart rates in male animals, longer 
QT intervals, as well as gender differences in ion channel expression [134-135, 144-148].  The 
exact mechanisms of the reduction of arrhythmias by estrogen are not fully understood but two 
potential indirect mechanisms have been proposed.  One potential indirect mechanism may be 
related to the ability of estradiol to reduce the incidence of cardiac ischemia [149].  Other work 
has suggested that high levels of estradiol in female and male rats may directly reduce 
arrhythmias, possibly by causing a slowing of the inward calcium current [149, 150].  Although 
multiple studies have investigated EKG changes in aging rodents, these parameters have not been 
determined in the NIA approved aging F344xBN rat model.   
 
CONNEXIN 43 
Gap junction function is particularly important for the proper regulation of cardiac 
contraction (Figure 2.3).  Changes in the expression, activation, and distribution of gap junction 
protein Cx43 may help to explain alterations in heart rhythm intervals during normal ventricular 
growth, age, and in some diseases [151-155].  It is thought that increases in Cx43 expression lower 
the susceptibility to lethal arrhythmias  as decreased Cx43 expression has been shown to cause 
an increase in R-R interval and decreases in intrinsic sinus rate [119, 156-159].  The regulation of 
Cx43 in different disease states is not well understood.  In the spontaneous hypertensive rat 
(SHR), Cx43 distribution appears altered compared to that seen in the normotensive animals  
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while Cx43 protein levels have been found to be increased, decreased, or unchanged in animals 
exhibiting heart failure and atrial fibrillation [157, 160-162].  In diabetic and ischemic hearts, Cx43 
levels are unchanged, however, the distribution of Cx43 is altered and its phosphorylation is 
increased [159, 163, 164].  Other data suggests that alterations in Cx43 expression may work in 
conjunction with other molecules to regulate cardiac 
  
FIGURE 2.3 
 
 
 
 
 
 
 
 
FIGURE 2.3: LOCATION AND STRUCTURE OF GAP JUNCTIONS IN THE CARDIOMYOCYTE 
MEMBRANE. (Photo credit: Landes Biosciences, 2004) 
 
conduction given the finding that the sodium channel (Nav1.5) expression appears to parallel 
changes seen in Cx43 [165].   
Similar to the differential regulation of Cx43 in different diseases, sex-associated 
differences in Cx43 have also been observed in aging males and female rats.  Cx43 expression has 
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been shown to be increased in female hearts compared to male hearts [166, 167].  Age-associated 
sex differences in Cx43 may be regulated, at least in part, by the levels of female and male 
hormones given that previous work has shown that estrogen increases and testosterone 
decreases Cx43 expression [135, 168, 169].  Thus far, very few studies have investigated the 
effects of hormones, ovariectomy, as well as natural menopause on Cx43 expression.  One study 
showed that estradiol administration increased Cx43 expression and phosphorylation during 
ischemia [170, 171].  These findings are consistent with the possibility that estradiol plays a role 
in the regulation of Cx43; however, no changes were found in Cx43 expression in the aged 
ovariectomized female rat heart [172].  Aging studies have also shown conflicting results with 
regards to the regulation of Cx43. Recent work has demonstrated that Cx43 expression is 
increased, decreased, or unchanged with aging [159, 173-175].    
 
CARDIAC OXIDATIVE STRESS AND ANTIOXIDANTS 
 Oxidative stress and reactive oxygen species (ROS) have been implicated in the 
pathogenesis of several different diseases including Alzheimer's disease, Parkinson's disease, 
cancer, aging, and CVD [176-181].  ROS are molecules that contain oxygen with an unpaired 
electron. There are several different species of ROS, including superoxide anions, hydroxyl 
radicals, superoxide, hydrogen peroxide, and peroxynitrite. 
           Oxidative stress can result from an increase in oxidant generation or a decrease in the levels 
of antioxidants. The main source of ROS in vivo is aerobic respiration.  ROS are also produced by 
the beta-oxidation of fatty acids, microsomal cytochrome P450 metabolism of xenobiotic 
compounds, stimulation of phagocytosis by pathogens or lipopolysaccharides (LPS), arginine 
  21 
 
metabolism, and tissue specific enzymes [182].  Under normal conditions, ROS are cleared from 
the cell by the action of superoxide dismutase (SOD), catalase (Cat), or glutathione (Gpx) 
peroxidase [183].  If excessive, elevated cellular ROS can cause damage to cellular lipids, proteins, 
and DNA (Figure 2.4).    
 
FIGURE 2.4 
 
FIGURE 2.4:  THE MECHANISM OF REACTIVE OXYGEN-NITROSATIVE SPECIES PRODUCTION 
AND OXIDATIVE-NITROSATIVE DAMAGE.  
 
AGING RELATED CHANGES IN CARDIAC OXIDATIVE STRESS AND ROS-RELATED SIGNALING  
 Aging in the heart is associated with the accumulation of oxidative damage to lipids and 
proteins as well as decline in mitochondrial enzymes [184].  In addition, an increasing amount of 
mutations in mitochondrial DNA (mtDNA) have been gradually observed during aging [185].  The 
level of 8-OHDG mtDNA adducts and deletions increase exponentially with age [185].  In human 
and non-human primate muscle, liver, and brain tissue, complex IV and mitochondrial oxidative 
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phosphorylation enzyme activities decline with age.  This decline in function is correlated with 
the accumulation of mtDNA mutations, including deletions, and base substitutions [185].  De la 
Asuncion and colleagues found increased levels of oxidized mitochondrial glutathione with aging 
in rats and mice [186].  Similarly, aged male rat hearts exhibit an increase in superoxide, 4-HNE, 
and nitrosative stress levels which appear to be highly correlated to increases in left ventricular 
thickness [187].  The exact role that increased levels of oxidative stress may play in the 
development and progression of age-associated CVD remains to be determined.   
 Compared to that observed in females, the hearts of aging male rats exhibited increases 
in protein carbonylation, advanced oxidation protein products, nitrotyrosine, non-protein thiol, 
reduced glutathione, and iron levels [5].  Although aging is associated with increases in oxidative 
stress in both male and female hearts, female rat hearts exhibited lower mitochondrial hydrogen 
peroxide production, oxidative damage, and greater mitochondria differentiation compared to 
that seen in male animals [6].  It is thought that female rats have a higher mitochondrial 
differentiation which is a metabolic adaptation to increase energy efficiency as it is associated 
with their lower mitochondrial free radical production and oxidative damage [6].  In addition to 
differences with sex, it is also likely that ROS levels vary with animal strain as female Wistar and 
F344 rats exhibit lower ROS production and indices of oxidative damage than that seen in female 
Sprague Dawley rats which may help to explain their greater mean life-span [188-190].   
Reactive oxygen species are signaling molecules that activate signal transduction 
pathways.  One signaling pathway, MAPK signaling, that is involved in many of the age-associated 
physiological changes (oxidative stress, hypertrophy, and apoptosis) as well as other cardiac 
pathologies, is activated by ROS.  The MAPK cascades are evolutionary conserved 
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serine/threonine protein kinases that regulate several important cellular functions including 
proliferation, differentiation, development, cell cycle, and cell death [191].  The major MAPK 
signaling pathways are the extracellular signal-regulated protein kinase cascade (p44/42), c-Jun 
amino-terminal kinase/stress-activated protein kinase cascade (JNK/SAPK), and the p38 cascade. 
Stimuli that include stress or injury typically activate the JNK and p38 MAPK kinases, while the 
p44/42 MAPKs are stimulated by mitogenic and growth factors [192, 193].  Work investigating 
MAPK signaling in aging human hearts have demonstrated reduced p38 MAPK activity/signaling 
in heart failure and impaired activation of MAPK target genes following increase in oxidative 
stress [194-196].  In the rodent heart, aging has been found to diminish and increase p44/42-, 
p38-, and JNK-MAPK activation [197-200].  
It is well recognized that increases in cellular stress cause the upregulation of the heat 
shock proteins (Hsp) [201].  Hsp are also involved in cardiac hypertrophy, in response to vascular 
wall injury, ischemic preconditioning, and aging [202].  During aging there is an accumulation of 
damaged or misfolded proteins which may cause a burden on maintaining proteostasis [203-205].  
An important function of heat shock proteins is to protect against age-related protein misfolding 
[204-207]. Studies in C. elegans and Drosophila have suggested that the overexpression of heat 
shock proteins increases lifespan [203, 208, 209].  In aged male F344 rats (24-months) it appears 
that aging decreases Hsp70 upregulation following chronic exercise and heat stress [210-212].   
Similar to the MAPK proteins, the nuclear factor-κβ (NF-κβ) pathway is thought to play a 
role in cardiac remodeling, apoptosis, acute ischemia and reperfusion, unstable angina, as well 
as heart failure in both humans and rodents [213-218]. .  The NF-κβ family consists of RelA (p65), 
c-Rel (Rel), RelB, NF-κβ1 (p50), and NF-κβ 2 (p52) (Figure 2.5).  In the cytoplasm, p50 and p65 are 
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found as an inactive heterodimer due to the binding of the Iκβ kinase inhibitory proteins (Iκκα 
and Iκκβ).  Cellular stimuli known to activate the NF-κβ pathway include ROS, tumor necrosis 
factor alpha (TNF-α), interleukin-1β (IL-1β), and bacterial LPS [219].  It has been shown that the 
Iκβs must first become phosphorylated and degraded before p50/p65 activation can occur [220-
221].  
 
Figure 2.5 
 
 
FIGURE 2.5:  THE NF-ΚΒ SIGNALING PATHWAY.   
The NF-κβ signaling pathway induces the transcription of chemokines, cytokines, 
adhesion molecules, and anti-apoptotic factors in response to increased levels of ROS, TNF-α, IL-
1β, and LPS. 
 
p50/p65 when phosphorylated (activated) then translocates into the nucleus to induce the 
transcription of chemokines (IL-8, MCP-1), cytokines (TNF-α, IL-1, IL-2, IL-6), adhesion molecules 
(ICAM-1, VCAM-1, E-selectin), acute phase proteins, antimicrobial peptides, secondary 
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inflammatory enzymes (COX-2, iNOS, PLA2, MnSOD), and anti-apoptotic factors [222-224].  Upon 
termination of the NF-κβ stimuli, p50/p65 binds to new Iκβs and the complex is translocated back 
to the cytoplasm.  It is thought that the MAPK pathway works in concert with the NF-κβ pathway 
to increase transcription of inflammatory genes [222-223].  Recent work using transgenic mice 
has suggested that p50 deletion in increased cardiac inflammation and matrix metalloproteinase 
activity [225].  Conversely, other work has demonstrated that p50 deletion is associated with 
decreased matrix metalloproteinase expression and collagen deposition in cardiac tissue [226].  
How aging may affect the regulation of NF-κβ pathway signaling is not well understood.  
    
ACTIVATION OF ROS-RELATED SIGNALING IN THE FEMALE AGING HEART 
Although the effects of estrogen on MAPK signaling have been studied in several  
pathological processes, e.g. breast cancer, migraines, and polycystic ovarian syndrome, little is 
known regarding how this molecule affects MAPK signaling in the heart.  It is thought that 
differences in MAPK activation between male and females may be regulated, at least in part, by 
the influence of estrogen [227-229].  Estrogen has been shown to stimulate the activation of 
p44/42 MAPK and JNK MAPK in different model systems including cardiomyocytes, mammary 
cancer cells, pituitary tumor cells, tissue slices of the hippocampus, and endometriotic stromal 
cells [230-234].  In males as well as ovariectomized females where estrogen is removed, MAPK 
signaling is decreased after acute ischemia [227, 229]. In a model of cardiac pressure overload, 
estradiol treatment appeared to exhibit anti-hypertrophic effects by increasing the expression of 
atrial naturietic peptide (ANP) and inhibiting p38-MAPK activation [235].  Conversely, in 
ovariectomized female mice subjected to coronary ligation or transverse aortic constriction, 
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estradiol treatment had no effect on the activation of p38-MAPK [236].  How aging may affect 
MAPK signaling in the female heart has yet to be elucidated.   
In addition to the regulation of MAPK proteins, there is evidence to suggest that gender 
also has an effect on the Hsp response.  In hearts that were not exposed to increased cellular 
stress, male hearts have twice as less Hsp72 expression than that observed in the female heart.   
Conversely, ovariectomy was found to reduce Hsp72 levels in female hearts [237].  Estradiol 
treatment has also been found to increase Hsp27, Hsp70, Hsp72, and Hsp90 expression in the 
heart [238-242].  To our knowledge, no studies have looked at Hsp27, Hsp70, and Hsp90 in the 
aging female heart.  More research is needed in order to determine how aging and gender affect 
the regulation of heat shock proteins in the cardiovascular system. 
 Aging female and male hearts show increased apoptosis, inflammation, as well as age-
associated gender differences found in NF-κβ signaling [234, 243].  To our knowledge, only a few 
studies have investigated the changes in NF-κβ expression and activity in the aging female rat 
heart.  Recent data has suggested that nuclear NF-κβ binding is increased in the brain, heart, 
and kidney of aged male as well as female mice even though the levels of p50 and p65 protein 
were not changed [244-245].  Whether age-related changes in NF-κβ activity are related to 
increased cardiovascular risk is not yet clear.   
 
AGING HEART APOPTOSIS 
Apoptosis or programmed cell death is a highly conserved and regulated cell response to 
inhibit the abnormal proliferation of cells [246].  Cardiomyocytes are not capable of self-
regeneration and are terminally differentiated but can undergo apoptosis, necrosis, or autophagy 
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when unduly stressed [247].  Apoptosis is increased in many cardiovascular diseases such as 
dilated and ischemic cardiomyopathy, hypertrophic heart disease, and in arrhythmias [246, 248-
251].  Increased age has been shown to cause apoptotic susceptibility in the heart following 
oxidative injury [252, 197].  Aging in the F344xBN heart is characterized by increases in the 
amount of cytochrome c, apoptosis inducing factor (AIF), Bax, rate of permeability transition pore 
opening, and fragmented DNA [253].  The age-associated increase in apoptosis appears to be due 
not only to the activation of pro-apoptotic molecules but also by decreases in anti-apoptotic NF-
κβ, Bcl-xL, and Grx1 signaling [252].  Other work has demonstrated that the aging male F344xBN 
rat heart is characterized by increases in TUNEL positive nuclei, caspase-3 activation, caspase-
dependent cleavage of alpha-fodrin, and diminished phosphorylation of protein kinase B/Akt 
(Thr308) [254].  The increase of apoptosis in the aging male F344xBN was highly correlated to 
age-associated increases in oxidative-nitrosative stress.  Although not demonstrating cause and 
effect, these results suggest that the increased cellular ROS and cardiomyocyte apoptosis may 
play a role in age-related cardiac remodeling.          
The incidence of cells undergoing apoptosis in the heart has been shown to differ with sex 
in humans, primates, and rodents. In humans, a higher number of TUNEL positive myocytes 
(indice of apoptosis) is seen in young males compared to females [89, 121, 255]. Similar to 
humans, aging does appears to increase cardiac apoptosis in male monkeys; however, there was 
no gender difference in apoptosis in male and female B6 mice in addition to the F344 rat [121,188, 
190, 256, 257].  These results suggest differences in apoptosis regulation between species.  How 
aging may affect cardiomyocyte apoptosis in the aging female F344xBN rat has, to our knowledge, 
not been investigated.   
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EFFECTS OF AGING ON AORTA STRUCTURE AND FUNCTION 
 Vascular aging, especially the aging aorta, also markedly increases the risk of 
cardiovascular disease in the elderly population [258, 259].  The aorta, the largest artery in the 
body, consists of smooth muscle, endothelial cells, fibroblasts, and extracellular matrix which  
 
FIGURE 2.6 
 
 
 
 
 
 
 
 
FIGURE 2.6:  COMPOSITION OF THE THREE AORTIC LAYERS.   
The location and the composition of the three layers of the aorta (tunica intima, tunica 
media, and tunica adventitia) are shown using a hematoxylin and eosin stain (H&E). 
 
are distributed into three layers - the tunica adventitia, tunica media, and tunica intima (Figure 
2.6) [260].  The outer layer of the aorta, the tunica adventitia is composed of collagen, which 
surrounds the tunica media.  The tunica media is primarily composed of smooth muscle, elastic 
tissue, and extracellular matrix.  The inner layer, the tunica intima, consists of a layer of 
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endothelial cells.  Structural changes found in the aging vasculature include an enlarged lumen; 
intima-medial thickening; irregular shaped endothelial cells; migration and proliferation of 
VSMCs; increased deposition of extracellular matrix; increased expression of adhesion molecules; 
and alterations in the expression of metalloproteinases as well as cytokines [13, 42, 261-263].  
Functional changes with age in the vasculature consist of impaired distensibility, increased 
stiffness, increased endothelial permeability, attenuation of β2-adrenoceptor vasodilator 
response to agonists, and diminished response to adrenergic receptor stimulation [13, 264-267].  
Like humans, rodents also appear to exhibit several age-associated changes in vascular structure 
and function including changes in intimal thickening, elevations in inflammation-associated 
molecule expression, and increased evidence of oxidative stress [13, 268-270].     
Similar to that seen in other parts of the cardiovascular system, differences in aortic 
structure and function between genders have also been observed in the aging human and 
animals.  In males, aortic wall and intimal-medial thickness are greater during aging than that 
observed in women; however, stiffness was not different between men and women [271].  
Similarly, there were no differences in distensibility in the aging aorta between men and women 
[266].  Although the human aging aorta did not show increases in aortic stiffness, it has been 
documented that the increased vascular stiffness with aging is more prominent in male than 
female animal models [259, 272].  
 Abnormal proliferation and migration of VSMCs play important roles in the 
pathophysiology of atherosclerotic diseases [273, 274].  Previous studies have shown that VSMCs 
isolated from old animals replicate more actively than those obtained from young animals [274-
276]. Similarly, aging has been shown to be associated with an increased proliferative response 
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of VSMCs after balloon angioplasty [277, 278].   
 
EFFECTS OF AGING ON AORTIC ENDOTHELIAL CELL FUNCTION  
Endothelial dysfunction is considered to be a common and early feature of vascular 
disease and impaired endothelium-dependent relaxation has been demonstrated in several 
animal models of hypertension, experimental diabetes, atherosclerosis, high salt diet, as well as 
aging [279-281].  The factors regulating endothelial dysfunction are likely complex and may vary 
between models and with aging.  Nitric oxide is a vasodilator that is produced by endothelial nitric 
oxide synthase (eNOS) that plays a crucial role in blood pressure regulation.  NO production is 
stimulated by shear stress, cyclic strain, acetylcholine (Ach), vascular endothelial growth factor, 
bradykinin, estrogen, sphingosine-1 phosphate (S-1P), hydrogen peroxide, and angiotensin II 
[282-285].  It is thought that eNOS activity is regulated by eNOS phosphorylation at Ser1177, 
Ser635, and Ser617 by phosphatidylinositol 3-kinase (PI3K)/Akt, adenosine monophosphate- 
activated protein kinase (AMPK), and cyclic AMP-dependent protein kinase (cAMPK) signaling 
[285, 286]. Given its important role in regulating vascular function it is not surprising that 
abnormalities in vascular NO production are thought to contribute to the pathogenesis of 
atherosclerosis and hypertension [287, 288].  Advanced age has also been found to be associated 
with impaired endothelial NO synthesis and endothelial dysfunction [289-292].  The mechanisms 
responsible for age-associated alterations in NO synthesis are not fully known but may include 
changes in activity or expression of eNOS; increased breakdown of NO due to oxidative 
stress/oxidative injury; changes in antioxidant defense systems; and decreased availability of 
eNOS substrate, L-arginine [293-299].  Although the activity of eNOS is generally thought to be 
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diminished with aging, the expression of eNOS has been shown to be decreased, increased, or 
not changed in the aorta [8, 300, 301, 302].  In addition to changes in eNOS activity, decreased 
NO availability during aging can also be caused by oxidative stress and alterations in eNOS 
structure [282, 291, 299, 300, 303-306].  The regulation of eNOS function during aging may also 
differ with sex.  In aging male but not female mice, eNOS-dependent aortic relaxation is impaired 
due to increased production of superoxide by nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase [307].  Whether estrogen may also play a role in modulating eNOS activity is 
currently unclear.  Although estrogen has been shown to activate eNOS, estrogen studies in 
animals have shown no effect or increased eNOS expression following estrogen treatment [8, 308, 
309-312].  Conversely, in humans, estrogen replacement appears to be largely ineffective as a 
means of decreasing CVD risk [309, 313-316]. To our knowledge no studies have investigated 
eNOS expression or function in the aging female F344xBN.  
 
SEX-RELATED DIFFERENCES IN AORTIC VSMCs WITH AGING 
In women, the incidence of vascular dysfunction is thought to be related, at least in part, 
to the cessation of ovarian hormone production [317, 318].  In VSMCs from young female Wistar 
Kyoto rats, estrogen inhibited VSMC proliferation following stimulation with fetal calf serum 
[319].  This effect was thought to be mediated by estrogen receptors [319].  Similar decreases in 
VSMC proliferation with estrogen treatment following cell stimulation by growth factors or 
mechanical stress have also been noted [317, 320, 321].  Like estrogen, progesterone is also 
thought to inhibit the proliferation of aortic VSMC, most likely via its ability to inhibit DNA 
synthesis [322].  Nonetheless, it should be noted that the effects of estrogen in vivo are likely 
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more complex than that seen in cell culture.  For example, in aortas from diabetic female rats, 
estrogen failed to reverse the impaired basal release of NO and the abnormal relaxation to 
histamine [323].  The importance of estrogen in the regulation of vascular smooth muscle cells 
has also been suggested in estrogen receptor knockout models as well as estrogen deficient 
rodent models.  In estrogen receptor knockout mice, there is a reduction in basal NO release as 
well as increased VSMC proliferation after injury [317, 324, 325].  In the estrogen-deficient 
aromatase-knockout [184] mouse, VSMCs exhibited abnormal proliferation and apoptosis in 
addition to slowed growth [317].   Although the effects of estrogen have begun to be investigated 
in animal models with different levels of estrogen, how alterations in estrogen levels during 
natural aging may affect aortic structure and function is not well understood.   
 
AGING AORTA SIGNALING 
The MAPK signaling pathways function regulates many processes in the aorta including 
VSMC proliferation, contraction, migration, differentiation, and cell survival [326-330].  Aging has 
also been shown to increase the activation (phosphorylation) of p44/42 and JNK MAPKs in the 
aorta while other work has shown that aging affects the ability of the aged aorta to activate p38 
and JNK MAPK signaling following mechanical loading [331, 332].  In aged animals, the activation 
of p44/42 MAPK in vascular smooth muscle was increased compared to young animals  [260, 273,  
274].   
 Similar to that observed for the heart, age-associated changes in the expression/activity 
of NF-κβ were found in the vascular smooth muscle cells of the aorta.  Aging has been found to 
increase the sensitivity of NF-κβ to glucose in aortic VSCM cells [333].  Other research has shown 
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that VSCM proliferation and NF-κβ activation stimulated by interlukin-1β was increased more in 
aged female rats than in young female rats [334].  In premenopausal women, receiving hormone 
treatment appeared to reduce NF-κβ activation [335] suggesting that estradiol reduces NF-κβ 
activation.  How estrogen may inhibit NF-κβ activity is currently unclear but may be related to 
increased Iκβ levels or decreased levels of circulating TNF-α [335, 336].    Whether age-related 
changes in estrogen affect the activity of NF-κβ in the aging female aorta remains unclear.   
 
CONCLUSION 
 The number one killer of women is CVD despite improved medical care and 
increased awareness/education [26, 43-47, 337-339].  Most cardiovascular deaths occur in 
women over 85 years of age [14, 36].  Aging is associated with an increased risk of developing 
cardiovascular disease such as myocardial infarction, stroke, atherosclerosis, peripheral occlusive 
disease, diabetes, and hypertension [340, 341].  Similar to that seen in humans, cardiovascular 
aging in rodents is characterized by cardiomyocyte loss, hypertrophy of the remaining 
cardiomyocytes, increased fibrosis, increased dilation of the lumen, thickening of the media and 
intima, increased stiffness, and endothelial dysfunction [13, 116, 117, 119, 339]. These structural 
changes adversely affect aging cardiovascular function by leading to systolic and diastolic 
dysfunction [114, 342].  In addition to structural and functional changes, there is also evidence 
that aging may also affect the regulation of several signaling pathways including the MAPK, NF-
κβ, eNOS, Hsp, and apoptotic signaling in the heart and aorta [332, 343-346].    It is thought that 
age-associated increase in oxidative-nitrosative stress and damage may be a possible mechanism 
to explain alterations in cardiovascular structure, function, and signaling pathways [184, 187].  
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The exact role that increased levels of oxidative stress may play in the development and 
progression of age -associated CVD remains to be determined.   
The effect of sex on cardiovascular risk has not been fully elucidated; however, data have 
suggested that pre-menopausal women have a decreased risk in CVD when compared to men of 
similar age [24, 69]. This cardio-protective benefit appears to be lost over time as the risk of 
developing CVD in post-menopausal women appears to be similar to that observed in men of a 
similar age [25].  Humans are the only species that undergo menopause.  In order to overcome 
the difficulties found in aging female human and non-human primate research models (ethics, 
cost, and long lifespan), rodents may provide the best animal model to investigate age-related 
changes in cardiovascular structure and function.  Although many studies have investigated 
cardiovascular aging in rodents, very few studies have investigated how aging may affect 
cardiovascular structure and function in an aged female rodent model (> 26-months) that does 
not exhibit an increased incidence of age-associated pathologies.  Methods of surgically-induced 
menopause may also complicate age-related research findings given the sudden loss of hormones 
that are characteristic of this procedure.  The NIA recommended male F344xBN rat model has 
been shown to exhibit many of the age-related changes in cardiovascular structure and function 
seen in the aged man; however, no study has investigated the age-associated alterations in the 
female F344xBN rat.  In order to distinguish between changes in the cardiovascular physiology 
and changes that occur with aging, menopause, and their interaction, a better understanding of 
aging in the cardiovascular system is needed in a natural aging animal model.  Whether aging in 
the female F344xBN rat is a fitting model for the age-related changes seen in human females is 
currently unclear and is the purpose of this dissertation research project. 
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CHAPTER 3 
 
THE EFFECTS OF AGING ON INDICES OF OXIDATIVE STRESS AND APOPTOSIS IN THE 
FEMALE F344xBN RAT 
 
Oxidative-nitrosative stress may play a role in age-associated cardiovascular disease as 
implied by recent studies. However, limited research has been conducted using aged female 
rodent models.  This chapter details the findings related to the age-associated alterations in 
cardiac ROS, oxidative-nitrosative damage, and apoptotic signaling outlined in Specific Aim 1.  
 
ABSTRACT 
Oxidative-nitrosative stress may play a role in age-associated CVD as implied by recent 
studies.  However, limited research has been conducted using aged female rodent models.  In this 
study, we examined hearts obtained from 6-, 26-, and 30-month old female F344xBN rats in order 
to examine how aging affects levels of cardiac oxidative-nitrosative stress and apoptosis.  
Oxidative (superoxide anion and 4-HNE) and nitrosative (protein nitrosylation) stress markers 
were increased 180 ± 17 %, 110 ± 3 %, and 14 ± 2 %, respectively in 30-month hearts compared 
to the hearts of 6-month female rats.  Coincident with these changes in oxidative-nitrosative 
stress, aging was also found to be associated with increases in the number of TUNEL-positive 
cardiomyocytes, alterations in the Bax/Bcl-2 ratio, and elevated cleavage of caspase-3.  
Regression analysis demonstrates significant correlation in the age-associated changes markers 
of oxidative–nitrosative stress with changes in apoptotic signaling.  The findings from this 
descriptive study imply that age-associated increases in mitochondrial-mediated apoptosis may 
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be associated with the increase in oxidative-nitrosative stress in the aging F344xBN female heart.     
    
INTRODUCTION 
Aging is thought to be a major risk factor for CVD, and is associated with a loss of 
cardiomyocytes by apoptosis, and increases in tissue fibrosis which can lead to systolic and 
diastolic dysfunction [89, 101, 116, 347, 348].  The effect of sex on cardiovascular risk has not 
been fully elucidated; however, data have suggested that pre-menopausal women have a 
decreased risk in CVD when compared to men of similar age [24, 69].  This cardio-protective 
benefit appears to be lost over time as the risk of developing CVD in post-menopausal women 
appears to be similar to that observed in men of a similar age [25].  The reason(s) for the increased 
risk of developing CVD following menopause is unclear but may be related to changes in estrogen 
levels.  Recent work has shown that pre-menopausal females appear to exhibit reduced levels of 
ROS [349].  Similarly, levels of oxidative-nitrosative stress are reduced in pre-menopausal rats  or 
estrogen treated rats due to increases in either antioxidant enzyme activity or increases in 
potential ROS scavenging [350].  Other studies have demonstrated that the mitochondria-
mediated pathway of apoptosis was activated in the heart in ovariectomized rats and this 
appeared to occur coincident with decreased antioxidant enzyme activity and increased indices 
of oxidative stress [83, 351].  Although these data are suggestive of estrogen playing a protective 
role in the cardiovascular system, how the natural loss of estrogen with aging affects cardiac ROS 
levels is not well known. 
Aging in the male F344xBN rat has been found to be associated with declines in cardiac 
function, increased markers of oxidative-nitrosative stress, and increased cardiomyocyte 
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apoptosis [187].  Whether these changes are also present in the aging female F344xBN heart is 
currently unclear.  Herein, we examine the effects of aging on indices of oxidative-nitrosative 
stress and apoptosis in 6-, 26-, and 30-month old female F344xBN rats.  Similar to that seen in the 
aging males, we hypothesized that aging in female F344xBN animals would be characterized by 
increases in oxidative-nitrosative stress and cardiomyocyte apoptosis.  The data presented in this 
descriptive report support this notion and are consistent with the possibility that age-related 
increases in oxidative-nitrosative stress in the female F344xBN heart could be responsible, at least 
in part, for the increased cardiomyocyte apoptosis observed in the aging heart. 
 
MATERIALS AND METHODS 
Materials 
Protein kinase B (Akt) Akt [#9272], phosphor-Akt(Ser473) [#9271], phosphor-Akt(Thr308) 
[#9275],  Bcl-2 (50E3) [#2870], caspase-12 [#2202], caspase-3 [#9662], cleaved caspase-3 Asp175  
[#9661], HSP27 [#2442], HSP90 (#4877), nitrotyrosine [#9691], GAPDH [#2118], 3T3 Control Cell 
Extracts [#9203], mouse secondary [#7076], rabbit secondary [#7074] and biotinylated protein 
ladder [#7727] were from Cell Signaling Technology (Beverly, MA).  The antibody for HSP70 [#sc-
1060], HeLa whole cell lysate [sc-2200], and L6 +IGF Cell Lysate [sc-24127] were purchased from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA).  Precast 10% and 15% PAGEr Gold Precast Gels 
were from Lonza (Rockland, ME), Precision Plus Protein Dual Color Standards [#161-0374] were 
obtained from Bio-Rad (Hercules, CA,) and ECL western blot detection reagent was from 
Amersham Biosciences (Piscataway, NJ). Restore western blot stripping buffer was purchased 
from Pierce (Rockford, IL), and the In Situ Cell Death Detection Kit was procured from Roche 
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Applied Science (Mannheim, Germany).  All other chemicals were obtained from Sigma (St. Louis, 
MO). 
 
Animals 
All animal procedures were conducted under the Animal Use Review Board of Marshall 
University using the criteria outlined by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AALAC) as proclaimed in the Animal Welfare Act (PL89-544, PL91-979, 
and PL94-279).  Adult (6-months of age, n = 9), aged (26-months, n = 8), and very aged (30-
months, n = 8) female F344xBN rats were obtained from the NIA (Bethesda, MD).  Two rats per 
cage were housed in AALAC approved vivarium with a 12 h: 12 h light-dark cycle at 22 ± 2˚C.  Food 
and water were provided ad libitum (LabDiet 5001, PMI Nutrition International, LLC, Brentwood, 
MO).  Animals were allowed to recover from shipping for at least two weeks before 
experimentation and monitored daily. Rats were removed from the study if they demonstrated 
signs of failure to thrive such as precipitous weight loss, disinterest in environment, or unexpected 
gait alterations. 
 
Heart Collection 
 Rats were anesthetized with an intraperitoneal injection of ketamine (40 mg/kg) and 
xylazine (10 mg/kg) and supplemented as necessary for reflexive response.  Hearts were removed 
following midline laparotomy, placed in Krebs-Ringer bicarbonate buffer (118 mM NaCl, 4.7 mM 
KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM Mg SO4, 24.2 mM NaHCO3, and 10 mM a-D-glucose; 
pH 7.4; equilibrated with 5% CO2/95% O2 at 37°C), massaged to remove any remaining blood, and 
quickly weighed before snap freezing in liquid nitrogen.  
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Histological and Immunohistochemical Analysis 
Hearts were sectioned (8 µm) onto poly-lysine coated slides using an IEC Minotome 
Cryostat.  The oxidative fluorescent dye, hydroethidine, was used to visualize superoxide in situ 
as previously described [187].   Digitized images were used to determine average pixel intensity 
of six randomly positioned regions (1000 µm2) per cross section to calculate the intensity of 
fluorescent ethidium-stained nuclei.  Eight images per section were analyzed with ≥ 500 nuclei 
per section examined.   
 Nitrotyrosine immunoreactivity was visualized with immunofluorescence as detailed by 
the manufacturer.  Briefly, sections were washed three times using a phosphate buffered saline 
with 0.5% Tween 20 (PBS-T) at pH 7.5.  Sections were incubated in a humidified chamber at 24°C 
for 1 h in a blocking solution (5% bovine serum albumin (BSA) with the nitrotyrosine antibody 
(1:1000 in PBS-T) and then washed three times with PBS.  Immunoreactivity was visualized 
following additional incubation for 30 min with FITC labeled anti-rabbit IgG (1:200) and 
counterstaining with 4, 6-diamidino-2-phenylindole (DAPI; 1.5 µg/ml).  Images were recorded 
using an Olympus fluorescence microscope (Melville, NY) at 20X.  
 
In situ TUNEL Staining 
 Cross-sections (8 µm) were fixed with 4% paraformaldehyde, washed with PBS (pH 7.4), 
and then permeabilized using 0.1% Triton X and 0.1% sodium citrate for 2 min at 4°C before TUNEL 
staining.  Sections were counter-stained for dystrophin immunoreactivity to illuminate the muscle 
membrane as outlined previously [352].  Terminal deoxynucleotidyl transferase (TdT) and 
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fluorescein-dUTP (TUNEL reaction mixture) was added to the sections before incubation in a dark 
humidified chamber at 37°C for 60 min.  After rinsing with PBS, sections were mounted and 
counterstained with DAPI to visualize nuclei.  Three randomly selected regions from each cross-
section were digitally recorded with a CCD camera (Olympus, Melville, NY) to visualize TUNEL 
positive nuclei using an Olympus fluorescence microscope (Melville, NY) with a 20X objective.   
Control experiments performed in parallel using DNase 1 or without TdT were used to verify 
specificity of labeling. 
 
Isolation of Protein Isolates 
Heart samples were pulverized using a mortar and pestle in liquid nitrogen to a fine 
powder and weighed.  TPER Lysis Buffer (10 µL/mg tissue; Pierce, Rockford, IL, USA) containing 
protease (P8340, 10 µL/mL Sigma-Aldrich, Inc., St. Louis, MO, USA) and phosphatase inhibitors 
(P5726, 10 µL/mL, Sigma-Aldrich, Inc., St. Louis, MO, USA) was added to each sample and the 
samples homogenized for 45 s.  After incubation on ice (30 min), this procedure was repeated 
and the samples were then centrifuged at 14,000 x g at 4°C for 5 min.  After centrifugation, the 
supernatants were removed and the protein concentration of each sample was determined in 
duplicate using the Pierce Reagent Assay (Pierce, Rockford, IL).  Samples were diluted to a 
concentration of 1.5 µg/mL in SDS-loading buffer and boiled for 5 min. Thirty micrograms of 
protein from each sample were separated using 10% or 15% SDS-PAGE gels.   
   
Immunoblot Analysis 
Proteins were transferred using standard conditions onto Hybond nitrocellulose 
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membranes after electrophoresis [353].  Rapid Stain (G-Biosciences, St. Louis, MO) was used to 
verify the transfer of protein, equal protein loading between samples, and for normalization 
between gels.  Before incubation with primary antibody, membranes were blocked using 5% milk 
TBS-T for 1 hour, and then incubated with primary antibody overnight (1:1000).  After extensive 
washing in TBS-T, membranes were incubated with horseradish peroxidase-(HRP)-labeled IgG 
secondary antibodies for 1 h.  Protein bands were visualized with ECL western blotting detection 
reagent before densitometry using a flatbed scanner (Epson Perfection 3200 PHOTO) and the 
AlphaEaseFC imaging software. The integrated optical densities were kept within a linear and 
non-saturated range by adjusting the exposure time.   
  
Statistical Analysis 
Results are presented as mean ± standard error of the mean (SEM).  The SigmaStat 11.2 
statistical program was used to perform one-way analysis of variance (ANOVA) for overall 
comparisons as well as to determine group differences using the Student-Newman-Keuls post hoc 
test where applicable.  A (p < 0.05) was accepted as the level of significance. 
 
RESULTS 
Superoxide production, markers of ROS stress, and protein nitrosylation are increased with aging 
 
 Compared to 6-month old animals, body weight (BW) and heart weight (HW) were 
significantly higher in the 26- and 30-month old rat (p < 0.05) (Table 3.2).  Hydroethidine which 
emits fluorescence upon oxidation by superoxide to ethidium bromide, was used to 
semiquantitatively determine superoxide production in heart tissue sections from each age 
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group.  Compared to 6-month old animals, ethidium fluorescence was 239% and 180% higher in 
26- and 30-month female hearts, respectively (p < 0.05, Figure 3.1).  In a similar fashion, aging 
increased tyrosine nitration in the 26- and 30-month old animals (p < 0.05, Figure 3.2).  The 
modification of proteins due to lipid peroxidation was examined using 4-HNE, a lipid peroxidation 
metabolite.  Compared to 6-month old animals, 4-HNE levels were 71% and 110% higher in the 
26- and 30-month hearts (p < 0.05, Figure 3.3).   
  
Age-associated cardiomyocyte apoptosis in the female F344xBN heart was associated with 
caspase activation and changes in the Bax/Bcl-2 ratio 
Similar to previous work, TUNEL staining was performed to determine if aging was 
associated with evidence of increased DNA fragmentation which is suggestive of cellular 
apoptosis [197, 254, 354, 355].  Compared to that observed in the 6-month animals, the number 
of TUNEL positive nuclei appeared to be increased in 26- and 30-month hearts (Figure 3.4). 
Because caspase-3 activation is an important step in the initiation of DNA fragmentation / 
apoptosis, we next examined if aging was associated with increased caspase-3 cleavage. With 
aging, total caspase-3 expression was 19% and 29% lower in the 26-month and 30-month hearts, 
respectively (p < 0.05, Figure 3.5).  Consistent with these data, this decrease in total caspase-3 
levels was paralleled by increases in the amount of cleaved caspase-3 (19- and 17-kDa fragments) 
of 167% and 290% at 30-months (p < 0.05; Figure 3.5).  To confirm these findings, we next 
examined the ratio of Bax (pro-apoptotic) to Bcl-2 (anti-apoptotic).  It is thought that Bax 
promotes apoptosis by forming a homodimer, which becomes inserted into the mitochondrial 
membrane where it forms a pore that potentiates the release of cytochrome-C from the 
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mitochondria.  With aging, Bax expression was 15% higher at 30-months when compared to that 
observed in the 6- and 26-month old animals (Figure 3.6).  Conversely, the amount of Bcl-2 protein 
was 13% lower in the 26-month old animals (Figure 3.6).  As expected from these data, the 
Bax/Bcl-2 ratio was 19% higher in 30-month animals compared to that observed for the 6- and 
26-month age groups (p < 0.05, Figure 3.6).     
 
DISCUSSION 
The F344xBN rat exhibits less age-associated pathologies and an increased longevity in 
comparison to other rat models [10, 11].  Although previous data has demonstrated increased 
levels of apoptosis and oxidative stress are associated with aging in the male heart, to our 
knowledge this is the first investigation to examine if these phenomena occur in the naturally 
menopausal aging female rat model [187, 254].  Herein, we observed evidence of increased 
superoxide, protein nitrosylation, and lipid peroxidation with aging (Figures 3.1 – 3.3).  Why aging 
may increase ROS levels is not yet fully understood, however, recent data has suggested that 
alterations in enzymatic activity of the xanthine and NADPH oxidoreductases, the mitochondrial 
electron transport chain, nitric oxide synthase activity, and lipoxygenase/cyclooxygenase may 
function as potential contributors [356, 357].  In addition to ROS production, it is thought that the 
amount of ROS present in the cell at any one time is determined, at least in part, by the balance 
between ROS generation and breakdown.  The antioxidant enzymes, SOD, Cat, and Gpx, are 
thought to remove ROS thereby functioning to prevent excessive accumulation of ROS [183, 350, 
358].  Recent studies have found that antioxidant activity is increased or decreased with age in 
the rodent heart [359, 360].  Adding to the confusion, we did not find any age-associated 
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alterations in the messenger RNA (mRNA) expression of SOD1, SOD2, Cat, and Gpx in the female 
F344xBN heart (data not shown).  Whether age-associated dysregulation in the amount of ROS 
produced, decreases in the abundance of antioxidant enzyme expression, or a combination of the 
two are responsible for our findings of elevated indicators of ROS in the aging rat heart is currently 
not known.  Future studies designed to directly examine the regulation of some, or several of the 
ROS generating and buffering pathways will be required to extend our understanding of the 
relationship between aging and cardiac ROS regulation. 
Elevated levels of superoxide are oftentimes associated with increased nitrosative stress 
given that superoxide can react with nitric oxide to form peroxynitrite.  Peroxynitrite, in turn, can 
cause tyrosine nitration and the measurement of nitrosylated tyrosine residues is thought to be 
an established marker for nitrosative stress [361].  Similar to that seen in the aging male F344xBN, 
we found that aging in the female heart was associated with increased protein tyrosine 
nitrosylation (Figure 3.2) [187].  This latter finding is different from previous work using the female 
Long-Evans/Wistar rat, which found no change in 3-nitrotyrosine levels with cardiac aging [362].  
The reasons for differences between the current study and previous is not entirely clear but may 
be related to differences in the animal strain used and/or animal age as the Long-Evans/Wistar 
hybrid rats were only 24-month of age at time of sacrifice as opposed to the 26- and 30-month 
old animals used in the present study.    
Similar to our analysis of nitrosative stress, and like that seen in the aging male F344xBN, 
we also observed that aging was associated with increased 4-hydroxynonenal (4-HNE) reactivity 
(Figure 3.3) [187].  It is thought that 4-HNE levels are a marker of lipid peroxidation and that 
increased levels of 4-HNE can result in alterations in lipid signaling and enzyme inactivation [363].  
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Studies have shown that production of 4-HNE occurs primarily from the mitochondria, and that 
the mitochondria are the primary target for lipid peroxidation damage [364].  This damage to the 
mitochondria, if extensive, can lead to alterations in ROS production and the release of 
cytochrome-C from the mitochondria.  To investigate this possibility, we next examined if aging 
was associated with increased evidence of cellular apoptosis. Similar to that seen in the aging 
male F344xBN hearts, TUNEL staining suggested the possibility of increased DNA fragmentation 
with aging in the female F344xBN heart (Figure 3.4) [254].  In an effort to elucidate the mechanism 
of apoptosis, we next investigated the effects of aging on the expression of proteins involved in 
apoptotic signaling.  It is thought that the mitochondrial-mediated apoptotic pathway employs 
the activation of caspase-3 [365].  Here we demonstrate that caspase-3 cleavage was increased 
with age in the female F344xBN heart (Figure 3.5).   In a similar fashion, we also found an increase 
in Bax expression and the ratio of Bax/Bcl-2 with aging (Figure 3.6).  Taken together, and like that 
previously proposed in the aging male F344xBN heart, these data suggest that age-associated 
increases in cellular apoptosis are mediated, at least in part, by the mitochondrial pathway.   
To examine the degree of relationship between the different dependent variables, we 
calculated the correlation between age, heart weight, number of TUNEL positive cardiomyocytes, 
HE levels, nitrotyrosine, and 4-HNE.  Very high correlation was observed between aging as well as 
superoxide production, levels of nitrosative-stress marker, and nitrotyrosine (Table 3.2A).  
Although the exact mechanism(s) cannot be concluded from this data, these findings are 
consistent with the possibility that the age-associated increases in superoxide production may 
lead to increased oxidative-nitrosative damage that include elevations in the amount of proteins 
undergoing 4-HNE and nitrotyrosine modification.  Interestingly, we also found that age-
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associated increases in oxidative-nitrosative damage were highly correlated with activation of the 
mitochondrial-mediated pathway of apoptosis (Table 3.2B).  Whether increases in age-related 
oxidative damage, as suggested by our nitrotyrosine and 4-HNE data, are responsible for initiating 
cellular apoptosis is currently unclear and beyond the scope of the present study.  Nonetheless, 
the data of the present study demonstrate that aging in the female F344xBN heart is 
characterized by increased levels of oxidative stress and pro-apoptotic signaling (Figure 3.9).  
Whether these biochemical changes result in adaptations in cardiac function is currently unclear 
and is the focus of ongoing experimentation (Figure 3.7). 
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TABLE 3.1:  THE HEART AND BODY WEIGHTS OF AGING F344XBN FEMALES.   
An asterisk (*) and a cross (†) indicate significant differences from the adult (6-month) and aged 
(26-month) values respectively (p < 0.05), n = 8 or 9 hearts per age group.   
 
Group Body WT (g) Heart WT (g) HW/BW ratio (x100) 
        
6m 230.5 ± 5.3 0.76 ± 0.03 0.330 ± 0.009 
26m 274.0 ± 4.9* 0.95 ± 0.01* 0.334 ± 0.019 
30m 321.3 ± 7.2*† 1.12 ± 0.05*† 0.351 ± 0.011 
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TABLE 3.2A:  THE REGRESSION ANALYSIS OF EXPRESSION LEVELS OF SPECIFIC PROTEINS AND 
AGE, HE STAINING INTENSITY, PROTEIN NITROTYROSINE LEVELS, 4-HNE LEVELS, HEART 
WEIGHT, AND TUNEL STAINING INTENSITY OF 6-, 26-, AND 30-MONTH FEMALE F344XBN 
HEARTS.   The following symbols indicate (*) low correlation (p < 0.05), (**) moderate 
correlation (p < 0.05), (***) high correlation (p < 0.05).  P values are found in parentheses below 
R values.  Numbers within parentheses near name of protein indicate protein size in kDa.  N.T. 
(not tested).   
 Age Heart 
Weight 
TUNEL HE Nitro-
tyrosine 
4-HNE 
       
Independent 
Variable 
      
Age 
 
N.T. 0.899*** 
(<0.001) 
0.690 
(0.40) 
0.965*** 
(<0.001) 
0.849*** 
(0.004) 
0.969*** 
(<0.001) 
HE 
 
0.965*** 
(<0.001) 
0.802** 
(0.009) 
0.722* 
(0.028) 
N.T. 0.767* 
(0.016) 
0.905*** 
(<0.001) 
Heart Weight 
 
0.286 
(0.455) 
N.T. 0.478 
(0.193) 
0.802** 
(0.009) 
0.911*** 
(<0.001) 
0.448 
(0.226) 
TUNEL 
 
0.690 
(0.40) 
0.478 
(0.193) 
N.T. 0.722* 
(0.028) 
0.597 
(0.090) 
0.718* 
(0.029) 
Nitro-tyrosine 
 
0.849** 
(0.004) 
0.911*** 
(<0.001) 
0.597 
(0.09) 
0.767* 
(0.016) 
N.T. 0.907*** 
(<0.001) 
4-HNE 
 
0.969*** 
(<0.001) 
0.924*** 
(<0.001) 
0.718* 
(0.029) 
0.905*** 
(<0.001) 
0.907*** 
(<0.001) 
N.T. 
 
 
 
 
  
  49 
 
TABLE 3.2B:  THE REGRESSION ANALYSIS OF EXPRESSION LEVELS OF SPECIFIC PROTEINS AND 
AGE, HE STAINING INTENSITY, PROTEIN NITRO-TYROSINE LEVELS, 4-HNE LEVELS, HEART 
WEIGHT, AND TUNEL STAINING INTENSITY OF 6-, 26-, AND 30-MONTH FEMALE F344XBN 
HEARTS.   The following symbols indicate (*) low correlation (p < 0.05), (**) moderate 
correlation (p < 0.05), (***) high correlation (p < 0.05).  P values are found in parentheses below 
R values.  Numbers within parentheses near name of protein indicate protein size in kDa.  N.T. 
(not tested).   
 Age Heart 
Weight 
TUNEL HE Nitro-
Tyrosine 
4-HNE 
       
Apoptotic Signaling       
Bax 
 
0.263 
(0.493) 
0.331 
(0.385) 
0.526 
(0.146) 
0.111 
(0.835) 
0.738 
(0.094) 
0.478 
(0.338) 
Bcl-2 
 
0.473 
(0.199) 
0.356 
(0.346) 
0.981** 
(0.009) 
0.862* 
(0.027) 
0.394 
(0.439) 
0.637 
(0.174) 
Casp-9 (51kDa) 
 
0.748 
(0.848) 
0.326 
(0.392) 
0.528 
(0.144) 
0.262 
(0.615) 
0.554 
(0.254) 
0.447 
(0.347) 
Casp-9 (40kDa) 
 
0.782* 
(0.013) 
0.651 
(0.058) 
0.676* 
(0.046) 
0.837* 
(0.038) 
0.640 
(0.171) 
0.847* 
(0.033) 
Casp-9 (38kDa) 
 
0.927*** 
(<0.001) 
0.811** 
(0.008) 
0.659 
(0.054) 
0.923** 
(0.009) 
0.705 
(0.118) 
0.924** 
(0.008) 
Casp-9 (17kDa) 
 
0.800* 
(0.01) 
0.820** 
(0.007) 
0.665 
(0.051) 
0.605 
(0.203) 
0.905* 
(0.013) 
0.865* 
(0.026) 
Casp-3 
 
0.878** 
(0.007) 
0.928*** 
(<0.001) 
0.537 
(0.136) 
0.940** 
(0.005) 
0.887* 
(0.019) 
0.974*** 
(<0.001) 
Casp-3 (19kDa) 
 
0.612 
(0.08) 
0.664 
(0.051) 
0.590 
(0.094) 
0.421 
(0.406) 
0.863* 
(0.027) 
0.737 
(0.094) 
Casp-3 (17kDa) 
 
0.683* 
(0.043) 
0.740* 
(0.023) 
0.598 
(0.089) 
0.511 
(0.301) 
0.894* 
(0.016) 
0.804 
(0.054) 
Akt 
 
0.409 
(0.275) 
0.899*** 
(<0.001) 
0.474 
(0.197) 
0.236 
(0.653) 
0.201 
(0.703) 
0.052 
(0.923) 
p-Akt(Ser473) 
 
 
0.560 
(0.117) 
0.336 
(0.337) 
0.690* 
(0.040) 
0.852* 
(0.031) 
0.372 
(0.467) 
0.634 
(0.176) 
 
Heat Shock Proteins       
Hsp70 
 
0.205 
(0.597) 
0.264 
(0.492) 
0.536 
(0.274) 
0.018 
(0.963) 
0.137 
(0.725) 
0.134 
(0.731) 
Hsp90 
 
0.094 
(0.809) 
0.084 
(0.830) 
0.132 
(0.803) 
0.145 
(0.710) 
0.117 
(0.764) 
0.058 
(0.883) 
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FIGURE 3.1 
 
FIGURE 3.1:  INCREASED SUPEROXIDE LEVELS IN THE AGING FEMALE F344XBN HEART.   
A. The detection of superoxide using the formation of dihydroethidium from 
hydroethidine staining in 6-, 26-, and 30-month female F344xBN rat hearts.  Scale bar = 100 µm.  
B.  Cardiac superoxide levels were quantified by the intensity of fluorescent Et-stained nuclei and 
these results were reported as the integrated optical density of pixel by micrometer.  Significant 
differences are indicated by an asterisk (*) and a cross (†) from the adult (6-month) value and 
aged (26-month) value, respectively (p < 0.01).   
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FIGURE 3.2 
 
 
FIGURE 3.2:  AGING INCREASES THE NITROSYLATION OF TYROSINE RESIDUES.   
A. Immunohistochemical staining of 6-, 26-, and 30-month female F344xBN hearts to 
determine the nitrosylation of tyrosine residues.  Scale bar = 100 µm.  B.  Immunoblot analysis of 
protein tyrosine nitration in the aging female F344xBN hearts.  Results were reported as fold 
change.  Significant differences are represented by an asterisk (*) and a cross (†) from the adult 
(6-month) value and aged (26-month) value, respectively (p < 0.05). 
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FIGURE 3.3
 
FIGURE 3.3:  LIPID PEROXIDATION INCREASES WITH AGE IN THE FEMALE HEART.  
A.  Immunohistochemical analysis of 4-HNE levels in the 6-, 26-, and 30-month female 
F344xBN heart.  Scale bar = 100 µm.  B.  The quantification of 4-HNE levels determined by 
immunoblotting.  The results were reported as fold change of the 6-month value.  Significant 
differences are represented by an asterisk (*) and a cross (†) from the adult (6-month) value and 
aged (26-month) value, respectively (p < 0.05). 
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FIGURE 3.4
 
 
FIGURE 3.4:  INDICES OF APOPTOSIS INCREASE IN THE AGING FEMALE HEART.    
All cardiomyocyte nuclei were stained with 4’, 6-diamidino-2-phenyllindole (DAPI) and 
nuclei with DNA fragmentation, an indice of apoptosis, were visualized with TUNEL staining.  The 
mouse monoclonal antibody dystrophin (C-terminus) was used to visualize cardiomyocyte 
borders.  Scale bar = 100 µm.   
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FIGURE 3.5 
 
FIGURE 3.5:  AGING ALTERS THE EXPRESSION AND ACTIVATION OF CASPASE-3 AND CASPASE-9.   
Expression of caspase-3 (a) and caspase-9 (b) in heart tissue of female F344xBN rats as 
determined by immunoblot analysis.  Caspase levels were normalized to amount of protein 
loaded into each lane.  Representative immunoblot images are shown for each group.  Data are 
reported as mean ± SEM.  (*) represents significant difference from 6-month age group (p < 0.05).  
(†) represents significant difference from 26-month group (p < 0.05).  
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FIGURE 3.6 
 
FIGURE 3.6:  AGING AFFECTS THE EXPRESSION AND/OR REGULATION OF APOPTOTIC 
REGULATORS BAX AND BCL-2.   
Bax and Bcl-2 expression of female F344xBN rat hearts with age as measured by 
immunoblot analysis.  Bax and Bcl-2 expression was normalized to amount of protein loaded into 
each lane.  Bax and Bcl-2 ratio is given for each group.  Representative immunoblot images are 
shown for each group.  Data are reported as mean ± SEM.  Significant differences from 6-month 
group (p < 0.05) are represented by an (*).  (†)  represents significant difference from 26-month 
group (p < 0.05).   
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FIGURE 3.7  
 
 
FIGURE 3.7:  SUMMARY OF FINDINGS IN THE AGING FEMALE F344XBN HEART.   
Aging in the female F344xBN heart involved increased oxidative-nitrosative stress and 
damage in addition to increased mitochondrial mediated apoptosis.   
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CHAPTER 4 
AGE-ASSOCIATED ALTERATIONS OF CARDIAC STRUCTURE AND FUNCTION IN THE 
FEMALE F344XBN RAT HEART 
  
 
In Chapter 3, the results showed that there was an age-associated increase in oxidative-
nitrosative stress and damage as well as apoptotic signaling.  According to the free radical theory 
of aging as well as previous studies, the accumulation of oxidative-nitrosative stress leads to 
cardiac dysfunction through alterations in cardiac structure and function.  This chapter 
investigated the age-associated alterations in cardiac structure and function in the female 
F344xBN outlined in Specific Aim II.  
 
ABSTRACT 
The F344xBN rat model exhibits an increased life span and fewer age-associated 
pathologies compared to commonly used F344.  How aging may affect cardiac structure and 
function in these animals, has to our knowledge, not been investigated.  Echocardiography was 
performed on female F344xBN rats at 6-, 26-, and 30-months of age using a Phillips 5500 
Echocardiography system.  Before sacrifice, electrocardiograms were measured in the female 
F344xBN in order to determine heart rhythm interval changes.  Aging was associated with an 
increase in heart to body weight ratio, cardiomyocyte CSA, posterior wall thickening, and left 
ventricle chamber dilatation.  Aging was associated with slight evidence of diastolic dysfunction.  
Alterations in heart rhythm intervals were associated with alterations in the spatial distribution 
of Cx43.  The incidence of arrhythmias was not different with age; however, valvular dysfunction 
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was increased.  These data suggest that aging in the female F344xBN rat heart is associated with 
changes in cardiac structure as well as function. Further investigation regarding other parameters 
of cardiac biochemistry and function is needed to better understand the normal compensated 
cardiovascular aging process in the female F344xBN. 
 
INTRODUCTION 
Aging is associated with an increased risk of developing myocardial infarction, stroke, 
atherosclerosis, peripheral occlusive disease, diabetes, and hypertension [340, 341].  Similar to 
that seen in humans, aging in rodents is characterized by cardiomyocyte loss, hypertrophy of the 
remaining cardiomyocytes, and increased fibrosis [13, 116, 117, 119]. These structural changes 
adversely affect aging cardiac function by prolonging contraction and relaxation leading to systolic 
and diastolic dysfunction [114, 342].   
The F344xBN rat has been recommended by the NIA for aging studies due to its increased 
life span and the presence of fewer age-associated pathologies when compared to other rodent 
models [10, 11].  It has been demonstrated that male F344xBN animals undergo similar age-
associated changes in cardiac structure and function to those seen in humans.  Whether female 
F344xBN animals exhibit similar alterations has, to our knowledge, not been examined.  
Normal cardiovascular aging can lead to structural changes in addition to decreased Cx43 
expression or increased heterogeneity which can lead to electrical abnormalities by disrupting 
normal myofiber organization as well as slowing conductance [172, 366]. Such changes in 
electrical conductance, electrolyte imbalance, and altered ion channels have been linked to 
various forms of cardiac disease and rhythm disturbances [119, 367, 368].  These adaptations are 
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capable of resulting in secondary cardiac dysfunction, which can include alterations in cardiac 
rhythm.  To our knowledge such changes have not been investigated in the female F344xBN.  
These changes, if present, in a non-pathological model of female aging may provide insight into 
the normal compensated cardiovascular aging process within the female heart [10].  
The purpose of this study was to examine how aging affects the structure and function of 
the female F344xBN rat heart and to determine if changes in tissue structure and function, if 
present, are associated with changes in electrocardiographic measures and Cx43 heterogeneity 
of distribution.  We hypothesize that alterations in cardiac structure and Cx43 heterogeneous 
distribution in the female F344xBN heart will be associated with cardiac dysfunction and heart 
rhythm interval changes. 
 
MATERIALS AND METHODS 
Animals 
All procedures were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
Animal Use Review Board of Marshall University.  All procedures were conducted in strict 
accordance with the Public Health Service Animal Welfare Policy.  Virgin adult (6-month), aged 
(26-month), and very aged (30-month) female F344xBN rats were obtained from the NIA and 
housed two per cage in an AAALAC approved vivarium.  Animal ages were chosen based on 
survivability curves from the National Institute of Aging to approximate females in the third, 
seventh, and eighth decade of life.  Given that previous data have demonstrated a complete loss 
of cyclicity at 16 months of age, the estrous phase was not monitored (PMID 17460359).  Housing 
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conditions consisted of a 12 h-12 h light-dark cycle and temperature was maintained at 22 ± 2˚C.  
Animals were provided with food and water ad libitum.  Rats were allowed to recover from 
shipment for at least two weeks before experimentation during which time the animals were 
carefully observed and weighed weekly.  Any of the rats showing signs of failure to thrive, such as 
precipitous weight loss, disinterest in environment, or unexpected gait alterations were excluded 
from the study.  
 
Echocardiographic procedures 
Rats (6-, 26-, and 30-month) were anesthetized using a cocktail of ketamine (40 mg/kg) 
and xylazine (10 kg/mg) which was injected into the intraperitoneal cavity in order to perform 
echocardiograms.  Echocardiographic procedures were done as previously described by Walker 
and colleagues [94].  In order to prevent disturbances of ultrasound waves, the ventral thorax was 
shaved and the rats were placed either on their backs or left side and covered with ultrasonic 
transmission gel.  A Phillips 5500 Echocardiographic system with a 12 MHz transducer was used 
to take two-dimensional echocardiographic measurements, two-dimensional guided motion 
mode (M-mode), Doppler M-mode, and parasternal long- and shot-axis views.  Parasternal long- 
and short-axis views were used to determine two-dimensional cardiac structural measurements.  
The echocardiographic views were then used to position the M-mode echocardiographic line.  
Valvular blood flow velocities were evaluated using pulse wave Doppler with the probe toward 
the apex (x-axis) and the depth along the y-axis (long axis procedure).  Positioning the probe 
toward the left ventricle and across the heart during short axis procedures made it possible to 
evaluate wall structure in order to calculate EF and FS during systole.  A digital echocardiographic 
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analysis system was used to analyze M-mode displays.  All echocardiography procedures and 
parameters were measured by the same echocardiogram technician to limit inter-observer 
variability.     
Left ventricular mass (LVM) was calculated according to the following equation on the 
basis of previous reports demonstrating a good correlation (r = 0.78, SEE = 0.124, P < 0.0001) 
between calculated and postmortem LVM [369, 370]. 
LVM= 1.04(IVSd+LVIDd+PWTd)3-LVIDd3 [371]  
 
Serum Collection 
 During tissue collection blood was collected by cardiac puncture into a BD Vacutainer 
serum collection tube.  The blood was centrifuged at 800 x g for 15 minutes to separate serum.  
The serum was collected and used to measure serum parameters using an Abaxis VetScan 
analyzer (Abaxis, Union City, CA).  The following parameters were determined: non-fasting serum 
glucose (GLU), alanine aminotransferase (ALT), alkaline phosphatase (ALP), blood urea nitrogen 
(BUN), albumin (ALB), calcium (Ca2+), creatinine (CRE), amylase (AMY), globulin (GLOB), 
potassium (K+), sodium (Na+), phosphorus (PHOS), total bilirubin (TBIL), and total protein [372]. 
  
Heart Collection 
Rats were anesthetized with an intraperitoneal injection of ketamine (40 mg/kg) and 
xylazine (10 mg/kg) and supplemented as necessary for reflexive response.  Before heart 
collection, a three lead EKG was performed on all animals using the Biopac Student Lab software 
(BIOPAC Systems, Inc., Microsoft).  After completion of the EKG, the heart was removed after a 
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midline laparotomy and placed in Krebs-Ringer bicarbonate buffer containing the following: 118 
mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM NaHCO3, and 10 
mM a-D-glucose (pH 7.4) equilibrated with 5% CO2/95% O2 and maintained at 37°C.  Isolated 
hearts were quickly massaged to remove any blood from the ventricles, cleaned of connective 
tissue, weighed, and immediately snap frozen in liquid nitrogen.   
 
Electrocardiographic analysis 
EKGs collected from the aging female rats were analyzed using BioPac Student Lab PRO 
software. All animals were evaluated for any electrical anomalies in all three leads. Lead II was 
used to evaluate changes in EKG parameters, a 6 rhythm section of the EKG was used to obtain 
data for comparison of ventricular acceleration time (VAT), heart rate, ST interval, T amplitude, 
QRS interval, QT interval, PR interval, T duration, T-T interval, R+S amplitude, S amplitude, R 
amplitude, Q amplitude, and P amplitude. Mean electrical axis was calculated from leads I and III 
after calibration of 2 cm/mV using the following formula derived by Singh and Athar [373, 374].  
tan𝜃 =
𝐼 + 2𝐼𝐼𝐼
√3𝐼
        
 
Heart rate was determined by the average intervals between R waves on lead II. 
 
Determination of myocyte cross sectional area and histological analysis 
An IEC Minotome Cryostat was used to section (8 µm) frozen hearts (n = 4) on poly-lysine 
coated slides.  To determine morphology, heart sections were stained with hematoxylin and eosin 
stain.  Picrosirius red staining (PSR) was employed to examine collagen.  The collagen area fraction 
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of the PSR-stained tissues was determined using Image J software. 
Immunostaining for dystrophin (NCL-DYS2, Novocastra Vector Laboratories, Burlingame, 
CA) and connexin-43 (Cell Signing Technology #3512, Danvers, MA) was visualized by 
immunofluorescence as outlined by the antibody manufacturer.   A phosphate-buffered saline 
(PBS) containing 0.5% Tween-20 (PBS-T) at pH 7.5 was used to wash sections three times before 
incubating for 30 min in a blocking solution (5% BSA).  The dystrophin antisera diluted in PSB-T 
(antibody dilution of 1:100) was added to sections for 1 h in a humidified chamber at 24°C.  After 
incubation the sections were washed three time with PBS, and incubated again for 30 min in a 
humidified chamber at 24°C with a secondary antibody solution containing a FITC anti-rabbit IgG 
(1:200) and DAPI (1.5 μg/ml) in order to visualize cell nuclei.  Sections were washed a final time 
with PBS before mounting.  The epifluorescence of specimens was visualized using an Olympus 
fluorescence microscope (Melville, NY, USA) fitted with a 40X objective.  Images were recorded 
digitally using A CCD camera and the Olympus MicroSuite™ Basic from Olympus America 
(Melville, NY, USA) were used to digitally record and analyze images, respectively.  The CSA of the 
cardiac myocytes was determined by measuring the area within the dystrophin positive staining.  
 
Statistics  
Results are given as mean ± SEM.  Statistical analyses were performed using Sigma Stat 
3.5 statistical software (Systat Software, Inc.).  Age comparisons between echocardiographic 
structural, functional parameters, and morphologic indices were evaluated by One Way ANOVA 
with the Student-Newman-Keuls post hoc test for parametric normally distributed data or 
Kruskal-Wallis One Way Analysis of Variance on Ranks with a Dunn's post hoc test for none 
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parametric distributions.  Linear regression analysis was performed with dependent variables 
against the independent variables age, correlation were ranked as low correlation (0.3 to 0.7), 
moderate correlation (0.5 to 0.7), high correlation (0.7 to 0.9), very high correlation (0.9 to 1) 
between parameters (supplemental data).    The level of significance accepted a priori was ≤ 
0.05.     
  
RESULTS 
Cardiac function is preserved in the aging female F344xBN rat 
Compared to 6-month old animals, heart and body weight was higher at 26-months (72 ± 
2 mg vs. 95 ± 2 mg, p < 0.001; 235.3 ± 1.7 g vs. 296.4 ± 6.5 g; p < 0.05) and 30-months (104 ± 4 
mg, p < 0.05); 235.3 ± 1.7 g vs. 315.6 ± 8.6 g; p < 0.05) (Table 4.1).  Compared to 6-month old 
animals, cardiac myocyte CSA was 20 ± 1.9 % and 28 ± 2.3 % higher in the 26- and 30-month old 
animals, respectively (p < 0.05) (Figure 4.2).  Histological analysis using picrosirius red staining 
demonstrated a significant age-related decrease in collagen reactivity (Figure 4.2, p < 0.05).  
Immunohistochemical staining of the aging female heart suggested alterations in Cx43 
localization from the cell ends to the lateral margins (Figure 4.3).  Alignment of the Cx43 staining 
appears to be uniform, localized, and linear within the 6 month tissues sections, as would be 
expected because of Cx43 localization along the intercalated disk.  The linearity of the staining 
appears to become less uniform and diffuse with aging which may indicate alteration in Cx43 
distribution within the cardiac myocyte.  In addition to changes in Cx43 immunoreactivity, aging 
also appeared to be associated with changes in cardiac rhythm.  In particular, aging appeared to 
be characterized by the presence of hyper-acute T waves, a long PR interval, a long P wave 
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duration, tall P waves, and significant Q waves (Figure 4.3, Table 4.4). No evidence of arrhythmias 
was observed in any age group.   
No age-associated changes in transmitral to mitral annular early diastolic velocity ratio (E-
E’) ratio was found in the female F344xBN rats.  Left ventricular IVRT was significantly higher in 
26-month old animals (0.036 ± 0.005 sec) compared to that seen in the 6-month old animals 
(0.015 ± 0.002 sec; p < 0.05).  Mitral valve deceleration time demonstrated no significant change 
with age.  Mitral valve Emax was significantly lower at 26- (61.5 ± 1.5 cm/sec) and 30-months 
(55.4 ± 1.4 cm/sec) when compared to that seen in the 6-month old animals (78.0 ± 3.3 cm/sec; 
p < 0.05).  Mitral valve Amax levels were lower at 30-months (35.1 ± 1.6 cm/sec) when compared 
to 6-months (41.5 ± 1.3 cm/sec; p < 0.05).  No significant changes were found in MV E/A ratio 
with age (Table 4.3). 
Compared to 6-month animals, EF was significantly higher at 26-months (82 ± 1.0 % vs. 74 
± 0.9 %; p < 0.05).    Fractional shortening was lower at 30-months (41.5 ± 1.7 %) when compared 
to that observed in 26-month old animals (45.6 ± 1.0 %; p < 0.05).  End systolic volume (ESV) was 
significantly lower at 26-months (0.082 ± 0.005 mL) when compared to 6-month old animals 
(0.143 ± 0.017 mL; p < 0.05).   However, heart rate was unaltered with age (Table 4.2). 
 
Aging increases septal and posterior wall thickness and valvular insufficiency in the female 
F344xBN heart 
Compared to 6-month old animals, left ventricular septal thickness (IVS) during systole 
was higher in 26-month old animals (0.193 ± 0.008 cm vs. 0.253 ± 0.003 cm; p < 0.05).  Left 
ventricular internal dimension during systole (LVIDs) significantly increased at 26-months (0.331 
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± 0.009 cm) compared to 6-month (0.378 ± 0.017 cm; p < 0.05).  During diastole LVID 
demonstrated no significant change.  Left ventricular posterior wall thickness (LVPW) during 
systole and diastole was significantly increased at 30-months (LVPWs: 0.288 ± 0.009 cm; LVPWs: 
0.189 ± 0.008 cm) compared to 6-months (LVPWs: 0.193 ± 0.002 cm; LVPWd: 0.153 ± 0.010 cm; p 
< 0.05).  No changes were found in right ventricular dimension (RVd) during diastole or left 
ventricular mass with age (Table 4.4). 
 The incidence of tricuspid, mitral, and pulmonary valve insufficiency was higher in 26- and 
30-month female hearts relative to that observed in 6-month animals. The presence of aortic 
insufficiency with age was only seen in the 30-month age group (Figure 4.5). 
 
Aging is associated with alterations in serum glucose and electrolytes in the female F344xBN rat  
In the aging female F344xBN non-fasting serum glucose levels were significantly 
decreased at 30-month (323.7 ± 13.3 mg/dl) compared to 6-month (372.8 ± 16.0 mg/dl) female 
F344xBN rat.  Serum levels of ALP, BUN, PHOS, and potassium (K+) significantly decreased at 26- 
and 30-months compared to that observed in the 6-month old animals.  TP, GLOB, and CRE 
increased significantly at 30-months (6.3 ± 0.1 g/dl; 2.12 ± 0.1 g/dl; 0.4 ± 0.03 mg/dl) compared 
to 6-months (5.8 ± 0.05 g/dl; 1.56 ± 0.12 g/dl; 0.3 ± 0.002 mg/dl).  In the 26-month old female 
F344xBN rat serum calcium (Ca2+, 11.2 ± 0.1 mg/dl) levels were significantly increased compared 
to 6-month female rats (10.7 ± 0.09 mg/dl).  No significant changes were found in serum ALB, ALT, 
sodium, and TBIL with age in the female F344xBN.  Significant increases of calcium to phosphate 
(Ca+/PHOS) and sodium to potassium (Na+/K+) ratios were observed in the 26- and 30-month age 
groups when compared to 6-month animals (p < 0.05).  Compared to 6-month animals, BUN/CRE 
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and the albumin to globulin (ALB/GLOB) ratios were lower in the 26- and 30-month age groups 
(Table 4.5, p < 0.05).  
 
DISCUSSION 
The purpose of this study was to examine how the aging process affects the cardiac 
structure and function in the female F344xBN rat.  Similar to previous work using male animals, 
our data indicated that aging in these animals is associated with an increase in the thickness of 
the septal and posterior walls between 6- and 30-months of age [94].  In addition to these 
changes, we also observed that aging was associated with increases in average cardiomyocyte 
muscle fiber CSA (Figure 4.2) and a trend towards increased left ventricular wall thickness (Table 
4.4).  These data, taken together, are consistent with the efforts of Boluyt and colleagues who 
noted an increase in thickness of septal and posterior walls at 30-months in the aging F344 model 
[2].  Unlike this study, previous echocardiography studies in humans, male F344xBN rats, and 
female F344 rats (at 30-months of age) have shown that LVM in female F344 rats is increased with 
age [26, 89, 94, 114].  Why discrepancies may exist between studies is currently unclear but may 
be related to differences in experimental design, differences across species, rat strain or in the 
time points chosen for examination. Future experiments perhaps using older female F344xBN 
rats may be useful for clarification. 
Aging is oftentimes associated with an increased risk of diastolic dysfunction which 
appears to exhibit a greater incidence in women compared to men [375].  Diastolic problems 
oftentimes, but not always, precede the development of systolic dysfunction [375].  In humans, 
diastolic dysfunction is defined by abnormal ventricular relaxation and filling that is characterized 
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by a low E wave velocity, a high A wave velocity, prolonged deceleration time, and prolonged IVRT 
[375].  In the present study, we observed age-related decrease in E’, increases in left ventricular 
relaxation time and a trend in MV decel time in the female F344xBN heart.  Nonetheless, we did 
not find any changes in the E/A ratio with age.  Conversely, Boluyt and colleagues, using aged 
female F344 animals, demonstrated increases in left ventricular IVRT, decreases in the E wave, 
and an increased A wave velocity [2].  Similar to previous findings by Boluyt and colleagues who 
used the aging female F344 model, we observed age-related increases in left ventricular 
relaxation time, decreased E’ wave velocity, and a trend in MV decel time but no change in the 
E/A ratio with aging in the female F344xBN heart [2].  Taken together, these data suggest that 
aging in the female F344 and F344xBN rats, like that seen in humans, is often characterized by 
alterations in diastolic function. 
Like prior work done in the F344 rat strain, aging in the female F344xBN rat did not appear 
to significantly impair systolic function [2, 118].  Similar to that observed in the aging F344 
animals, we also noted a slight increase in ejection fraction at 26-months although this parameter 
must be interpreted with caution since animals at this time point also exhibited increased 
evidence of valvular regurgitation [2].  Interestingly, work by Forman and colleagues reported that 
F344 males had a higher occurrence of mitral regurgitation (MR) than that seen in their female 
counterparts which may help explain the differences in function between the sexes [118].  This 
finding is consistent with previous work from our laboratory which demonstrated a higher 
percentage of MR with age in male F344xBN (unpublished data).  Why differences may exist 
between aged male and female F344xBN rats will require further investigation. 
Probabilities of survival curves generated by the NIA were used in the current study in an 
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effort to approximate aging humans in the 3rd, 7th, and 8th decade of life.  It is likely that aging in 
the female F344xBN does not closely mimic the changes seen in aging women at similar time 
points along the aging spectrum.  Why aging in female rodents might differ from that seen in 
humans is likely complex and poorly understood but may be related to dissimilarities in hormonal 
regulation during aging.  Previous data has demonstrated that the F344xBN estrous cycle ceases 
at 16 months of age which suggests that the 26- and 30-month old animals used in the present 
study are likely to represent animals that are moderate and late post-menopausal [376].  Unlike 
that seen in humans, this loss in function is characterized as persistent estrous with maintained 
levels of estrogen, lower levels of progesterone, the absence of LH surges, and ovulation.  This 
initial decline, in turn, is followed by the final stage where aged female rodents have low levels of 
plasma estradiol, progesterone, and (no or little) developing ovarian follicles [377].  Whether 
estrogen, if present, may have blunted the age-associated changes typically seen in male animals 
is currently unclear.      
 
Age-associated alterations in heart rhythm in the female F344xBN heart 
Unlike the aging male F344xBN rats, no evidence of arrhythmias were detected with age 
in the female F344xBN [94].  Nonetheless, our data suggest that aging in the female F344xBN is 
associated with changes in heart rhythm including increases in the VAT, ST interval, T amplitude, 
QRS interval, QT interval, T duration, Q amplitude, P amplitude, and a shift in the mean electrical 
axis with age (Table 4.2), increase in heart weight, myocyte CSA, and LVM.  Alterations in heart 
rhythm intervals such as increased PR interval, P wave amplitude, and QRS complex are 
oftentimes indicative of myocardial disease [378].  Previous studies have shown that aged male 
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rats (20-months) had no difference in R-R interval, P wave, as well as QRS length; however, PR and 
QT interval were increased with age [132].  Our current findings support the existence of 
alterations in cardiac conductance but provide little information as to the underlying mechanism. 
The elevation in VAT and QRS interval suggest that aging might not only affect depolarization but 
that it may also be associated with changes in the ability of the heart to undergo repolarization. 
Correlation analysis demonstrated a high correlation between heart weight to MV A max velocity 
(0.752 cm/sec) and MV A max velocity to CSA (0.827) (Table S-4.1- S-4.4).  Because the nature of 
correlation does not denote causation, it is important to note that further research is required to 
delineate the nature of these correlations and to better elucidate the causation of the age-
associated changes listed in this study.  Similarly, whether the changes in VAT and QRS interval we 
observed in the current study are due to differences in ion handling, ion channel density, 
alterations in how electrical signals may propagate through the myocardium or if they reflect age-
associated increases in myocyte CSA or chamber dimensions (Figure 4.2, Table 4.4) is currently 
unclear and will require additional experimentation.    
Heart rhythm propagation is dependent on cell to cell coupling between cardiomyocytes 
and this coupling is dependent, at least in part, on ion channels and gap junctions.  Previous 
studies have shown that age-related changes in impulse propagation may be related to 
abnormalities in the pattern of ventricular activation [119].  Recent data has suggested that 
alterations in heart rhythm intervals during aging may be associated with alterations in Cx43 
expression/activation/heterogeneity, fibrosis, and hypertrophy [119, 163-165, 379].  Other work 
examining Cx43 has demonstrated increases in atrial fibrillation in patients exhibiting increased 
heterogeneity of Cx43 distribution [368].  These possibilities appear to be consistent with our 
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data, where we observed qualitative alterations in Cx43 localization with aging in the female 
F344xBN heart (Figure 4.3).  Future experiments to directly investigate if or how changes in Cx43 
protein abundance and localization may affect cardiac rhythm in the aging female F344xBN rat 
model may be helpful in delineating whether Cx43 may play a role in the aging female heart.  
In addition, we also examined if age-related changes in heart rhythm were associated with 
alterations in blood chemistry.  It has been suggested that electrolyte disorders can affect the ion 
currents in the heart and that such changes might be related to the development of cardiac 
arrhythmias [367].  For example, previous studies have shown that decreased plasma sodium, 
potassium, and ionized calcium levels are associated with a higher risk of arrhythmias in 
hemodialysis patients [380, 381].  Although very little is known about the role of serum 
electrolytes in influencing cardiac function during aging, alterations in serum electrolytes have 
been associated with increased all-cause mortality among patients suffering from 
coronary heart disease [382].  For the most part, we found that age-related changes in blood 
chemistry appeared to be within the normal range.  Recent work has suggested that decreases in 
plasma potassium may be related to the development of tachyarrhythmias [383].  Whether the 
age-associated reduction in potassium levels seen in this study, although within the normal 
physiological range, might play a role in the changes seen in the EKG data will require further 
investigation.    
In conclusion, this study provides reference values for cardiac structure and function in 
the aging female F344xBN heart. Taken together, our data suggest that the female, unlike the 
male, F344xBN rat demonstrates subtle age-associated changes in cardiac structure, function, 
and conductance.  The age-associated increase in heart wall thickness in the absence of fibrosis 
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and increase heterogeneity of Cx43 distribution may partially explain the age-associated 
alterations in heart rhythm intervals.  The possibility of altered serum ion levels may also 
contribute to reduced conductance. Further study is needed to better understand the 
mechanistic basis of how aging may affect cardiac structure and function in the female F344xBN 
rat.  
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TABLE 4.1:  TOTAL BODY WEIGHT (BW) AND HEART WEIGHT (HW) IN FEMALE F344XBN RATS 
AT 6-, 26-, AND 30-MONTHS OF AGE (MEANS ± SEM).  6-month animal; 26-month animal; 30-
month animal; (*, p < 0.05) significant difference from 6-month animal; (†, p < 0.05) significantly 
different from 26-month animal. 
     
Groups 6-month 26-month 30-month 
N 4 22 10 
Heart Weight (g) 0.72 ± 0.02 0.95 ± 0.02* 1.0 ± 0.04*† 
Body Weight (g) 235.3 ± 1.7 296.4 ± 6.5* 315.6 ± 8.6* 
HW/BW Ratio (%) 0.317 ± 0.02 0.32 ± 0.01 0.33 ± 0.01 
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TABLE 4.2:  ELECTROCARDIOGRAPHIC EVALUATION OF CARDIAC CONDUCTION PARAMETERS 
IN AGING FEMALE F344XBN RATS (MEAN ± SEM).  6-month animal; 26-month animal; 30-
month animal; (*, p < 0.05) significant difference from 6-month animal; (†, p < 0.05) significantly 
different from 26-month animal. 
 
EKG Measurements 6-months 26-months 30-months 
Heart Rate 277.8 ± 4.67 277.6 ± 4.27 277.6 ± 6.45 
VAT 0.036 ± 0.0013 0.044 ± 0.0010* 0.046 ± 0.0007* 
ST Interval 0.055 ± 0.0035 0.080 ± 0.0018* 0.073 ± 0.0013* 
T Amplitude 0.090 ± 0.0065 0.123 ± 0.0071* 0.098 ± 0.0080† 
QS Interval 0.055 ± 0.0010 0.066 ± 0.0013* 0.070 ± 0.0005*† 
QT Interval 0.110 ± 0.0035 0.146 ± 0.0023* 0.143 ± 0.0012* 
PR Interval 0.035 ± 0.0027 0.033 ± 0.0015 0.032 ± 0.0010 
T Duration 0.055 ± 0.0035 0.080 ± 0.0018* 0.073 ± 0.0013* 
T-T Interval 0.217 ± 0.0034 0.217 ± 0.0032 0.218 ± 0.0050 
R + S Amplitude 0.321 ± 0.0105 0.280 ± 0.0161 0.276 ± 0.0247 
S Amplitude -0.009 ± 0.0061 -0.007 ± 0.0049 -0.029 ± 0.0121 
R Amplitude 0.035 ± 0.0027 0.033 ± 0.0015 0.032 ± 0.0010 
Q Amplitude -0.005 ± 0.0019 -0.014 ± 0.0024* -0.018 ± 0.0017* 
P Amplitude 0.006 ± 0.0052 0.037 ± 0.0018* 0.037 ± 0.0020* 
P Duration 0.035 ± 0.0027 0.033 ± 0.0015 0.032 ± 0.0010 
Mean Electrical Axis 34.41 ± 5.99 63.13 ± 4.86* 63.26 ± 3.72* 
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TABLE 4.3:  ECHOCARDIOGRAPHIC EVALUATION OF CARDIAC FUNCTIONAL PARAMETERS IN 
AGING FEMALE F344XBN RATS (MEAN ± SEM).  6-month animal; 26-month animal; 30-month 
animal; (*, p < 0.05) significantly different from 6-month animal. 
 
 
Groups 6-month 26-month 30-month 
EF (%) 74 ± 0.9 82 ± 1.0* 78 ± 1.8 
FS (%) 38 ± 0.7 46 ± 1.0 42 ± 1.7 
ESV (mL) 0.143 ± 0.017 0.082 ± 0.005* 0.114 ± 0.10 
EDV (mL) 0.535 ± 0.052 0.492 ± 0.20 0.523 ± 0.022 
Heart Rate (bpm) 281 ± 16.5 259 ± 8.8 278 ± 10.1 
E-E’ 20.8 ± 1.02 14.7 ± 0.64 21.9 ± 2.63 
LV IVRT (sec) 0.015 ± 0.002 0.036 ± 0.005* 0.030 ± 0.000 
MV Dec Time (sec) 0.053 ± 0.005 0.057 ± 0.002 0.063 ± 0.003 
MV Emax (cm/sec) 78 ± 3.3 62 ± 1.5* 55 ± 1.4* 
MV Amax (cm/sec) 42 ± 1.3 36 ± 0.9 35 ± 1.6* 
MV E/A 1.75 ± 0.03 1.60 ± 0.06 1.66 ± 0.10 
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TABLE 4.4:  ECHOCARDIOGRAPHIC EVALUATION OF CARDIAC STRUCTURAL PARAMETERS IN 
AGING FEMALE F344XBN RATS (MEAN ± SEM).  6-month animal; 26-month animal; 30-month 
animal; (*, p < 0.05) significantly different from 6-month animal. 
 
 
Groups 6-month 26-month 30-month 
IVSs (cm) 0.193 ± 0.008 0.253 ± 0.003* 0.239 ± 0.013 
IVSd (cm) 0.118 ± 0.012 0.151 ± 0.003 0.149 ± 0.004 
LVIDs (cm) 0.378 ± 0.017 0.331 ± 0.009* 0.356 ± 0.011 
LVIDd (cm) 0.610 ± 0.022 0.593 ± 0.009 0.606 ± 0.10 
LVPWs (cm) 0.193 ± 0.002 0.267 ± 0.007 0.288 ± 0.009* 
LVPWd (cm) 0.153 ± 0.010 0.166 ± 0.004 0.189 ± 0.008* 
RVDd (cm) 0.105 ± 0.016 0.138 ± 0.009 0.111 ± 0.006 
LVM (g) 0.487 ± 0.10 0.658 ± 0.09 0.646 ± 0.04 
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TABLE 4.5:  BLOOD PARAMETERS FOR THE AGING FEMALE F344XBN RAT (MEAN ± SEM).    6-
month animal; 26-month animal; 30-month animal; (*, p < 0.05) significantly different from 6-
month animal; n = 4 - 6 group. 
Parameters  6-month  26-month  30-month 
       
ALB (g/dL)  4.4 ± 0.03  4.4 ± 0.1  4.2 ± 0.1 
       
ALP (u/L)  217.9 ± 10.7  168.0 ± 9.6*   167.8 ± 7.4* 
       
ALT (u/L)  45.1 ± 2.2  57.6 ± 3.7  49.8 ± 2.4 
       
AMY (u/L)  551.1 ± 22.1  640.3 ± 29.6*  589.8 ± 18.0 
       
TBIL (mg/dL)  0.2 ± 0.02  0.2 ± 0.02  0.3 ± 0.03 
       
BUN (mg/dL)  17.5 ± 0.4  15.4 ± 0.6*  15.7 ± 0.5* 
       
Ca+2 (mg/dL)  10.7 ± 0.09  11.2 ± 00.13*  11.0 ± 0.1 
       
PHOS (mg/dL)  10.2 ± 0.4  8.1 ± 0.2*  7.8 ± 0.2* 
       
CRE (mg/dL)  0.3 ± 0.02  0.4 ± 0.02  0.4 ± 0.03* 
       
GLU (mg/dL)  372.8 ± 16.0  346.9 ± 10.3  323.7 ± 13.3* 
       
Na+ (mmol/L)  141.8 ± 0.9  142.0 ± 0.6  141.1 ± 0.5 
       
K+ (mmol/L)  7.12 ± 0.06  6.4 ± 0.14*  6.0 ± 0.11*  
       
TP (g/dL)  5.8 ± 0.05  6.4 ± 0.08*  6.3 ± 0.11* 
       
GLOB (g/dL)  1.56 ± 0.12  2.00 ± 0.10*  2.12 ± 0.11* 
       
Ca/P (ratio)  1.03 ± 0.12  1.39 ± 0.12*  1.44 ± 0.14* 
       
Na/K (ratio)  19.90 ± 0.66  22.40 ± 1.99*  23.58 ± 1.94* 
       
BUN/CRE (ratio)  68.96 ± 16.1  46.77 ± 16.9*  49.64 ± 17.6* 
       
A/G (ratio)  3.29 ± 0.68  3.32 ± 0.61*  2.14 ± 0.60* 
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FIGURE 4.1 
 
FIGURE 4.1:  STRUCTURAL DIAGRAM OF THE FEMALE F344XBN HEART.    
(Photo credit: Patrick J. Lynch, medical illustrator).   
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FIGURE 4.2 
 
  
FIGURE 4.2:  CSA, TISSUE MORPHOLOGY, AND FIBROSIS IN THE AGING FEMALE F344XBN 
HEART.   
(A) Immunohistochemical staining of cardiac tissue stained with dystrophin.  Bar = 100 
µm. (B) Cross-sectional area of cardiac myocytes as determined by dystrophin staining, (C) 
Hematoxylin and Eosin, and (D) Picrosirius red staining of 6-, 26-, and 30-month female 
F344xBN hearts. (*, p < 0.05) significantly different from 6-month animal.   
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FIGURE 4.3 
 
FIGURE 4.3:  AGE-ASSOCIATED CHANGES IN CONNEXIN 43 DISTRIBUTION IN THE AGING 
FEMALE F344XBN HEART.   
Distribution of connexin 43 in (A) 6-, (B) 26-, and (C) 30-month female F344xBN hearts.  
Bar = 50 µm.   
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FIGURE 4.4 
 
 
 
 
FIGURE 4.4:  EKG IN THE AGING FEMALE F344XBN HEART.   
(A) EKG interval diagram and (B) representative EKG tracing of leads I, II, and III obtained 
from 6- , 26, and 30-month females.    
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FIGURE 4.5 
 
FIGURE 4.5:  AGE-ASSOCIATED VALVE DYSFUNCTION IN THE FEMALE F344XBN HEART.  
Percentage of female F344xBN rats with valve dysfunction at 6-, 26-, and 30-months.   
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SUPPLEMENTAL DATA 
TABLE S-4.1:  REGRESSION ANALYSIS OF THE RELATIONSHIP BETWEEN HEART RHYTHM INTERVALS, AGE, BODY 
WEIGHT, HEART WEIGHT, CONNEXIN 43 EXPRESSION, CARDIOMYOCYTE CROSS SECTIONAL AREA, AND COLLAGEN 
STAINING INTENSITY OF 6-, 26-, AND 30-MONTH FEMALE F344XBN HEARTS.   The following symbols indicate:  (*) 
low correlation (p < 0.05); (†) moderate correlation (p < 0.05); (††) high correlation (p < 0.05); (†††) very high 
correlation (p < 0.05) between parameters.  P values are located within parentheses.  N.A. (not applicable) N.T. (not 
tested).   
 
 
 
 
 
 
Age (m) ALB(g/dl) ALP(u/l) ALT(u/l) AMY(u/l) TBIL(mg/dl) BUN(mg/dl) Ca+2(mg/dl) PHOS(mg/dl) CRE(mg/dl) GLU(mg/dl) Na+(mmol/l)
Age(m) N.T. 0.107  -0.073  0.127  0.389 * 0.216  -0.145  0.276  -0.551 † 0.209  -0.348 * -0.112  
ALB(g/dl) 0.107  N.T. 0.115  0.272  0.108  -0.539 † -0.516 † 0.072  0.000  0.294  0.271  -0.214  
ALP(u/l) -0.073  0.115  N.T. -0.184  0.193  0.039  -0.277  -0.462 * -0.182  0.060  -0.098  -0.037  
ALT(u/l) 0.127  0.272  -0.184  N.T. 0.449 * -0.231  -0.043  -0.069  -0.127  -0.329 * 0.076  -0.439 *
AMY(u/l) 0.389 * 0.108  0.193  0.449 * N.T. -0.071  -0.184  -0.284  -0.537 † 0.027  0.284  -0.663 †
TBIL(mg/dl) 0.216  -0.539 † 0.039  -0.231  -0.071  N.T. 0.399 * 0.033  -0.006  0.029  -0.232  0.151  
BUN(mg/dl) -0.145  -0.516 † -0.277  -0.043  -0.184  0.399 * N.T. -0.240  -0.217  0.109  -0.252  -0.103  
Ca+2(mg/dl) 0.276  0.072  -0.462 * -0.069  -0.284  0.033  -0.240  N.T. 0.477 * 0.146  -0.044  0.493 *
PHOS(mg/dl) -0.551 † 0.000  -0.182  -0.127  -0.537 † -0.006  -0.217  0.477 * N.T. -0.054  0.427 * 0.289  
CRE(mg/dl) 0.209  0.294  0.060  -0.329 * 0.027  0.029  0.109  0.146  -0.054  N.T. 0.262  -0.278  
GLU(mg/dl) -0.348 * 0.271  -0.098  0.076  0.284  -0.232  -0.252  -0.044  0.427 * 0.262  N.T. -0.559 †
Na+(mmol/l) -0.112  -0.214  -0.037  -0.439 * -0.663 † 0.151  -0.103  0.493 * 0.289  -0.278  -0.559 † N.T.
K+(mmol/l) -0.679 † -0.169  -0.074  -0.062  -0.378 * 0.102  -0.181  0.211  0.778 †† -0.184  0.258  0.342 *
TP(g/dl) 0.721 †† 0.551 † 0.109  0.143  0.339 * 0.045  -0.411 * 0.373 * -0.266  0.216  -0.127  -0.027  
GLOB(g/dl) 0.739 †† -0.143  0.070  -0.087  0.308 * 0.491 * -0.102  0.368 * -0.289  0.052  -0.327 * 0.116  
Ca/Phos 0.710 †† 0.036  0.034  0.111  0.518 † 0.055  0.113  -0.130  -0.915 ††† 0.072  -0.411 * -0.131  
Na/K 0.660 † 0.111  0.079  -0.045  0.248  -0.067  0.192  -0.140  -0.741 †† 0.148  -0.337 * -0.176  
E/E' 0.049  0.143  0.441 * -0.273  0.226  0.265  -0.269  -0.172  -0.249  -0.002  -0.077  0.195  
RVDd -0.022  0.129  -0.393 * 0.111  0.031  -0.031  0.100  0.217  0.068  -0.125  -0.173  0.048  
IVSD 0.468 * 0.209  0.285  0.419 * 0.298  -0.027  0.037  -0.062  -0.351 * -0.072  -0.489 * -0.102  
IVSs 0.473 * 0.172  -0.098  0.194  0.302 * -0.251  -0.136  0.062  -0.070  -0.012  0.221  -0.444 *
LVIDd 0.265  0.121  -0.664 † 0.443 * 0.312 * -0.252  -0.133  0.351 * 0.087  -0.231  0.260  -0.322 *
LVIDs -0.135  -0.239  -0.473 * 0.478 * 0.043  0.306 * 0.317 * 0.120  0.338 * -0.446 * 0.117  -0.199  
LVPWd 0.345 * -0.013  -0.068  0.373 * -0.049  0.248  0.291  0.139  -0.310 * -0.357 * -0.518 † 0.296  
LVPWs 0.747 †† 0.172  0.344 * -0.261  0.155  0.225  -0.275  0.031  -0.569 † 0.164  -0.371 * 0.174  
FS% 0.497 * 0.368 * -0.204  -0.031  0.284  -0.595 † -0.481 * 0.226  -0.334 * 0.182  0.093  -0.117  
EDV ml 0.270  0.151  -0.662 † 0.430 * 0.305 * -0.271  -0.162  0.373 * 0.115  -0.175  0.294  -0.336 *
ESV ml -0.203  -0.268  -0.496 * 0.439 * -0.035  0.282  0.305 * 0.089  0.381 * -0.469 * 0.131  -0.175  
EF% 0.540 † 0.402 * -0.135  0.008  0.360 * -0.588 † -0.502 † 0.240  -0.344 * 0.205  0.115  -0.152  
Tricuspid Dysfunction 0.693 † -0.064  0.343 * 0.047  0.197  0.592 † 0.061  -0.004  -0.545 † -0.038  -0.607 † 0.180  
Mitral Dysfunction 0.286  0.202  -0.517 † 0.083  0.213  -0.505 † -0.240  0.316 * 0.069  0.284  0.375 * -0.354 *
Aortic  Dysfunction 0.693 † -0.064  0.343 * 0.047  0.197  0.592 † 0.061  -0.004  -0.545 † -0.038  -0.607 † 0.180  
Pulmonary  Dysfunction 0.874 †† 0.000  0.206  0.084  0.290  0.493 * -0.017  0.110  -0.597 † 0.059  -0.557 † 0.078  
MV E max vel -0.842 †† -0.295  0.169  -0.246  -0.430 * -0.090  0.033  -0.231  0.442 * -0.352 * 0.236  0.329 *
MV A max vel -0.615 † -0.351 * -0.080  -0.357 * -0.182  -0.185  -0.151  0.235  0.598 † -0.061  0.366 * 0.250  
MV E/A -0.127  0.000  0.172  0.038  -0.350 * 0.194  0.373 * -0.683 † -0.555 † -0.268  -0.292  -0.009  
MV Dec time 0.214  -0.605 † -0.310 * -0.537 † -0.008  0.477 * 0.121  0.270  0.103  0.168  -0.011  0.116  
LV IVRT 0.830 †† 0.238  -0.341 * -0.076  0.242  -0.038  -0.265  0.403 * -0.328 * 0.213  -0.212  -0.025  
Body Weight 0.832 †† 0.147  0.066  0.335 * 0.707 †† -0.113  -0.450 * 0.055  -0.514 † -0.007  -0.108  -0.346 *
Heart Weight 0.899 †† 0.188  0.159  0.047  0.271  0.150  -0.235  0.046  -0.618 † 0.023  -0.388 * -0.057  
BW/HW 0.155  0.090  0.055  -0.261  -0.488 * 0.272  0.292  -0.031  -0.209  0.005  -0.392 * 0.298  
Electrical Axis 0.556 † 0.154  -0.582 † 0.242  0.212  0.292  0.213  0.423 * -0.093  -0.050  -0.007  -0.231  
Heart Rate -0.004  0.111  -0.009  -0.117  -0.554 † -0.033  0.260  -0.123  -0.079  0.290  -0.090  0.037  
VAT 0.720 †† 0.660 † 0.010  -0.108  0.279  -0.177  -0.260  0.389 * -0.474 * 0.467 * -0.314 * 0.055  
ST interval 0.673 † 0.307 * -0.303 * 0.071  0.232  -0.184  -0.274  0.371 * -0.136  -0.201  -0.351 * 0.073  
T amplitude 0.231  0.362 * -0.442 * 0.058  0.206  0.096  -0.416 * 0.585 † 0.234  -0.254  0.066  0.195  
QRS Interval 0.823 †† 0.630 † -0.084  -0.151  0.164  -0.095  -0.174  0.447 * -0.381 * 0.487 * -0.260  0.042  
QT Interval 0.823 †† 0.476 * -0.256  -0.008  0.239  -0.173  -0.270  0.450 * -0.252  0.047  -0.361 * 0.070  
PR Interval -0.223  -0.239  0.143  -0.224  -0.151  0.220  0.166  -0.123  0.303 * 0.397 * 0.521 † -0.206  
T duration 0.673 † 0.307 * -0.303 * 0.071  0.232  -0.184  -0.274  0.371 * -0.136  -0.201  -0.351 * 0.073  
T-T Interval 0.025  -0.111  0.000  0.145  0.593 † 0.048  -0.228  0.110  0.033  -0.281  0.091  -0.070  
R + S Amplitude -0.235  -0.230  0.489 * -0.162  0.114  -0.238  -0.327 * -0.264  0.165  -0.055  0.016  0.102  
S Amplitude -0.148  -0.181  -0.564 † 0.122  -0.252  0.468 * 0.416 * 0.063  0.084  -0.386 * 0.028  0.001  
R Amplitude -0.223  -0.239  0.143  -0.224  -0.151  0.220  0.166  -0.123  0.303 * 0.397 * 0.521 † -0.206  
Q Amplitude -0.634 † -0.661 † -0.215  -0.143  -0.529 † 0.260  0.532 † -0.322 * 0.368 * -0.165  0.259  -0.079  
P Amplitude 0.677 † 0.655 † 0.017  0.199  0.400 * -0.362 * -0.173  0.418 * -0.373 * 0.588 † 0.000  -0.194  
P Duration -0.223  -0.239  0.143  -0.224  -0.151  0.220  0.166  -0.123  0.303 * 0.397 * 0.521 † -0.206  
CSA Cardiac Myocytes 0.993 ††† 0.084  -0.007  0.120  0.374 * 0.290  -0.118  0.243  -0.577 † 0.178  -0.408 * -0.068  
fibrosis -0.338 * -0.204  0.512 † -0.089  -0.232  0.485 * 0.244  -0.325 * -0.039  -0.290  -0.351 * 0.354 *
LVM (gm) 0.510 † 0.156  -0.313 * 0.704 †† 0.321 * -0.099  0.081  0.189  -0.293  -0.329 * -0.257  -0.185  
E` -0.635 † -0.408 * -0.238  0.001  -0.405 * -0.242  0.373 * -0.097  0.414 * -0.181  0.254  -0.027  
  84 
 
 
TABLE S-4.2 – S-4.5:  REGRESSION ANALYSIS OF THE RELATIONSHIP BETWEEN STRUCTURAL AND FUNCTIONAL 
ECHOCARDIOGRAPHIC PARAMETERS AGE, BODY WEIGHT, HEART WEIGHT, CARDIOMYOCYTE CROSS SECTIONAL 
AREA, AND COLLAGEN STAINING INTENSITY OF 6-, 26-, AND 30-MONTH FEMALE F344XBN HEARTS.  The following 
symbols indicate:  (*) low correlation (p < 0.05); (†) moderate correlation (p < 0.05); (††) high correlation (p < 0.05); 
(†††) very high correlation (p < 0.05) between parameters.  P values for correlations are located within parentheses.  
    
 
 
 
K+(mmol/l) TP(g/dl) GLOB(g/dl) Ca/Phos Na/K E/E' RVDd IVSD IVSs LVIDd LVIDs LVPWd
Age(m) -0.679 † 0.721 †† 0.739 †† 0.710 †† 0.660 † 0.049  -0.022  0.468 * 0.473 * 0.265  -0.135  0.345 *
ALB(g/dl) -0.169  0.551 † -0.143  0.036  0.111  0.143  0.129  0.209  0.172  0.121  -0.239  -0.013  
ALP(u/l) -0.074  0.109  0.070  0.034  0.079  0.441 * -0.393 * 0.285  -0.098  -0.664 † -0.473 * -0.068  
ALT(u/l) -0.062  0.143  -0.087  0.111  -0.045  -0.273  0.111  0.419 * 0.194  0.443 * 0.478 * 0.373 *
AMY(u/l) -0.378 * 0.339 * 0.308 * 0.518 † 0.248  0.226  0.031  0.298  0.302 * 0.312 * 0.043  -0.049  
TBIL(mg/dl) 0.102  0.045  0.491 * 0.055  -0.067  0.265  -0.031  -0.027  -0.251  -0.252  0.306 * 0.248  
BUN(mg/dl) -0.181  -0.411 * -0.102  0.113  0.192  -0.269  0.100  0.037  -0.136  -0.133  0.317 * 0.291  
Ca+2(mg/dl) 0.211  0.373 * 0.368 * -0.130  -0.140  -0.172  0.217  -0.062  0.062  0.351 * 0.120  0.139  
PHOS(mg/dl) 0.778 †† -0.266  -0.289  -0.915 ††† -0.741 †† -0.249  0.068  -0.351 * -0.070  0.087  0.338 * -0.310 *
CRE(mg/dl) -0.184  0.216  0.052  0.072  0.148  -0.002  -0.125  -0.072  -0.012  -0.231  -0.446 * -0.357 *
GLU(mg/dl) 0.258  -0.127  -0.327 * -0.411 * -0.337 * -0.077  -0.173  -0.489 * 0.221  0.260  0.117  -0.518 †
Na+(mmol/l) 0.342 * -0.027  0.116  -0.131  -0.176  0.195  0.048  -0.102  -0.444 * -0.322 * -0.199  0.296  
K+(mmol/l) N.T. -0.458 * -0.366 * -0.785 †† -0.982 ††† -0.015  0.114  -0.485 * -0.596 † -0.250  0.172  -0.365 *
TP(g/dl) -0.458 * N.T. 0.742 †† 0.463 * 0.447 * 0.151  0.263  0.279  0.299  0.250  -0.057  0.308 *
GLOB(g/dl) -0.366 * 0.742 †† N.T. 0.483 * 0.393 * 0.076  0.239  0.115  0.192  0.173  0.109  0.293  
Ca/Phos -0.785 †† 0.463 * 0.483 * N.T. 0.777 †† 0.336 * -0.042  0.337 * 0.110  0.055  -0.315 * 0.455 *
Na/K -0.982 ††† 0.447 * 0.393 * 0.777 †† N.T. 0.040  -0.154  0.452 * 0.554 † 0.190  -0.216  0.435 *
E/E' -0.015  0.151  0.076  0.336 * 0.040  N.T. -0.243  0.089  -0.394 * -0.409 * -0.395 * 0.087  
RVDd 0.114  0.263  0.239  -0.042  -0.154  -0.243  N.T. -0.132  -0.123  0.322 * 0.422 * -0.072  
IVSD -0.485 * 0.279  0.115  0.337 * 0.452 * 0.089  -0.132  N.T. 0.340 * 0.037  0.015  0.491 *
IVSs -0.596 † 0.299  0.192  0.110  0.554 † -0.394 * -0.123  0.340 * N.T. 0.408 * 0.070  0.138  
LVIDd -0.250  0.250  0.173  0.055  0.190  -0.409 * 0.322 * 0.037  0.408 * N.T. 0.622 † -0.017  
LVIDs 0.172  -0.057  0.109  -0.315 * -0.216  -0.395 * 0.422 * 0.015  0.070  0.622 † N.T. 0.166  
LVPWd -0.365 * 0.308 * 0.293  0.455 * 0.435 * 0.087  -0.072  0.491 * 0.138  -0.017  0.166  N.T.
LVPWs -0.613 † 0.596 † 0.544 † 0.694 † 0.666 † 0.494 * -0.348 * 0.355 * 0.307 * -0.236  -0.553 † 0.387 *
FS% -0.507 † 0.348 * 0.101  0.462 * 0.493 * 0.002  -0.109  0.058  0.398 * 0.436 * -0.430 * -0.160  
EDV ml -0.228  0.271  0.178  0.024  0.165  -0.449 * 0.332 * 0.002  0.419 * 0.996 ††† 0.600 † -0.062  
ESV ml 0.240  -0.136  0.042  -0.388 * -0.282  -0.429 * 0.422 * -0.060  0.032  0.610 † 0.991 ††† 0.088  
EF% -0.543 † 0.416 * 0.154  0.490 * 0.526 † 0.015  -0.142  0.115  0.455 * 0.413 * -0.445 * -0.106  
Tricuspid Dysfunction -0.421 * 0.604 † 0.745 †† 0.625 † 0.455 * 0.330 * -0.032  0.439 * 0.106  -0.313 * -0.148  0.638 †
Mitral Dysfunction -0.232  0.047  -0.110  0.008  0.168  -0.378 * 0.018  -0.046  0.398 * 0.712 †† 0.040  -0.447 *
Aortic  Dysfunction -0.421 * 0.604 † 0.745 †† 0.625 † 0.455 * 0.330 * -0.032  0.439 * 0.106  -0.313 * -0.148  0.638 †
Pulmonary  Dysfunction -0.564 † 0.707 †† 0.811 †† 0.717 †† 0.580 † 0.247  -0.031  0.488 * 0.260  -0.110  -0.155  0.576 †
MV E max vel 0.582 † -0.738 †† -0.637 † -0.519 † -0.504 † 0.203  -0.370 * -0.418 * -0.501 † -0.298  -0.008  -0.169  
MV A max vel 0.687 † -0.484 * -0.241  -0.568 † -0.649 † -0.177  0.084  -0.695 † -0.292  -0.087  -0.043  -0.580 †
MV E/A -0.301 * -0.190  -0.276  0.306 * 0.317 * 0.314 * -0.284  0.133  -0.195  -0.350 * -0.051  0.451 *
MV Dec time 0.156  -0.099  0.411 * -0.029  -0.140  -0.081  0.218  -0.445 * -0.002  0.088  0.053  -0.422 *
LV IVRT -0.546 † 0.614 † 0.524 † 0.503 † 0.528 † -0.028  0.217  0.258  0.569 † 0.382 * -0.175  0.083  
Body Weight -0.527 † 0.509 † 0.474 * 0.600 † 0.450 * 0.132  -0.105  0.496 * 0.474 * 0.382 * -0.142  0.056  
Heart Weight -0.770 †† 0.771 †† 0.736 †† 0.703 †† 0.785 †† 0.083  -0.043  0.422 * 0.486 * 0.192  -0.168  0.403 *
BW/HW -0.385 * 0.377 * 0.350 * 0.198  0.483 * -0.119  0.163  -0.022  0.064  -0.141  0.026  0.474 *
Electrical Axis -0.488 * 0.509 † 0.607 † 0.301 * 0.487 * -0.273  0.535 † 0.196  0.699 † 0.710 †† 0.468 * 0.456 *
Heart Rate -0.142  0.109  0.068  -0.050  0.187  -0.423 * -0.048  -0.344 * -0.200  -0.063  -0.001  -0.005  
VAT -0.704 †† 0.784 †† 0.627 † 0.709 †† 0.724 †† 0.323 * -0.012  0.346 * 0.252  0.167  -0.396 * 0.313 *
ST interval -0.458 * 0.403 * 0.320 * 0.317 * 0.451 * 0.133  0.251  0.524 † 0.554 † 0.618 † 0.159  0.218  
T amplitude 0.027  0.501 † 0.474 * -0.005  -0.038  0.195  0.522 † -0.085  -0.180  0.688 † 0.481 * -0.141  
QRS Interval -0.708 †† 0.819 †† 0.706 †† 0.607 † 0.735 †† 0.088  0.114  0.286  0.490 * 0.162  -0.322 * 0.366 *
QT Interval -0.618 † 0.622 † 0.516 † 0.474 * 0.624 † 0.133  0.230  0.499 * 0.604 † 0.517 † -0.015  0.309 *
PR Interval 0.474 * -0.195  -0.018  -0.460 * -0.501 † -0.307 * 0.213  -0.669 † -0.480 * -0.261  0.066  -0.614 †
T duration -0.458 * 0.403 * 0.320 * 0.317 * 0.451 * 0.133  0.251  0.524 † 0.554 † 0.618 † 0.159  0.218  
T-T Interval 0.110  -0.093  -0.048  0.103  -0.158  0.432 * 0.046  0.348 * 0.200  0.058  -0.004  0.046  
R + S Amplitude 0.429 * -0.505 † -0.529 † -0.295  -0.449 * 0.271  -0.375 * 0.159  -0.098  -0.538 † -0.464 * -0.398 *
S Amplitude -0.066  0.109  0.274  -0.049  0.085  -0.080  0.337 * -0.289  -0.339 * 0.557 † 0.647 † -0.001  
R Amplitude 0.474 * -0.195  -0.018  -0.460 * -0.501 † -0.307 * 0.213  -0.669 † -0.480 * -0.261  0.066  -0.614 †
Q Amplitude 0.416 * -0.632 † -0.407 * -0.609 † -0.409 * -0.615 † 0.144  -0.541 † -0.087  -0.069  0.394 * -0.312 *
P Amplitude -0.562 † 0.628 † 0.390 * 0.596 † 0.551 † 0.129  -0.242  0.387 * 0.206  0.128  -0.370 * 0.332 *
P Duration 0.474 * -0.195  -0.018  -0.460 * -0.501 † -0.307 * 0.213  -0.669 † -0.480 * -0.261  0.066  -0.614 †
CSA Cardiac Myocytes -0.669 † 0.737 †† 0.777 †† 0.731 †† 0.659 † 0.099  -0.025  0.485 * 0.433 * 0.179  -0.144  0.411 *
fibrosis 0.264  -0.084  0.069  -0.046  -0.200  0.313 * -0.016  0.020  -0.418 * -0.716 †† -0.033  0.422 *
LVM (gm) -0.534 † 0.261  0.427 * 0.412 * 0.501 † -0.613 † 0.651 † 0.433 * 0.652 † 0.479 * 0.641 † 0.128  
E` 0.288  -0.111  0.126  -0.548 † -0.257  -0.039  0.142  0.324 * -0.202  -0.715 †† -0.235  0.147  
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TABLE S-4.3:   
 
LVPWs FS% EDV ml ESV ml EF%
Tricuspid 
Dysfunction
Mitral 
Dysfunction
Aortic  
Dysfunction
Pulmonary  
Dysfunction MV E max vel MV A max vel MV E/A
Age(m) 0.747 †† 0.497 * 0.270  -0.203  0.540 † 0.693 † 0.286  0.693 † 0.874 †† -0.842 †† -0.615 † -0.127  
ALB(g/dl) 0.172  0.368 * 0.151  -0.268  0.402 * -0.064  0.202  -0.064  0.000  -0.295  -0.351 * 0.000  
ALP(u/l) 0.344 * -0.204  -0.662 † -0.496 * -0.135  0.343 * -0.517 † 0.343 * 0.206  0.169  -0.080  0.172  
ALT(u/l) -0.261  -0.031  0.430 * 0.439 * 0.008  0.047  0.083  0.047  0.084  -0.246  -0.357 * 0.038  
AMY(u/l) 0.155  0.284  0.305 * -0.035  0.360 * 0.197  0.213  0.197  0.290  -0.430 * -0.182  -0.350 *
TBIL(mg/dl) 0.225  -0.595 † -0.271  0.282  -0.588 † 0.592 † -0.505 † 0.592 † 0.493 * -0.090  -0.185  0.194  
BUN(mg/dl) -0.275  -0.481 * -0.162  0.305 * -0.502 † 0.061  -0.240  0.061  -0.017  0.033  -0.151  0.373 *
Ca+2(mg/dl) 0.031  0.226  0.373 * 0.089  0.240  -0.004  0.316 * -0.004  0.110  -0.231  0.235  -0.683 †
PHOS(mg/dl) -0.569 † -0.334 * 0.115  0.381 * -0.344 * -0.545 † 0.069  -0.545 † -0.597 † 0.442 * 0.598 † -0.555 †
CRE(mg/dl) 0.164  0.182  -0.175  -0.469 * 0.205  -0.038  0.284  -0.038  0.059  -0.352 * -0.061  -0.268  
GLU(mg/dl) -0.371 * 0.093  0.294  0.131  0.115  -0.607 † 0.375 * -0.607 † -0.557 † 0.236  0.366 * -0.292  
Na+(mmol/l) 0.174  -0.117  -0.336 * -0.175  -0.152  0.180  -0.354 * 0.180  0.078  0.329 * 0.250  -0.009  
K+(mmol/l) -0.613 † -0.507 † -0.228  0.240  -0.543 † -0.421 * -0.232  -0.421 * -0.564 † 0.582 † 0.687 † -0.301 *
TP(g/dl) 0.596 † 0.348 * 0.271  -0.136  0.416 * 0.604 † 0.047  0.604 † 0.707 †† -0.738 †† -0.484 * -0.190  
GLOB(g/dl) 0.544 † 0.101  0.178  0.042  0.154  0.745 †† -0.110  0.745 †† 0.811 †† -0.637 † -0.241  -0.276  
Ca/Phos 0.694 † 0.462 * 0.024  -0.388 * 0.490 * 0.625 † 0.008  0.625 † 0.717 †† -0.519 † -0.568 † 0.306 *
Na/K 0.666 † 0.493 * 0.165  -0.282  0.526 † 0.455 * 0.168  0.455 * 0.580 † -0.504 † -0.649 † 0.317 *
E/E' 0.494 * 0.002  -0.449 * -0.429 * 0.015  0.330 * -0.378 * 0.330 * 0.247  0.203  -0.177  0.314 *
RVDd -0.348 * -0.109  0.332 * 0.422 * -0.142  -0.032  0.018  -0.032  -0.031  -0.370 * 0.084  -0.284  
IVSD 0.355 * 0.058  0.002  -0.060  0.115  0.439 * -0.046  0.439 * 0.488 * -0.418 * -0.695 † 0.133  
IVSs 0.307 * 0.398 * 0.419 * 0.032  0.455 * 0.106  0.398 * 0.106  0.260  -0.501 † -0.292  -0.195  
LVIDd -0.236  0.436 * 0.996 ††† 0.610 † 0.413 * -0.313 * 0.712 †† -0.313 * -0.110  -0.298  -0.087  -0.350 *
LVIDs -0.553 † -0.430 * 0.600 † 0.991 ††† -0.445 * -0.148  0.040  -0.148  -0.155  -0.008  -0.043  -0.051  
LVPWd 0.387 * -0.160  -0.062  0.088  -0.106  0.638 † -0.447 * 0.638 † 0.576 † -0.169  -0.580 † 0.451 *
LVPWs N.T. 0.407 * -0.245  -0.606 † 0.453 * 0.747 †† -0.135  0.747 †† 0.811 †† -0.443 * -0.560 † 0.253  
FS% 0.407 * N.T. 0.451 * -0.436 * 0.990 ††† -0.137  0.744 †† -0.137  0.103  -0.351 * -0.095  -0.286  
EDV ml -0.245  0.451 * N.T. 0.591 † 0.430 * -0.329 * 0.739 †† -0.329 * -0.119  -0.325 * -0.062  -0.396 *
ESV ml -0.606 † -0.436 * 0.591 † N.T. -0.465 * -0.219  0.059  -0.219  -0.231  0.053  0.019  -0.036  
EF% 0.453 * 0.990 ††† 0.430 * -0.465 * N.T. -0.071  0.706 †† -0.071  0.165  -0.392 * -0.123  -0.315 *
Tricuspid Dysfunction 0.747 †† -0.137  -0.329 * -0.219  -0.071  N.T. -0.492 * 1.000 ††† 0.956 ††† -0.520 † -0.608 † 0.316 *
Mitral Dysfunction -0.135  0.744 †† 0.739 †† 0.059  0.706 †† -0.492 * N.T. -0.492 * -0.215  -0.272  0.101  -0.529 †
Aortic  Dysfunction 0.747 †† -0.137  -0.329 * -0.219  -0.071  1.000 ††† -0.492 * N.T. 0.956 ††† -0.520 † -0.608 † 0.316 *
Pulmonary  Dysfunction 0.811 †† 0.103  -0.119  -0.231  0.165  0.956 ††† -0.215  0.956 ††† N.T. -0.692 † -0.663 † 0.174  
MV E max vel -0.443 * -0.351 * -0.325 * 0.053  -0.392 * -0.520 † -0.272  -0.520 † -0.692 † N.T. 0.552 † 0.320 *
MV A max vel -0.560 † -0.095  -0.062  0.019  -0.123  -0.608 † 0.101  -0.608 † -0.663 † 0.552 † N.T. -0.571 †
MV E/A 0.253  -0.286  -0.396 * -0.036  -0.315 * 0.316 * -0.529 † 0.316 * 0.174  0.320 * -0.571 † N.T.
MV Dec time 0.030  0.041  0.106  0.084  -0.005  0.020  0.217  0.020  0.098  -0.193  0.397 * -0.462 *
LV IVRT 0.605 † 0.665 † 0.397 * -0.209  0.667 † 0.351 * 0.481 * 0.351 * 0.571 † -0.805 †† -0.389 * -0.312 *
Body Weight 0.551 † 0.680 † 0.381 * -0.192  0.729 †† 0.409 * 0.418 * 0.409 * 0.618 † -0.673 † -0.477 * -0.250  
Heart Weight 0.808 †† 0.501 † 0.193  -0.221  0.552 † 0.754 †† 0.057  0.754 †† 0.882 †† -0.715 †† -0.752 †† 0.161  
BW/HW 0.317 * -0.172  -0.140  0.017  -0.171  0.454 * -0.400 * 0.454 * 0.374 * -0.157  -0.443 * 0.517 †
Electrical Axis 0.272  0.229  0.704 †† 0.397 * 0.262  0.323 * 0.258  0.323 * 0.447 * -0.682 † -0.470 * -0.090  
Heart Rate -0.114  -0.091  -0.025  0.044  -0.124  -0.002  -0.002  -0.002  -0.003  0.071  -0.087  0.321 *
VAT 0.768 †† 0.738 †† 0.172  -0.471 * 0.798 †† 0.456 * 0.255  0.456 * 0.613 † -0.589 † -0.598 † -0.067  
ST interval 0.406 * 0.611 † 0.588 † 0.116  0.611 † 0.194  0.516 † 0.194  0.415 * -0.479 * -0.491 * -0.136  
T amplitude -0.139  0.244  0.673 † 0.474 * 0.199  -0.127  0.410 * -0.127  0.011  -0.059  -0.022  -0.326 *
QRS Interval 0.764 †† 0.634 † 0.181  -0.393 * 0.701 †† 0.560 † 0.244  0.560 † 0.727 †† -0.727 †† -0.595 † -0.092  
QT Interval 0.608 † 0.705 †† 0.503 † -0.076  0.732 †† 0.366 * 0.478 * 0.366 * 0.595 † -0.646 † -0.601 † -0.138  
PR Interval -0.572 † -0.470 * -0.206  0.119  -0.493 * -0.193  -0.016  -0.193  -0.225  0.226  0.644 † -0.279  
T duration 0.406 * 0.611 † 0.588 † 0.116  0.611 † 0.194  0.516 † 0.194  0.415 * -0.479 * -0.491 * -0.136  
T-T Interval 0.133  0.092  0.018  -0.054  0.130  0.036  -0.015  0.036  0.035  -0.091  0.057  -0.297  
R + S Amplitude -0.021  -0.089  -0.542 † -0.434 * -0.083  -0.132  -0.104  -0.132  -0.189  0.288  0.420 * -0.229  
S Amplitude -0.387 * -0.129  0.536 † 0.665 † -0.198  -0.257  0.143  -0.257  -0.237  0.218  -0.049  0.325 *
R Amplitude -0.572 † -0.470 * -0.206  0.119  -0.493 * -0.193  -0.016  -0.193  -0.225  0.226  0.644 † -0.279  
Q Amplitude -0.674 † -0.611 † -0.051  0.480 * -0.692 † -0.459 * -0.155  -0.459 * -0.579 † 0.372 * 0.471 * 0.148  
P Amplitude 0.507 † 0.624 † 0.144  -0.458 * 0.721 †† 0.345 * 0.340 * 0.345 * 0.519 † -0.484 * -0.461 * -0.225  
P Duration -0.572 † -0.470 * -0.206  0.119  -0.493 * -0.193  -0.016  -0.193  -0.225  0.226  0.644 † -0.279  
CSA Cardiac Myocytes 0.782 †† 0.413 * 0.181  -0.215  0.461 * 0.773 †† 0.172  0.773 †† 0.925 ††† -0.827 †† -0.643 † -0.055  
fibrosis 0.092  -0.760 †† -0.743 †† -0.047  -0.724 †† 0.444 * -0.999 ††† 0.444 * 0.161  0.313 * -0.067  0.528 †
LVM (gm) 0.236  0.618 † 0.408 * 0.270  0.977 ††† 0.243  0.255  0.378 * 0.378 * -0.613 † 0.059  -0.370 *
E` 0.388 * -0.274  -0.052  -0.667 † 0.156  -0.711 †† 0.574 † 0.517 † -0.711 †† -0.039  -0.579 † 0.597 †
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TABLE S-4.4: 
 
 
 
MV Dec time LV IVRT Body Weight Heart Weight HW/BW Electrical Axis Heart Rate VAT ST interval T amplitude QRS Interval QT Interval PR Interval
Age(m) 0.214  0.830 †† 0.832 †† 0.899 †† 0.155  0.556 † -0.004  0.720 †† 0.673 † 0.231  0.823 †† 0.823 †† -0.223  
ALB(g/dl) -0.605 † 0.238  0.147  0.188  0.090  0.154  0.111  0.660 † 0.307 * 0.362 * 0.630 † 0.476 * -0.239  
ALP(u/l) -0.310 * -0.341 * 0.066  0.159  0.055  -0.582 † -0.009  0.010  -0.303 * -0.442 * -0.084  -0.256  0.143  
ALT(u/l) -0.537 † -0.076  0.335 * 0.047  -0.261  0.242  -0.117  -0.108  0.071  0.058  -0.151  -0.008  -0.224  
AMY(u/l) -0.008  0.242  0.707 †† 0.271  -0.488 * 0.212  -0.554 † 0.279  0.232  0.206  0.164  0.239  -0.151  
TBIL(mg/dl) 0.477 * -0.038  -0.113  0.150  0.272  0.292  -0.033  -0.177  -0.184  0.096  -0.095  -0.173  0.220  
BUN(mg/dl) 0.121  -0.265  -0.450 * -0.235  0.292  0.213  0.260  -0.260  -0.274  -0.416 * -0.174  -0.270  0.166  
Ca+2(mg/dl) 0.270  0.403 * 0.055  0.046  -0.031  0.423 * -0.123  0.389 * 0.371 * 0.585 † 0.447 * 0.450 * -0.123  
PHOS(mg/dl) 0.103  -0.328 * -0.514 † -0.618 † -0.209  -0.093  -0.079  -0.474 * -0.136  0.234  -0.381 * -0.252  0.303 *
CRE(mg/dl) 0.168  0.213  -0.007  0.023  0.005  -0.050  0.290  0.467 * -0.201  -0.254  0.487 * 0.047  0.397 *
GLU(mg/dl) -0.011  -0.212  -0.108  -0.388 * -0.392 * -0.007  -0.090  -0.314 * -0.351 * 0.066  -0.260  -0.361 * 0.521 †
Na+(mmol/l) 0.116  -0.025  -0.346 * -0.057  0.298  -0.231  0.037  0.055  0.073  0.195  0.042  0.070  -0.206  
K+(mmol/l) 0.156  -0.546 † -0.527 † -0.770 †† -0.385 * -0.488 * -0.142  -0.704 †† -0.458 * 0.027  -0.708 †† -0.618 † 0.474 *
TP(g/dl) -0.099  0.614 † 0.509 † 0.771 †† 0.377 * 0.509 † 0.109  0.784 †† 0.403 * 0.501 † 0.819 †† 0.622 † -0.195  
GLOB(g/dl) 0.411 * 0.524 † 0.474 * 0.736 †† 0.350 * 0.607 † 0.068  0.627 † 0.320 * 0.474 * 0.706 †† 0.516 † -0.018  
Ca/Phos -0.029  0.503 † 0.600 † 0.703 †† 0.198  0.301 * -0.050  0.709 †† 0.317 * -0.005  0.607 † 0.474 * -0.460 *
Na/K -0.140  0.528 † 0.450 * 0.785 †† 0.483 * 0.487 * 0.187  0.724 †† 0.451 * -0.038  0.735 †† 0.624 † -0.501 †
E/E' -0.081  -0.028  0.132  0.083  -0.119  -0.273  -0.423 * 0.323 * 0.133  0.195  0.088  0.133  -0.307 *
RVDd 0.218  0.217  -0.105  -0.043  0.163  0.535 † -0.048  -0.012  0.251  0.522 † 0.114  0.230  0.213  
IVSD -0.445 * 0.258  0.496 * 0.422 * -0.022  0.196  -0.344 * 0.346 * 0.524 † -0.085  0.286  0.499 * -0.669 †
IVSs -0.002  0.569 † 0.474 * 0.486 * 0.064  0.699 † -0.200  0.252  0.554 † -0.180  0.490 * 0.604 † -0.480 *
LVIDd 0.088  0.382 * 0.382 * 0.192  -0.141  0.710 †† -0.063  0.167  0.618 † 0.688 † 0.162  0.517 † -0.261  
LVIDs 0.053  -0.175  -0.142  -0.168  0.026  0.468 * -0.001  -0.396 * 0.159  0.481 * -0.322 * -0.015  0.066  
LVPWd -0.422 * 0.083  0.056  0.403 * 0.474 * 0.456 * -0.005  0.313 * 0.218  -0.141  0.366 * 0.309 * -0.614 †
LVPWs 0.030  0.605 † 0.551 † 0.808 †† 0.317 * 0.272  -0.114  0.768 †† 0.406 * -0.139  0.764 †† 0.608 † -0.572 †
FS% 0.041  0.665 † 0.680 † 0.501 † -0.172  0.229  -0.091  0.738 †† 0.611 † 0.244  0.634 † 0.705 †† -0.470 *
EDV ml 0.106  0.397 * 0.381 * 0.193  -0.140  0.704 †† -0.025  0.172  0.588 † 0.673 † 0.181  0.503 † -0.206  
ESV ml 0.084  -0.209  -0.192  -0.221  0.017  0.397 * 0.044  -0.471 * 0.116  0.474 * -0.393 * -0.076  0.119  
EF% -0.005  0.667 † 0.729 †† 0.552 † -0.171  0.262  -0.124  0.798 †† 0.611 † 0.199  0.701 †† 0.732 †† -0.493 *
Tricuspid Dysfunction 0.020  0.351 * 0.409 * 0.754 †† 0.454 * 0.323 * -0.002  0.456 * 0.194  -0.127  0.560 † 0.366 * -0.193  
Mitral Dysfunction 0.217  0.481 * 0.418 * 0.057  -0.400 * 0.258  -0.002  0.255  0.516 † 0.410 * 0.244  0.478 * -0.016  
Aortic  Dysfunction 0.020  0.351 * 0.409 * 0.754 †† 0.454 * 0.323 * -0.002  0.456 * 0.194  -0.127  0.560 † 0.366 * -0.193  
Pulmonary  Dysfunction 0.098  0.571 † 0.618 † 0.882 †† 0.374 * 0.447 * -0.003  0.613 † 0.415 * 0.011  0.727 †† 0.595 † -0.225  
MV E max vel -0.193  -0.805 †† -0.673 † -0.715 †† -0.157  -0.682 † 0.071  -0.589 † -0.479 * -0.059  -0.727 †† -0.646 † 0.226  
MV A max vel 0.397 * -0.389 * -0.477 * -0.752 †† -0.443 * -0.470 * -0.087  -0.598 † -0.491 * -0.022  -0.595 † -0.601 † 0.644 †
MV E/A -0.462 * -0.312 * -0.250  0.161  0.517 † -0.090  0.321 * -0.067  -0.136  -0.326 * -0.092  -0.138  -0.279  
MV Dec time N.T. 0.359 * 0.114  0.019  -0.148  0.219  -0.188  -0.118  0.081  0.149  0.001  0.059  0.329 *
LV IVRT 0.359 * N.T. 0.682 † 0.683 † 0.071  0.677 † -0.260  0.676 † 0.763 †† 0.204  0.783 †† 0.876 †† -0.523 †
Body Weight 0.114  0.682 † N.T. 0.684 † -0.322 * 0.344 * -0.434 * 0.565 † 0.635 † 0.178  0.464 * 0.653 † -0.533 †
Heart Weight 0.019  0.683 † 0.684 † N.T. 0.463 * 0.501 † 0.158  0.761 †† 0.507 † 0.108  0.806 †† 0.699 † -0.444 *
BW/HW -0.148  0.071  -0.322 * 0.463 * N.T. 0.450 * 0.674 † 0.308 * -0.033  -0.030  0.476 * 0.170  0.020  
Electrical Axis 0.219  0.677 † 0.344 * 0.501 † 0.450 * N.T. -0.145  0.415 * 0.610 † 0.264  0.634 † 0.684 † -0.387 *
Heart Rate -0.188  -0.260  -0.434 * 0.158  0.674 † -0.145  N.T. 0.016  -0.375 * 0.004  0.117  -0.230  0.554 †
VAT -0.118  0.676 † 0.565 † 0.761 †† 0.308 * 0.415 * 0.016  N.T. 0.486 * 0.222  0.910 ††† 0.720 †† -0.415 *
ST interval 0.081  0.763 †† 0.635 † 0.507 † -0.033  0.610 † -0.375 * 0.486 * N.T. 0.589 † 0.509 † 0.939 ††† -0.531 †
T amplitude 0.149  0.204  0.178  0.108  -0.030  0.264  0.004  0.222  0.589 † N.T. 0.141  0.490 * 0.072  
QRS Interval 0.001  0.783 †† 0.464 * 0.806 †† 0.476 * 0.634 † 0.117  0.910 ††† 0.509 † 0.141  N.T. 0.773 †† -0.297  
QT Interval 0.059  0.876 †† 0.653 † 0.699 † 0.170  0.684 † -0.230  0.720 †† 0.939 ††† 0.490 * 0.773 †† N.T. -0.510 †
PR Interval 0.329 * -0.523 † -0.533 † -0.444 * 0.020  -0.387 * 0.554 † -0.415 * -0.531 † 0.072  -0.297  -0.510 † N.T.
T duration 0.081  0.763 †† 0.635 † 0.507 † -0.033  0.610 † -0.375 * 0.486 * 1.000 ††† 0.589 † 0.509 † 0.939 ††† -0.531 †
T-T Interval 0.173  0.263  0.447 * -0.140  -0.664 † 0.165  -0.998 ††† 0.005  0.362 * -0.024  -0.097  0.228  -0.561 †
R + S Amplitude 0.085  -0.171  0.094  -0.420 * -0.668 † -0.605 † -0.540 † -0.387 * -0.129  -0.380 * -0.443 * -0.271  0.015  
S Amplitude 0.003  -0.245  -0.261  -0.022  0.304 * 0.150  0.436 * -0.034  0.104  0.707 †† -0.122  0.028  0.208  
R Amplitude 0.329 * -0.523 † -0.533 † -0.444 * 0.020  -0.387 * 0.554 † -0.415 * -0.531 † 0.208  -0.297  -0.510 † 1.000 †††
Q Amplitude 0.322 * -0.472 * -0.712 †† -0.513 † 0.166  -0.127  0.379 * -0.776 †† -0.539 † 0.456 * -0.594 † -0.634 † 0.456 *
P Amplitude -0.357 * 0.399 * 0.512 † 0.501 † 0.049  0.199  0.109  0.805 †† 0.259  -0.746 †† 0.730 †† 0.482 * -0.148  
P Duration 0.329 * -0.523 † -0.533 † -0.444 * 0.020  -0.387 * 0.554 † -0.415 * -0.531 † -0.148  -0.297  -0.510 † 1.000 †††
CSA Cardiac Myocytes 0.191  0.788 †† 0.802 †† 0.919 ††† 0.212  0.543 † -0.004  0.715 †† 0.630 † -0.645 † 0.823 †† 0.792 †† -0.230  
fibrosis -0.225  -0.518 † -0.455 * -0.104  0.385 * -0.285  0.002  -0.287  -0.541 † -0.225  -0.282  -0.511 † 0.028  
LVM (gm) 0.332 * 0.140  0.465 * 0.093  0.672 † -0.105  0.343 * 0.593 † 0.288  -0.266  0.564 † -0.626 † 0.593 †
E` -0.100  -0.604 † -0.254  0.427 * -0.675 † -0.465 * -0.216  -0.604 † -0.586 † 0.098  -0.465 * -0.445 * -0.454 *
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TABLE S-4.5: 
 
 
 
 
T duration T-T Interval R + S Amplitude S Amplitude R Amplitude Q Amplitude P Amplitude P Duration
CSA Cardiac 
Myocytes fibrosis LVM (gm) E`
Age(m) 0.673 † 0.025  -0.235  -0.148  -0.223  -0.634 † 0.677 † -0.223  0.993 ††† -0.338 * 0.510 † -0.635 †
ALB(g/dl) 0.307 * -0.111  -0.230  -0.181  -0.239  -0.661 † 0.655 † -0.239  0.084  -0.204  0.156  -0.408 *
ALP(u/l) -0.303 * 0.000  0.489 * -0.564 † 0.143  -0.215  0.017  0.143  -0.007  0.512 † -0.313 * -0.238  
ALT(u/l) 0.071  0.145  -0.162  0.122  -0.224  -0.143  0.199  -0.224  0.120  -0.089  0.704 †† 0.001  
AMY(u/l) 0.232  0.593 † 0.114  -0.252  -0.151  -0.529 † 0.400 * -0.151  0.374 * -0.232  0.321 * -0.405 *
TBIL(mg/dl) -0.184  0.048  -0.238  0.468 * 0.220  0.260  -0.362 * 0.220  0.290  0.485 * -0.099  -0.242  
BUN(mg/dl) -0.274  -0.228  -0.327 * 0.416 * 0.166  0.532 † -0.173  0.166  -0.118  0.244  0.081  0.373 *
Ca+2(mg/dl) 0.371 * 0.110  -0.264  0.063  -0.123  -0.322 * 0.418 * -0.123  0.243  -0.325 * 0.189  -0.097  
PHOS(mg/dl) -0.136  0.033  0.165  0.084  0.303 * 0.368 * -0.373 * 0.303 * -0.577 † -0.039  -0.293  0.414 *
CRE(mg/dl) -0.201  -0.281  -0.055  -0.386 * 0.397 * -0.165  0.588 † 0.397 * 0.178  -0.290  -0.329 * -0.181  
GLU(mg/dl) -0.351 * 0.091  0.016  0.028  0.521 † 0.259  0.000  0.521 † -0.408 * -0.351 * -0.257  0.254  
Na+(mmol/l) 0.073  -0.070  0.102  0.001  -0.206  -0.079  -0.194  -0.206  -0.068  0.354 * -0.185  -0.027  
K+(mmol/l) -0.458 * 0.110  0.429 * -0.066  0.474 * 0.416 * -0.562 † 0.474 * -0.669 † 0.264  -0.534 † 0.288  
TP(g/dl) 0.403 * -0.093  -0.505 † 0.109  -0.195  -0.632 † 0.628 † -0.195  0.737 †† -0.084  0.261  -0.111  
GLOB(g/dl) 0.320 * -0.048  -0.529 † 0.274  -0.018  -0.407 * 0.390 * -0.018  0.777 †† 0.069  0.427 * 0.126  
Ca/Phos 0.317 * 0.103  -0.295  -0.049  -0.460 * -0.609 † 0.596 † -0.460 * 0.731 †† -0.046  0.412 * -0.548 †
Na/K 0.451 * -0.158  -0.449 * 0.085  -0.501 † -0.409 * 0.551 † -0.501 † 0.659 † -0.200  0.501 † -0.257  
E/E' 0.133  0.432 * 0.271  -0.080  -0.307 * -0.615 † 0.129  -0.307 * 0.099  0.313 * -0.613 † -0.039  
RVDd 0.251  0.046  -0.375 * 0.337 * 0.213  0.144  -0.242  0.213  -0.025  -0.016  0.651 † 0.142  
IVSD 0.524 † 0.348 * 0.159  -0.289  -0.669 † -0.541 † 0.387 * -0.669 † 0.485 * 0.020  0.433 * 0.324 *
IVSs 0.554 † 0.200  -0.098  -0.339 * -0.480 * -0.087  0.206  -0.480 * 0.433 * -0.418 * 0.652 † -0.202  
LVIDd 0.618 † 0.058  -0.538 † 0.557 † -0.261  -0.069  0.128  -0.261  0.179  -0.716 †† 0.479 * -0.715 ††
LVIDs 0.159  -0.004  -0.464 * 0.647 † 0.066  0.394 * -0.370 * 0.066  -0.144  -0.033  0.641 † -0.235  
LVPWd 0.218  0.046  -0.398 * -0.001  -0.614 † -0.312 * 0.332 * -0.614 † 0.411 * 0.422 * 0.128  0.147  
LVPWs 0.406 * 0.133  -0.021  -0.387 * -0.572 † -0.674 † 0.507 † -0.572 † 0.782 †† 0.092  0.236  0.388 *
FS% 0.611 † 0.092  -0.089  -0.129  -0.470 * -0.611 † 0.624 † -0.470 * 0.413 * -0.760 †† 0.618 † -0.274  
EDV ml 0.588 † 0.018  -0.542 † 0.536 † -0.206  -0.051  0.144  -0.206  0.181  -0.743 †† 0.408 * -0.052  
ESV ml 0.116  -0.054  -0.434 * 0.665 † 0.119  0.480 * -0.458 * 0.119  -0.215  -0.047  0.270  -0.667 †
EF% 0.611 † 0.130  -0.083  -0.198  -0.493 * -0.692 † 0.721 †† -0.493 * 0.461 * -0.724 †† 0.977 ††† 0.156  
Tricuspid Dysfunction 0.194  0.036  -0.132  -0.257  -0.193  -0.459 * 0.345 * -0.193  0.773 †† 0.444 * 0.243  -0.711 ††
Mitral Dysfunction 0.516 † -0.015  -0.104  0.143  -0.016  -0.155  0.340 * -0.016  0.172  -0.999 ††† 0.255  0.574 †
Aortic  Dysfunction 0.194  0.036  -0.132  -0.257  -0.193  -0.459 * 0.345 * -0.193  0.773 †† 0.444 * 0.378 * 0.517 †
Pulmonary  Dysfunction 0.415 * 0.035  -0.189  -0.237  -0.225  -0.579 † 0.519 † -0.225  0.925 ††† 0.161  0.378 * -0.711 ††
MV E max vel -0.479 * -0.091  0.288  0.218  0.226  0.372 * -0.484 * 0.226  -0.827 †† 0.313 * -0.613 † -0.039  
MV A max vel -0.491 * 0.057  0.420 * -0.049  0.644 † 0.471 * -0.461 * 0.644 † -0.643 † -0.067  0.059  -0.579 †
MV E/A -0.136  -0.297  -0.229  0.325 * -0.279  0.148  -0.225  -0.279  -0.055  0.528 † -0.370 * 0.597 †
MV Dec time 0.081  0.173  0.085  0.003  0.329 * 0.322 * -0.357 * 0.329 * 0.191  -0.225  0.332 * -0.100  
LV IVRT 0.763 †† 0.263  -0.171  -0.245  -0.523 † -0.472 * 0.399 * -0.523 † 0.788 †† -0.518 † 0.140  -0.604 †
Body Weight 0.635 † 0.447 * 0.094  -0.261  -0.533 † -0.712 †† 0.512 † -0.533 † 0.802 †† -0.455 * 0.465 * -0.254  
Heart Weight 0.507 † -0.140  -0.420 * -0.022  -0.444 * -0.513 † 0.501 † -0.444 * 0.919 ††† -0.104  0.093  0.427 *
BW/HW -0.033  -0.664 † -0.668 † 0.304 * 0.020  0.166  0.049  0.020  0.212  0.385 * 0.672 † -0.675 †
Electrical Axis 0.610 † 0.165  -0.605 † 0.150  -0.387 * -0.127  0.199  -0.387 * 0.543 † -0.285  -0.105  -0.465 *
Heart Rate -0.375 * -0.998 ††† -0.540 † 0.436 * 0.554 † 0.379 * 0.109  0.554 † -0.004  0.002  0.343 * -0.216  
VAT 0.486 * 0.005  -0.387 * -0.034  -0.415 * -0.776 †† 0.805 †† -0.415 * 0.715 †† -0.287  0.593 † -0.604 †
ST interval 1.000 ††† 0.362 * -0.129  0.104  -0.531 † -0.539 † 0.259  -0.531 † 0.630 † -0.541 † 0.288  -0.586 †
T amplitude 0.589 † -0.024  -0.380 * 0.707 †† 0.208  0.456 * -0.746 †† -0.148  -0.645 † -0.225  -0.266  0.098  
QRS Interval 0.509 † -0.097  -0.443 * -0.122  -0.297  -0.594 † 0.730 †† -0.297  0.823 †† -0.282  0.564 † -0.465 *
QT Interval 0.939 ††† 0.228  -0.271  0.028  -0.510 † -0.634 † 0.482 * -0.510 † 0.792 †† -0.511 † -0.626 † -0.445 *
PR Interval -0.531 † -0.561 † 0.015  0.208  1.000 ††† 0.456 * -0.148  1.000 ††† -0.230  0.028  0.593 † -0.454 *
T duration N.T. 0.362 * -0.129  0.104  -0.531 † -0.539 † 0.259  -0.531 † 0.630 † -0.541 † 0.126  -0.062  
T-T Interval 0.362 * N.T. 0.516 † -0.440 * -0.561 † -0.395 * -0.075  -0.561 † 0.028  0.013  0.139  0.297  
R + S Amplitude -0.129  0.516 † N.T. -0.698 † 0.015  -0.061  -0.254  0.015  -0.231  0.114  0.251  0.807 ††
S Amplitude 0.104  -0.440 * -0.698 † N.T. 0.208  0.207  -0.141  0.208  -0.173  -0.133  -0.626 † -0.428 *
R Amplitude -0.531 † -0.561 † 0.015  0.208  N.T. 0.456 * -0.148  1.000 ††† -0.230  0.028  -0.361 * 0.428 *
Q Amplitude -0.539 † -0.395 * -0.061  0.207  0.456 * N.T. -0.746 †† 0.456 * -0.639 † 0.185  0.400 * 0.613 †
P Amplitude 0.259  -0.075  -0.254  -0.141  -0.148  -0.746 †† N.T. -0.148  0.659 † -0.369 * -0.626 † -0.671 †
P Duration -0.531 † -0.561 † 0.015  0.208  1.000 ††† 0.456 * -0.148  N.T. -0.230  0.028  -0.172  -0.119  
CSA Cardiac Myocytes 0.630 † 0.028  -0.231  -0.173  -0.230  -0.639 † 0.659 † -0.230  N.T. -0.225  -0.266  0.098  
fibrosis -0.541 † 0.013  0.114  -0.133  0.028  0.185  -0.369 * 0.028  -0.225  N.T. -0.266  -0.119  
LVM (gm) 0.126  0.139  0.251  -0.626 † -0.361 * 0.400 * -0.626 † -0.172  -0.266  -0.266  N.T. -0.106  
E` -0.062  0.297  0.807 †† -0.428 * 0.428 * 0.613 † -0.671 † -0.119  0.098  -0.119  -0.106  N.T.
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CHAPTER 5 
AGE-ASSOCIATED ALTERATIONS OF MORPHOLOGY AND PROTEIN SIGNALING IN 
THE FEMALE F344XBN RAT AORTA 
 
 
Although the age-associated alterations in cardiac structure and function were found 
concurrently with increased oxidative-nitrosative stress, the direct relationship between the two 
remains unclear.  Similar to the heart, aging has been shown to alter aortic structure and function 
in men in addition to the aging male F344xBN rat [346].  This chapter details the findings in 
regards to alterations in aortic structure and signaling in the aging female F344xBN aorta as 
outlined in Specific Aim III.  
 
 
ABSTRACT 
The F344xBN male rat has been shown to undergo many of the same age-associated 
vascular changes seen in humans [346].  However, limited research has been done to determine 
if the female F344xBN rat is a good aging female rodent model to study age-associated changes 
in the vasculature.  Aortae from 6-, 26-, and 30-month female F344xBN rats were stained with 
hematoxylin and eosin, and a trichrome stain to determine intima-medial thickness and fibrosis, 
respectively.  Age-associated changes in expression and phosphorylation of proteins were 
measured by immunoblotting.  Aging in the female F344xBN rat was associated with an increase 
in aortic intima-medial thickness, activation of p44/42 MAPK and Hsp27 expression, in addition 
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to decreased activation of NF-κβ p50.   Hsp90 expression decreased with age in the female 
F344xBN aorta.  There were no age-associated changes in activation of eNOS or Akt or expression 
of the apoptotic regulators Bax and Bcl-2.  Taken together, these data are consistent with the 
possibility that the female F344xBN rat may be an appropriate animal model to study age-
associated changes in the cardiovascular system.   
 
INTRODUCTION 
Cardiovascular disease remains the leading cause of death despite new discoveries in 
medical technology and increased awareness/education [337-339].  Aging in the human 
vasculature is associated with increased dilation of the lumen, thickening of the media and intima, 
increased stiffness, and endothelial dysfunction [339].  Sex may also play a role in age-associated 
alterations in vascular structure.  Lower incidences of CVD-associated morbidity and mortality in 
premenopausal women compared to age-matched men have been reported [384].  Currently, the 
NIA recommends the F344xBN rat as an aging model for various age associated pathologies 
including CVD.  This model has been shown to be excellent to study age-associated changes in 
the vasculature of male rats; however, no investigations have been performed to determine if 
age-associated changes are present in the female F344xBN rat [10, 11, 385] .             
  In addition to structural and functional changes, there is also evidence that aging may 
also affect the regulation of several signaling pathways including the MAPK, NF-κβ, eNOS, Hsp, 
and apoptotic signaling in the male rat aorta [332, 343-346].    The MAPKs are serine/threonine 
protein kinases that play a role in the regulation of cellular proliferation, differentiation, 
development, cell cycle, and cell death [191].  The major MAPK signaling pathways include the 
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extracellular signal-regulated protein kinase cascade (p44/42 cascade), c-Jun amino-terminal 
kinase/stress-activated protein kinase cascade (JNK/SAPK), and the p38-MAPK cascade.  Signaling 
through the MAPK pathways is activated by growth factors, cytokines, physical, and chemical 
stress which causes the activation of the upstream activator of MAPK kinase kinase [166] and the 
MAPK kinase (MKK) [166, 191].  The MKK then phosphorylates the downstream MAPK on serine 
and threonine residues leading to MAPK activation [191].  In the aorta, the MAPKs have been 
shown to participate in several different processes including VSMC proliferation, contraction, 
migration, differentiation, and cell survival following activation by oxidative-nitrosative stress 
[326-330].  Whether aging may affect the regulation of these pathways in the aging female rat 
aorta is currently unclear. 
The production of NO is stimulated by growth factors, mechanical forces, estrogen, 
hydrogen peroxide, and angiotensin II [282-285].  Endothelial nitric oxide synthase, like most 
enzymes, is regulated by phosphorylation as it is thought that eNOS phosphorylation by Akt and 
AMPK is associated with increased activity.  In addition to phosphorylation, eNOS is also indirectly 
regulated by calmodulin and Hsp90 which function to stabilize eNOS levels [386, 387].  It is 
thought that aging is associated with increased endothelial dysfunction that is characterized by 
decreased NO levels [387-390].  Whether the decreases in NO with aging are due to decreased 
NOS levels, NO production or increased NO scavenging is not entirely understood [293, 304, 305].  
The purpose, therefore, of this study was to examine if age-associated changes in structure and 
protein signaling are present in the aging female F344xBN aorta.  We hypothesized that aging 
female F344xBN, similar to that seen in humans, would be associated with increased intima-
medial thickness and alterations in the regulation of intracellular signaling pathways.      
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MATERIALS AND METHODS  
Animals 
All procedures were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society, the Animal 
Use Review Board of Marshall University, as well as the Public Health Service Animal Welfare 
Policy.  Adult (6-month), aged (26-month), and very aged (30-month) female F344xBN rats were 
obtained from the NIA and housed two per cage in an AAALAC approved vivarium.  Animals were 
housed under the following conditions: 12 h-12 h light-dark cycle and temperature of 22 ± 2˚C; 
food and water were provided ad libitum.  Rats were allowed to recover from shipment for at 
least two weeks before experimentation, during which time the animals were carefully observed 
and weighed weekly.  Rats were removed from the study if they had signs of failure to thrive such 
as precipitous weight loss, disinterest in environment, or unexpected gait alterations. 
 
Materials 
Antibodies against p38 [#9212], p-p38 MAPK (T180/Y182) [#4631], p44/42 MAPK [#9102], 
p-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) [#4377], SAPK/JNK [#9252], p-JNK [#9251], AMPKα 
[#2532], p-AMPKα (Thr172) [#2535], eNOS [#9572], p-eNOS (Ser1177) [#9571], NF-κβ p65 
[#3987], p-NF-κβ p65 (Ser536) (93H1) [#3033], Hsp27 (rodent preferred) [#2442], Bcl-2 (50E3) 
[#2870], Akt [#9272], phospho-Akt(Ser473) [#9271], phospho-Akt(Thr308) [#9275], HSP90 
(C45G5) Rabbit mAB [#4877], GAPDH (14C10) Rabbit mAB [#2118], 3T3 Control Cell Extracts 
[#9203], biotinylated protein ladder [#7727], mouse and rabbit IgG antibodies [#7076, #7074] 
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were purchased from Cell Signaling Technology (Beverly, MA).  Antibodies against NF-κβ p50 [#sc-
8414], p-NF-κβ p50 [#sc-33022], HSP70 (K-20) [#sc-1060], HeLa Whole Cell Lysate [sc-2200], L6 
+IGF Cell Lysate [sc-24127], and Bax (N-20) [#sc-493] were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA).  The following materials were acquired and used for 
immunoblotting procedures:  Precision Plus Protein Dual Color Standards (Bio-Rad, Hercules, CA, 
[#161-0374]); precast 10% and 15% PAGE r Gold Precast Gels (Lonza, Rockland, ME);  Amersham 
Hybond-enhanced chemiluminescence (ECL) membranes (Amersham Biosciences, Piscataway, 
NJ, [RPN2020D]); ECL western blot detection reagent (Amersham Biosciences, Piscataway, NJ); 
Restore western blot stripping buffer (Pierce, (Rockford, IL); and  albumin from bovine serum 
(minimum 98% electrophoresis, Sigma, St. Louis, MO).  All other chemicals were purchased from 
Sigma (St. Louis, MO). 
 
Aorta Collection 
Anesthetization of female F344xBN rats was achieved with an intraperitoneal injection of 
ketamine (40 mg/kg) and xylazine (10 mg/kg), supplemented as necessary for reflexive responses.   
A midline laparotomy was performed in order to remove the aorta from the left ventricle to the 
branching of the renal arteries.  The aortae were stored in a Krebs-Ringer bicarbonate buffer (118 
mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM NaHCO3, 10 mM 
α-D-glucose; pH 7.4) equilibrated with 5% CO2/95% O2 and maintained at 37°C as previously 
described by Rice and colleagues for the removal of blood and connective tissue.  Aortae were 
weighed before they were snap frozen in liquid nitrogen [166]. 
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Histological Analysis 
Frozen aortae (n = 4) were sectioned (8 µm) onto poly-lysine coated slides using an IEC 
Minotome Cryostat.  Aortic sections were stained using hematoxylin and eosin stain to determine 
morphology.  
 
Immunoblot Analysis 
 Aortic tissues were pulverized in liquid nitrogen and washed in ice cold PBS as previously 
published [345].  The samples were centrifuged at 4000 x g at 4°C for 20 minutes.  The pellet was 
resuspended in TPER buffer supplemented with 0.5 M EDTA, 0.1 M EGTA, 1.0 M MgCl2, 0.1 M 
NaVO3, 0.5 M PMSF, phosphatase inhibitor cocktail 3 (P0044, Sigma), and proteinase inhibitor 
cocktail (P8340, Sigma).  Samples were incubated on ice for 30 minutes and vortexed every five 
minutes during the incubation.  The samples were centrifuged at 4000 x g at 4°C for 20 minutes, 
after which the supernatants were then transferred into new tubes and stored at -80°C.  Protein 
concentration was measured using the Pierce 660 nm Protein Assay (Rockford, IL), following 
manufacturer's instructions.  Briefly, concentrations of triplicates of each sample and BSA as a 
standard were measured using a SpectraMax Plus 384 kinetic microplate reader (Molecular 
Devices, Sunnyvale, CA).  Each sample was diluted to 5 µg/µl using SDS-loading buffer and boiled 
for 5 minutes at 95°C.  Proteins were separated on 10% and 15% SDS-PAGE gels and transferred 
to nitrocellulose membrane in order to probe with primary and secondary antibodies as 
described previously [345].  Chemoluminescent images were captured using the FlourChemE 
system, and band intensity was determined using Alphaview software (Cell Biosciences, CA).  
GAPDH band intensity was used to normalize the band intensity of the signaling protein.     
  94 
 
 
Statistical Methods 
Results are given as mean ± SEM.  The statistical software Sigma Stat 11.0 was used to 
perform statistical analyses.  Age comparisons between morphologic indices and protein 
expression were evaluated by One Way ANOVA, or Kruskal-Wallis One Way Analysis of Variance 
on Ranks with the Student-Newman-Keuls, or Dunn's methods as the post hoc test, respectively.  
Regression analysis was performed with dependent variables against the independent variables 
age and intima-medial thickness.    The level of significance accepted a priori was ≤ 0.05.     
 
RESULTS 
Aortic intima-medial thickness increases with age in the female F344xBN 
As reported previously, body weight was increased at 26- (274.0 ± 4.9 g) and 30-months 
(321.3 ± 7.2 g) compared to that observed in the 6-month female F344xBN rats (Chapter 3, Table 
3.2).  Aortic intima-medial thickness was higher at 26- (97.3 + 4.0 µm) and at 30-months (140.2 + 
2.0 µm) compared to that observed in the 6-month old animals (86.2 + 6.3 µm, Figure 5.1).  No 
apparent changes in structure were observed with trichrome staining. 
   
Phosphorylation of p44/42 MAPK is altered with aging but not AMPKα, p38 MAPK, or JNK MAPK 
No age-associated changes in expression or phosphorylation of AMPKα or total MAPK 
protein levels were observed with aging (Table 5.1, Figure 5.2).  Compared to that found in the 6-
month aortae, the phosphorylation (activation) of p44/42 MAPK at Thr202 and Tyr204 was 
increased 125% at 26-months and 187% at 30-months (Table 5.1, Figure 5.3).  The 
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phosphorylation of p38 and JNK MAPK activation did not change with age.   
 
No change in eNOS, Akt, or apoptosis in the aging female F344xBN aorta  
Immunoblotting was used in order to determine age-associated alterations in expression 
and/or activity of eNOS.  Aging was not associated with a significant change in the regulation of 
eNOS and Akt (Figures 5.4A - B; Table 5.1).  No significant difference was found in the expression 
of Bax, Bcl-2, or the Bax/Bcl-2 ratio with aging (Table 5.1, Figure 5.5).    
 
Differential regulation of heat shock proteins in the aging female aorta 
Hsp27 expression increased 32% at 30-months when compared to that observed in 6-
month aortae (Figure 5.6, Table 5.1).  Conversely, Hsp90 protein levels were decreased 59% and 
52% at 26- and 30-months (Figure 5.6, Table 5.1).  The expression of Hsp70 was unaltered with 
aging (Figure 5.6, Table 5.1).   
 
Activation of NF-κβ p50 is decreased with age 
 The protein levels of NF-κβ p50 and NF- κβ p65 did not change with age. The ratio of total 
to phosphorylated NF-κβ p50 was decreased 50% and 55% at 26- and 30-months, respectively, 
compared to that found in the 6-month old animals (Figure 5.7, Table 5.1).  
 
DISCUSSION 
 
 An increase in aortic intima-medial thickness has been shown to be correlated with the 
development of CVD [268].  Consistent with previous work from our laboratory using the  male 
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F344xBN model, we found that aging in the female F344xBN aorta is also characterized by 
increases in intima-media thickness [346].  To investigate the potential mechanism(s) responsible 
for this finding, we next examined the regulation of MAPK signaling.  The MAPK proteins play a 
role in several different signaling pathways and are involved in the control of cell growth, 
proliferation, survival, motility, and differentiation [274].  It is thought that the MAPKs participate 
in the pathogenesis of aortic dysfunction in several diseases [391].  In the male F344xBN aorta, 
the phosphorylation (activation) of p44/42, p38, and JNK MAPKs was reduced, increased, or 
slightly increased with age [332].  Conversely, in the female F334xBN aorta, the activation of 
p44/42 MAPK was significantly increased with age.  Previous studies have found that this age-
associated increase of p44/42 MAPK activation was associated with increases in VSMC 
proliferation and migration [260, 273, 274, 392].  Consistent with these findings, we also noted 
that elevations in p44/p42 MAPK phosphorylation appeared to be highly correlated with 
increases in intima-medial thickness (Figure 5.1, Table 5.2A).  Whether this increase in p44/p42 
MAPK phosphorylation is solely responsible for the aortic remodeling we observed in the current 
study is currently unclear and will require further investigation.   
 Age-associated endothelial dysfunction has been linked to changes in expression and 
activity of eNOS [298].  It is currently unclear how aging may affect eNOS expression and activity.  
In the current study, we found no significant change in total eNOS expression or phosphorylation 
(activation) with increasing age.  Consistent with this finding, we also found that expression and 
phosphorylation of Akt, which functions as an upstream regulator of eNOS, is also unchanged 
with aging.  Like Akt, Hsp90 also plays an important role in the regulation of eNOS and NO 
production. It is thought that association of Hsp90 with eNOS increases NO generation [393].  We 
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found a decrease in Hsp90 expression with increasing age (Figure 5.6).  This decreased expression 
may be associated with a reduction in NO production.  Whether this finding is associated with 
diminished aortic relaxation or alterations in animal blood pressure with aging will require 
additional study.  
Heat shock proteins are induced by cell stress and function to stabilize protein structure 
or to protect the cell from injury [394, 395].  Supporting this notion, with aging we found that 
Hsp27 expression was increased in the female F344xBN aorta (Figure 5.6).  Similar to our findings 
for p44/p42 MAPK, this increase in Hsp27 was also found to be highly correlated to increases in 
intima-medial thickness (Table 5.2B).  Previous data has suggested that decreased levels of Hsp27 
are associated with the pathogenesis of atherosclerosis [396].  Whether this increase in Hsp27 
levels is a compensatory response to aging or diminished estrogen levels to maintain aortic 
function with aging is currently unclear.  
 NF-κβ is an important proinflammatory transcription factor that induces transcription of 
chemokines, cytokines, adhesion molecules, secondary inflammatory enzymes, and anti-
apoptotic factors [223, 224].  Previous work in our laboratory demonstrated that aging was not 
associated with alterations in NF-κβ expression in the male F344xBN [187].  Conversely, in the 
present study we found that the phosphorylation (activation) of NF-κβ p50 was increased with 
age. Why aging might increase NF-κβ p50 activity levels is not yet clear, however, previous studies 
have demonstrated that increases in NF-κβ expression are regulated, at least in part, by ROS levels  
and that it may function in the control of VSMC proliferation [327-329, 397, 398].  Whether NF-
κβ p50 might functions in a similar manner in the aging F344xBN aorta will require further 
investigation.      
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 In conclusion, our data suggest that aging in the female F344xBN aorta is characterized by 
increases in intima-medial thickness, increased p44/42 MAPK activation, decreased Hsp90, 
increased Hsp27 protein levels, and increased activation of NF-κβ p50.  This combination of age-
associated signaling alterations may be a compensatory response by the aorta to mitigate the 
age-related loss in circulating estrogen.  Whether similar findings are also seen in aging women is 
currently unclear. Additional work is needed to more fully understand the underlying mechanisms 
of the age-associated changes in the aging female F344xBN aorta.   
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TABLE 5.1:  AORTIC TISSUE EXPRESSION FOR TOTAL AND PHOSPHORYLATED PROTEINS IN 
AORTA FROM 6-MONTH, 26-MONTH, AND 30-MONTH FEMALE F344XBN RATS.  Data are 
presented as changes of 6-month adult value ± SE.  Values for proteins were obtained from n = 5 
aortae per age group.  An asterisk (*) indicates significant difference from 6-month age group (p 
< 0.05). 
 
    
 6-month 26-month 30-month 
    
Metabolic    
AMPKα 100.0 ±  6.4 + 4.1 ± 11.2  -16.1 ±  3.5 
p-AMPKα 100.0 ± 10.8 +93.3 ± 33.1 +39.0 ± 30.8 
    
Signaling    
JNK 100.0 ± 13.3 +1.0 ± 6.6 +16.3 ± 5.1 
p-JNK 100.0 ±  9.9 -9.8 ± 4.2 +2.8 ± 24.4 
p38 100.0 ± 22.1 -38.2 ± 8.8 -22.7 ± 13.7 
p-p38 100.0 ±   9.7 +34.5 ± 17.0 +54.6 ± 22.0 
p44/42 100.0 ± 14.7 +8.9 ± 4.0 +14.9 ± 16.5 
p-p44/42 100.0 ±  6.4 +124.5 ± 28.4* +187.3 ± 47.6* 
eNOS 100.0 ±  7.3 +76.5 ± 15.9 +110.5 ± 39.9* 
p-eNOS (Ser1177) 100.0 ± 30.2 +125.3 ± 52.7 +23.8 ± 43.0 
Akt 100.0 ± 29.1 +34.4 ± 31.9 -1.5 ± 35.7 
p-Akt (Ser473) 100.0 ± 12.8 +27.5 ± 12.1 -7.5 ± 7.7 
p-Akt (Thr308) 100.0 ± 21.2 +69.2 ± 48.3 +35.6 ± 12.4 
    
Apoptotic Regulators    
Bax 100.0 ± 11.8 -34.7 ± 16.7 -41.9 ± 16.1 
Bcl-2 100.0 ± 29.1 -6.8 ± 13.3 -30.1 ± 14.3 
    
Heat shock proteins    
Hsp27 100.0 ± 6.8 +2.2 ± 3.5* +31.8 ± 6.2* 
Hsp70 100.0 ± 8.1 +55.5 ± 23.6 +19.7 ± 11.4 
Hsp90 100.0 ± 20.3 -59.4 ± 5.2* -52.0 ± 9.3* 
    
Transcription Factors    
NF-κβ p50 100.0 ± 13.1 +65.8 ± 40.9 +49.3 ± 17.7 
pNF-κβ p50 100.0 ±  8.6 -20.3 ± 5.6 -31.0 ± 4.4* 
NF-κβ p65 100.0 ± 10.3 +3.0 ± 19.9 -11.9 ± 28.8 
pNF-κβ p65 100.0 ± 11.9 +5.1 ± 9.4 
 
-2.9 ± 7.8 
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TABLE 5.2A:  REGRESSION ANALYSIS OF THE RELATIONSHIP BETWEEN SIGNALING PROTEINS 
TO AGE AND INTIMA-MEDIAL THICKNESS IN THE AORTAE OF 6-, 26-, AND 30-MONTH OLD 
FEMALE F344XBN RATS.  Values for proteins and thickness were obtained from n = 5 aortae for 
each age group.  The following symbols indicate: (*) low correlation (p < 0.05) and (**) 
moderate correlation (p < 0.05) between parameters.  P values are located within parentheses.  
N.T. (not tested). 
 
    
 Age Intima-medial Thickness  
    
Independent Variable    
Age 
 
N.T. 0.741* 
(0.022) 
 
Intima-medial 
thickness 
 
0.741* 
(0.022) 
N.T.  
Metabolic    
AMPKα 
 
0.326 
(0.391) 
0.690* 
(0.04) 
 
p-AMPKα 
 
0.555 
(0.121) 
0.067 
(0.864) 
 
Signaling    
JNK 
 
0.389 
(0.301) 
0.498 
(0.172) 
 
p-JNK 
 
0.044 
(0.91) 
0.024 
(0.952) 
 
p38 
 
0.547 
(0.128) 
0.082 
(0.834) 
 
p-p38 
 
0.740* 
(0.023) 
0.692* 
(0.039) 
 
p44/42 
 
0.364 
(0.336) 
0.204 
(0.589) 
 
p-p44/42 
 
0.888** 
(0.001) 
0.732* 
(0.025) 
 
eNOS 
 
0.837** 
(0.005) 
0.709* 
(0.032) 
 
p-eNOS (Ser1177) 
 
0.384 
(0.307) 
0.189 
(0.627) 
 
Akt 
 
0.132 
(0.736) 
0.214 
(0.581) 
 
p-Akt(Ser473) 
 
0.123 
(0.753) 
0.354 
(0.35) 
 
p-Akt(Thr308) 0.486 
(0.185) 
0.075 
(0.849) 
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TABLE 5.2B: REGRESSION ANALYSIS OF THE RELATIONSHIP BETWEEN SIGNALING PROTEINS TO 
AGE AND INTIMA-MEDIAL THICKNESS IN THE AORTAE OF 6-, 26-, AND 30-MONTH OLD 
FEMALE F344XBN RATS.  Values for proteins and thickness were obtained from n = 5 aortae for 
each age group.  The following symbols indicate: (*) low correlation (p < 0.05), (†) moderate 
correlation (p < 0.05), (††) high correlation (p < 0.05), and (†††) very high correlation (p < 0.05) 
between parameters.  P values are located within parentheses.  N.T. (not tested). 
 
    
 Age Intima-medial Thickness  
    
Independent Variable    
    
Apoptotic Regulators    
Bax 
 
0.725* 
(0.027) 
0.483 
(0.188) 
 
Bcl-2 0.377 
(0.317) 
0.579 
(0.102) 
 
    
Heat Shock Proteins    
Hsp27 
 
0.615 
(0.078) 
0.903††† 
(<0.001) 
 
Hsp70 
 
0.519 
(0.152) 
0.004 
(0.993) 
 
Hsp90 0.834†† 
(0.005) 
0.388 
(0.302) 
 
    
Transcription Factors    
NF-κβ p50 
 
0.851 
(0.004) 
0.701 
(0.035) 
 
p-NF-κβ p50 
 
0.617 
(0.077) 
0.329 
(0.387) 
 
NF-κβ p65 
 
0.120 
(0.758) 
0.159 
(0.682) 
 
p-NF-κβ p65 
 
0.001 
(0.999) 
0.032 
(0.934) 
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FIGURE 5.1  
 
FIGURE 5.1:  AGING INCREASES INTIMA-MEDIAL THICKNESS IN THE FEMALE F344XBN AORTA.   
Hematoxylin and eosin staining of 6-, 26-, and 30-month female F344xBN aortae.  Bar 
indicates 100 µm.  n = 4 aortae per age group.  
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FIGURE 5.2 
 
 
FIGURE 5.2:  AGING DOES NOT ALTER THE EXPRESSIONS OF MAPKS AND AMPK-ΑLPHA IN THE 
F344XBN AORTA.  
Total levels of aortic AMPK-α as well as p38, p44/42, and JNK MAPKs were determined 
by immunoblotting in 6-, 26-, and 30-month female rats.  Results were normalized to GAPDH 
expression and expressed as fold change of the 6-month value.  n = 5 aortae per group.  
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FIGURE 5.3 
 
 
FIGURE 5.3:  PHOSPHORYLATION STATUS OF P44/42 MAPK IS INCREASED WITH AGE IN THE 
FEMALE RAT AORTA BUT NOT P38 MAPK, JNK MAPK, OR AMPK-ALPHA.  
Age-related changes in phosphorylated AMPKα in addition to p38, p44/42, and JNK 
MAPK expression were analyzed by immunoblotting in 6-, 26-, and 30-month female rat aortae.  
Results were normalized to GAPDH expression and expressed as fold change of the 6-month 
value.  An asterisk (*) indicates significance difference from the 6-month value, (p < 0.05) or 
less, n = 5 aortae per group. 
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FIGURE 5.4 
 
 
 
 
FIGURE 5.4: ENOS AND AKT ACTIVATION ARE NOT ALTERED WITH AGING IN THE FEMALE 
F344XBN AORTA.   
Immunoblotting was used to detect (A) the ratio p-eNOS(Ser1177) / total eNOS 
expression. (B) Akt, p-Akt (Ser473), and p-Akt (Thr308) in 6-, 26-, and 30-month female rat 
aortae.  Results were normalized to GAPDH expression and expressed as fold change of the 6-
month value, n = 5 aortae per group.   
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FIGURE 5.5 
 
FIGURE 5.5:  NO AGE-ASSOCIATED INCREASE IN APOPTOSIS WITH AGE IN THE FEMALE RAT 
AORTA.  
Protein expression of Bax and Bcl-2 were detected by immunoblotting in 6-, 26-, and 30-
month female rat aortae.  Results were normalized to GAPDH expression and expressed as fold 
change of the 6-month value.  n = 5 aortae per group. 
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FIGURE 5.6 
 
FIGURE 5.6:  DIFFERENTIAL REGULATION OF HSPS IN THE AGING FEMALE RAT AORTA.   
Age-related changes in Hsp27, Hsp70, and Hsp90 expression were analyzed by 
immunoblotting in 6-, 26-, and 30-month female rat aortae.  Results were normalized to GAPDH 
expression and expressed as fold change of the 6-month value.  An asterisk (*) indicates 
significant difference from the 6-month value (p < 0.05) or less.  (†) indicates significant 
difference from 26-month value (p < 0.05), n = 5 aortae per group. 
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FIGURE 5.7 
 
 
FIGURE 5.7:  ACTIVATION OF NF-ΚΒ P50 IS DECREASED WITH AGE.   
Transcriptional regulation in the 6-, 26-, and 30-month female F344xBN aorta was 
determined by analyzing the expression of NF-κβ p50, p-NF-κβ p50, NF-κβ p65, and p-NF-κβ 
p65.  Results were normalized to GAPDH expression and expressed as percent of the 6-month 
value.  An asterisk (*) indicates significance difference from the 6-month value (p < 0.05) or less, 
n = 5 aortae per group. 
  
  109 
 
CHAPTER 6 
DISCUSSION AND CONCLUSIONS 
 
 
The number of elderly persons in the United States is projected to increase by more than 
20% by the year 2030.  This growth in the elderly population is expected to significantly test our 
already overloaded health care system due to the fact that aging is a primary risk factor for the 
development of CVD. The effect of sex on cardiovascular risk has not been fully elucidated; 
however, recent data suggests that premenopausal women have a decreased risk of CVD 
compared to men of comparable age [24, 69].  This cardio-protective benefit appears to be lost 
over time as the risk of CVD in postmenopausal women is similar to that seen in aged men [25].  
Whether aging in animal models induces many of the cardiovascular changes seen in humans is 
not well understood.  The primary purpose of this study was to investigate how aging affects 
cardiovascular structure and function in the female F344xBN rat. 
 
CARDIAC AGING IS ASSOCIATED WITH INCREASES IN OXIDATIVE STRESS AND APOPTOSIS IN 
THE FEMALE F344XBN RAT 
 Recent work has suggested that aging in the female Wistar, Fisher 344, and Sprague-
Dawley rats as well as B6 mice is associated with increased ROS levels [5, 6, 188-190].  How aging 
may affect the levels of oxidative-nitrosative stress in the aging female F344xBN rodent model 
has not been elucidated.  Similar to that observed in other aging models, the findings of this study 
suggest there is an increase in oxidative-nitrosative stress and apoptosis in the female F344xBN 
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heart.  Specifically, aging was found to be associated with increased levels of superoxide, 4-HNE, 
and nitrotyrosine.  It is thought that oxidative stress is typically caused by increases in ROS 
production, a decline in antioxidant buffering capacity, or some combination of both.  In this 
study, the mRNA expression of SOD1, SOD2, Cat, and Gpx were not altered with aging.  This 
suggests that the increase in oxidative-nitrosative stress is probably not due to a decrease in 
antioxidant buffering capacity.   
 
FIGURE 6.1 
 
FIGURE 6.1:  POTENTIAL MECHANISM OF AGE-ASSOCIATED OXIDATIVE-NITROSATIVE DAMAGE 
IN THE FEMALE F344XBN HEART.   
Solid arrows indicated findings from study.  Dotted arrows represent potential 
mechanism of oxidative-nitrosative damage. 
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OXIDATIVE-NITROSATIVE STRESS AND APOPTOSIS IN THE AGING MALE AND FEMALE F344XBN 
RAT HEART 
Cardiac aging is typically characterized by increases in oxidative-nitrosative stress in male 
rodent models [184, 187, 399].  Compared to that observed in females, the hearts of aging male 
rats exhibited increases in protein carbonylation, advanced oxidation protein products, 
nitrotyrosine, non-protein thiol, reduced glutathione, and iron levels [5].  Although aging is 
associated with increases in oxidative stress in both male and female hearts, female rat hearts 
exhibited lower mitochondrial hydrogen peroxide production and oxidative damage, as well as a 
greater mitochondria differentiation [6].  It is thought that females have a higher mitochondrial 
differentiation which is a metabolic adaptation to increase energy efficiency, as it is associated 
with their lower mitochondrial free radical production and oxidative damage [6].  Previous studies 
have shown that female Sprague Dawley, Wistar, and F344 rats have lower ROS production in 
addition to oxidative levels compared to males, which may explain the greater mean life-span 
[188-190].   
Similar to humans and other rodent models, aging in the male and female F344xBN rat 
was associated with increased superoxide production as well as oxidative-nitrosative stress as 
indicated by increased levels of lipid peroxidation and protein nitrosylation (Table 6.1).  Although 
antioxidant activity was not determined in this study, we did not observe differences in the 
antioxidant mRNA expression with aging in the female F344xBN heart.  Whether age is associated 
with alterations in antioxidant levels and activity in the male F344xBN heart is unknown.   
While indices of oxidative-nitrosative stress were increased in both male and female 
F344xBN rats, male animals appeared to exhibit greater levels of oxidative-nitrosative cardiac 
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damage [197].  One possible explanation could be sex-associated differences in ROS/RNS 
production as well as antioxidant expression/activity.  Indeed, previous research has suggested 
that ROS production is lower in aged female compared to male Wistar rats [189].  Similarly, other 
data has demonstrated that the aging female Fisher 344 rat exhibits lower ROS production and 
increased SOD2 and Gpx levels when compared to its male counterpart [189, 190, 400].  It is 
thought that hormones may be responsible, at least in part, for sex related differences as estrogen 
has been shown to increase the expression of antioxidant genes/activity [189, 401].  Conversely, 
other work has shown that estrogen levels are not predictive of antioxidant activity suggesting 
that estrogen levels alone may not be the sole determinant of ROS levels with aging [190, 402, 
403]. 
 
APOPTOSIS IN THE AGING MALE AND FEMALE F344XBN HEART 
Aged cardiomyocytes exhibit increased susceptibility to mitochondrial permeability 
transition pore opening which may be a cause of increased ROS production and apoptosis [404, 
405].  In addition to changes in oxidative stress, aging in the female F344xBN heart was also 
associated with an increase in the number of TUNEL positive nuclei and evidence of 
mitochondrial–mediated apoptosis.  Although mitochondrial-mediated apoptosis signaling was 
increased in both aging male and female F344xBN hearts, the magnitude of age-related change 
appeared to be less in the female animals [197] (Figure 3.5-7).  Consistent with this finding, Bax 
was increased with age in the male but unchanged in the female hearts.  In addition to Bax, we 
also observed differences in the regulation of Akt. Akt signaling is thought to be largely anti-
apoptotic given its proclivity to inactivate Bad and procaspase-9 by phosphorylation [406-409].  
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Akt exhibited decreased expression and activation with age in the male F344xBN hearts while the 
p-Akt/Akt ratio was increased in the aging female hearts (data not shown).  Whether these 
changes in signaling can fully explain the apparent differences in age-related cardiac apoptosis 
observed between male and female hearts is currently unclear and will require further 
investigation. 
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TABLE 6.1: AGE-ASSOCIATED ALTERATIONS IN OXIDATIVE-NITROSATIVE STRESS AND 
APOPTOTIC SIGNALING THE MALE AND FEMALE F344XBN HEART.  Age-associated comparisons 
of oxidative-nitrosative stress and protein signaling in female and male F344xBN rats.  Arrows 
indicate significant increase (↑) and decrease (↓) in parameters (p < 0.05) compared to 6-
month age groups within gender.  N.A. – not applicable.  N.C. - no change.  N.D. - not 
determined.  Parentheses indicate size of protein fragment in kilodaltons (kDa).     
  Female Female  Male Male 
  26m 30m  30m 36m 
       
Oxidative-Nitrosative 
Stress 
      
HE  ↑ ↑  ↑             ↑ 
Nitro-Tyrosine  ↑ ↑  ↑ ↑ 
4-HNE  ↑ ↑  ↑ ↑ 
       
Apoptotic Signaling       
TUNEL  ↑ ↑  ↑ ↑ 
Bax  N.C. N.C.  N.C. ↑ 
Bcl-2  ↓ ↑  ↑ ↑ 
Bax/Bcl-2  N.C. ↑  N.D. N.D. 
Casp-9  N.C. N.C.  N.C. ↑ 
Casp-9 (40kDa)  N.C. N.C.  N.C. ↑ 
Casp-9 (38kDa)  ↑ ↑  N.C. N.C. 
Casp-9 (17kDa)  ↑ ↑  N.D. N.D. 
Casp-3  ↓ ↓  ↑ ↓ 
Casp-3 (19kDa)  N.C. ↑  ↓ ↑ 
Casp-3 (17kDa)  N.C. ↑  N.D. N.D. 
Akt  N.C. N.C.  ↓ N.C. 
p-Akt (Ser473)  N.C. N.C.  ↓ N.C. 
p-Akt (Thr308)       N.D. N.D.  ↓       N.D. 
p-Akt(473)/Akt        ↑ ↑  N.D.       N.D. 
       
Heat Shock Proteins       
Hsp27  N.C. N.C.  ↑ ↑ 
Hsp70  N.C. N.C.  ↑ ↑ 
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CARDIAC STRUCTURE AND FUNCTION IS LARGELY PRESERVED IN THE AGING FEMALE F344XBN 
RAT 
 Aging in mammals is typically characterized by increased cardiomyocyte death, impaired 
contractility, and ventricular remodeling [221, 90].  Previous studies from our laboratory and 
others have demonstrated that aging in the male F344xBN is associated with left ventricle 
chamber dilatation, mild left ventricular hypertrophy, decrements in systolic function, and 
increased diastolic dysfunction [94].  Data from the current study suggest that aging in the female 
F344xBN heart is associated with cardiac hypertrophy (increase in posterior wall thickness and 
cardiomyocyte CSA), diastolic dysfunction (increase in LV IVRT), increased valvular dysfunction, 
and alterations in heart rhythm intervals.  These data are consistent with the previous work by 
Boluyt and colleagues using the aging female F344 rodent [2].  In their study, diastolic dysfunction 
in the female F344 was attributed to changes in the amount of collagen, increased collagen 
crosslinking, and a shift from alpha to beta myosin heavy chain [2, 4, 122, 123, 411].  Although 
we did not determine if aging in the F344xBN was associated with changes in myosin heavy chain 
isoform expression, we did find that collagen deposition did not appear to change appreciably.  
Whether this discrepancy between studies is due to differences in animal strain, age investigated, 
or other factors is currently unclear.  
Our data suggest that aging in the female F344xBN is characterized by changes in cardiac 
rhythm including an increased VAT, ST interval, T amplitude, QRS interval, QT interval, T duration, 
Q amplitude, P amplitude, and a shift in the mean electrical axis.  Previous studies have found 
that cardiac conduction is slowed during aging in humans and rats [130, 412-415].   To our 
knowledge, this is the first study to investigate alterations in heart rhythm intervals in the female 
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F344xBN rat model.  Potential explanations for the slowing of cardiac conduction could include 
differences in cardiomyocyte excitability, cardiomyocyte structure, or alterations in 
cardiomyocyte orientation [41, 412, 416-419].  Specific to this study, the prolonged conduction in 
the aging female F344xBN heart might be related to cardiomyocyte hypertrophy as previous work 
has demonstrated that cardiomyocyte enlargement appears to be associated with slowed cardiac 
conduction [412].  The prolonged heart intervals in the aging female F344xBN rat heart may also 
be related to the alterations in the spatial distribution of Cx43 (Figure 4.3).  Additional study, 
perhaps examining Cx43 phosphorylation with aging, may be useful to determine what role, if 
any, Cx43 may play in the delayed cardiac conduction we observed.   
 
TABLE 6.2:  SUMMARY OF FINDINGS OF CARDIAC STRUCTURE AND FUNCTION IN THE AGING 
FEMALE F344XBN HEART.  ↑ and ↓ indicates increase and decrease respectively. 
 
 
 
COMPARISON OF AGING CARDIAC STRUCTURE AND FUNCTION IN THE MALE AND FEMALE 
F344XBN RAT 
Hypertrophy 
 
Recent studies have demonstrated that the aging heart exhibits an accumulation of 
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damaged, high-ROS producing mitochondria that may result in the activation of MAPK signaling 
which is important in the induction of cardiac hypertrophy [420-423].  Previous data has 
suggested that aging in the male F344xBN rat is associated with cardiac hypertrophy (increased 
heart weight to body weight ratio, LVM, and posterior wall thickening), increased ROS levels, and 
the activation of MAPK signaling [187].  In the aging female F344xBN heart, we did not find 
evidence of significant hypertrophy although cardiomyocyte CSA and posterior wall thickness was 
increased.  Whether this lack of hypertrophy in the aging female F344xBN is due to lower levels 
of oxidative-nitrosative stress is currently unclear and will require additional experimentation.  
 
Systolic Function 
 Systolic dysfunction is defined as impaired ventricular contraction which can be caused by 
alterations in cardiac signaling, increased blood pressure, as well as cardiac valve regurgitation.  
Previous data has demonstrated that aging in the male F344xBN is associated with increased end 
systolic volume suggesting decreased ventricular ejection [94].  Conversely, systolic function in 
the aging female F344xBN heart appeared to be largely conserved.  This absence of systolic 
dysfunction seems to fit well to that observed in other aging studies that employed healthy 
women and with our finding that aging in the female animals appeared to occur without the 
development of cardiac hypertrophy [466].   
 
Diastolic Function 
 Diastolic dysfunction, or impaired filling of the ventricles, has been shown to increase in 
aging women [424, 425].  While aging in both male and female F344xBN rats was associated with 
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evidence of diastolic dysfunction, the degree and mechanism of impairment appeared to differ.  
For example, aging in the male F344xBN rats was associated with a significant increase in the E/A 
ratio and evidence of increased cardiac fibrosis [94].  Conversely, in the female rats, we noted 
significant and progressive decreases in Emax and increasing trends in LV IVRT as well as MV decel 
time but no evidence of age-associated fibrosis.  It is thought that diastolic dysfunction can be 
caused by alterations in the re-uptake of calcium, decreased sarco/endoplasmic reticulum Ca2+ 
(SERCA)-2 protein expression, valvular dysfunction, as well as increases in the deposition of 
extracellular matrix (fibrosis) [426-428].  Similarly, increases in oxidative-nitrosative stress have 
also been shown to contribute to diastolic dysfunction by impairing SERCA2 function, increasing 
the phosphorylation of phospholamban, and altering ryanodine receptor channel function [429].  
In addition to increases in ROS levels, we also noted that aging in the female F344xBN heart was 
associated with increased incidence of mitral regurgitation.  Although not observed here, the 
accumulation of extracellular matrix can lead to increased fibrosis causing increased cardiac 
stiffness, decreased compliance, and alterations in myocardial excitation-contraction coupling 
[426, 427].  Whether further studies in addition to immunoblotting to assess calcium signaling 
would yield meaningful data is not yet clear.   
 
GENDER COMPARISON OF ARRHYTHMIAS IN THE F344XBN RAT 
Although previous data has demonstrated that aging in the male F344xBN is associated 
with increases in the number of premature ventricular contractions, we failed to find evidence of 
similar phenomena in the aging female rats.  Why the incidence of cardiac arrhythmia may differ 
between male and female animals is not clear but may be explained, at least in part, by 
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differences in the cardiac gap junction protein Cx43.  Kakarla and colleagues found that Cx43 
levels were decreased in the aging male F344xBN heart (unpublished data).  Paralleling this 
decrease in Cx43, they also observed that aging was associated with increased cardiac fibrosis 
[197].  In the aging female, neither Cx43 levels nor the degree of ventricular fibrosis appeared to 
change with aging.  Whether these two differences, alone, are responsible for the absence of 
arrhythmias we see in the aging female heart will require further investigation.  
Although we did not find evidence of arrhythmias, aging in the female F344xBN heart did 
appear to be associated with prolonged cardiac conduction.  Whether similar alterations in 
cardiac conduction also occur in the male F344xBN heart is, to our knowledge, unknown.  Why 
aging may slow cardiac conduction is not clear; however, we did note that the presence of 
conduction abnormalities appeared to be associated with alterations in the subcellular 
distribution of Cx43.  Other work has shown that the expression of Cx43 is significantly higher in 
female compared to male rats [167].  Whether this increased expression of Cx43 in the female 
F344xBN functions to attenuate the development of cardiac conduction abnormalities with aging 
is unclear.  
In summary, our data suggest that aging in the F344xBN rat, similar to that seen in 
humans, is associated with sex related differences in cardiac structure and function.  The male 
F344xBN exhibited progressive diastolic and systolic left ventricular chamber dilatation; mild 
diastolic and systolic left ventricular hypertrophy; progressive age-associated decrements in 
resting left ventricular systolic function; and mild diastolic dysfunction [94].  Aging in the female 
F344xBN was characterized by increased cardiomyocyte CSA, posterior wall thickening, left 
ventricle chamber dilatation, slight diastolic dysfunction, and alterations in heart rhythm intervals 
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that were associated with alterations in the spatial distribution of Cx43.  Whether additional 
changes or if the magnitude of existing alterations increases further with aging progression in 
female rat is unclear.  
 
TABLE 6.3:  COMPARISON OF CARDIAC STRUCTURE IN MALE AND FEMALE F344XBN RATS.  
Age-associated comparisons of cardiac morphology and structure in female and male F344xBN 
rats.  Arrows indicate significant (p < 0.05) increase (↑) or decrease (↓) in parameters 
compared to 6-month age groups within gender.  N.A. – not applicable. N.C. -- no change.  N.D. 
– not determined.  PVC- premature ventricular contractions.  (d) – diastole.  (s) – systole. 
 Female 
26m 
Female 
30m 
 Male 
30m 
Male 
36m 
      
Tissue Weights      
BW ↑ ↑  ↑ ↑ 
HW ↑ ↑  ↑ ↑ 
HW/BW N.C. N.C.  ↑ ↑ 
LVM 
 
N.C. N.C.  ↑ N.C. 
Cardiac structure      
IVS(d) N.C. N.C.  N.C. N.C. 
IVS(s) ↑ N.C.  ↑ ↑ 
LVID(d) N.C. N.C.  ↑ ↑ 
LVID(s) ↓ N.C.  ↑ ↑ 
LVPW(d) N.C. ↑  ↑ N.C. 
LVPW(s) N.C. ↑  ↑ N.C. 
RVDd 
 
N.C. N.C.  N.C. N.C. 
Histology      
Fibrosis N.C. N.C.  N.C. ↑ 
Loss of cardiomyocytes N.D. N.D.  N.C. ↑ 
Cross striations 
 
N.D. N.D.  N.C. ↑ 
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TABLE 6.4:  COMPARISON OF CARDIAC FUNCTION IN MALE AND FEMALE F344XBN RATS.  Age-
associated comparisons of cardiac function in female and male F344xBN rats.  Arrows indicate 
significant (p < 0.05) increase (↑) or decrease (↓) in parameters compared to 6-month age 
groups within gender.  N.A. – not applicable. N.C. -- no change.  N.D. – not determined.  PVC- 
premature ventricular contractions.  
 Female 
26m 
Female 
30m 
 Male 
30m 
Male 
36m 
      
Systolic Function      
EF ↑ N.C.  N.C. N.C. 
FS N.C. N.C.  N.C. N.C. 
ESV 
 
↓ N.C.  ↑ ↑ 
Diastolic Function      
MV Decel time N.C. N.C.  N.C. N.C. 
Emax ↓ ↓  ↑ ↑ 
Amax N.C. ↓  N.C. N.C. 
E/A 
 
N.C. N.C.  N.C. ↑ 
Heart Rhythms      
Arrhythmias None None  PVC (1/10) PVC (13/18) 
Conduction ↑ ↑  N.D. N.D. 
Cx43 Redistributed Redistributed  ↓ ↓ 
      
Valve Function      
Valve dysfunction ↑ ↑  N.D. N.D. 
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AORTIC AGING IN THE FEMALE F344XBN RAT IS ASSOCIATED WITH INCREASES IN MEDIAL 
THICKNESS 
 Alterations in vascular structure and function increase the risk for CVD [42, 258, 268].  Age-
associated alterations in aorta structure and function include intima-medial thickening, 
deposition of extracellular matrix, infiltration of leukocytes, endothelial dysfunction, impaired 
distensibility, and increased stiffness [13, 263, 264, 266, 268, 430].  In the male F344xBN aorta, 
previous data has suggested that aging is associated with increases in oxidative stress, apoptosis, 
and intima-medial thickness [271].  The data of the current study indicate that aging in the female 
F344xBN rat aorta is associated with an increase in intima-medial thickness and alterations in the 
p44/42 MAPK, NF-κβ p50, and Hsp27 expression.  Whether these alterations are due to increased 
levels of oxidative stress, as has been posited for the aging male F344xBN aorta cannot be 
determined as indices of oxidative-nitrosative stress were not measured in this study [345].  
 The MAPKs regulate many cellular processes including VSCM proliferation, contraction, 
migration, differentiation, and cell survival [14-18].  Although not investigated here, the 
increased phosphorylation (activation) of p44/42 MAPK observed in the present study may be 
due to the de-differentiation of the VSMCs to a more proliferative phenotype as noted by others 
[274].  Similarly, although not measured, age-related decreases in estrogen levels might also have 
contributed to the increased intima-medial thickness as estrogen is thought to inhibit VSMC 
proliferation [319].   
 Consistent with previous studies, we found no change in eNOS expression with age [8, 
300, 431].  Two important signaling molecules, Akt and Hsp90, which are involved in the 
activation of eNOS by estrogen, were also investigated in this study.  Recent work has suggested 
  123 
 
that eNOS activation is dependent, at least in part, on Akt phosphorylation and that reduced 
expression of Akt might be a potential mechanism underlying endothelial dysfunction and the 
decreased NO bioavailability observed in aging endothelial cells [283, 292, 432].  The 
disassociation of Hsp90 and eNOS has also been shown to cause reduced NO bioactivity and 
endothelial dysfunction [393, 433-439].  In the current study, we did not find any changes in Akt 
expression; however, aging did appear to diminish Hsp90 expression.  More work is needed in 
order to determine how these age-associated changes in aortic structure and protein signaling 
are related to each other as well as their potential impact on aortic function.    
 
DIFFERENCES IN AORTIC AND CARDIAC AGING IN THE FEMALE F344XBN RAT 
It is thought that aging is associated with increased intima-medial thickness of the aorta 
[88, 89, 344, 346].  The thickness of the arterial wall, as indexed by the thickness of the intimal 
and medial layers, increases in a linear fashion nearly threefold between the ages of 20 and 90 
years, even in the absence of atherosclerotic plaques [440].  Similar to that seen in humans, we 
found that aging in the female F344xBN aorta is characterized by increases in the intima-medial 
thickness.  The factor(s) responsible for the increased wall thickness are currently unclear but 
may be related to VSMC proliferation.  Indeed, unlike cardiac muscle, VSMC appear to adopt more 
of a proliferative phenotype with increased aging [274, 441-443].  It has been hypothesized that 
the p44/42 MAPK signaling pathway contributes to the proliferative phenotype  and aging has 
been shown to be associated with increased p44/42 MAPK activation in the aorta [260, 273, 274, 
392, 444, 445,  446].  Consistent with these data, we also found that aging significantly increased 
p44/42 MAPK phosphorylation.  
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 The differential regulation of Hsp expression in the aging female F344xBN heart and aorta 
also indicate a tissue-specific response to stress.  Heat shock protein expression is normally 
induced with increased cellular stress [201].  No alterations in Hsp expression were observed in 
the aging female F344xBN heart although we did observe an age-associated increase in oxidative-
nitrosative stress.  Conversely, we found an increased expression of Hsp27 as well as a decreased 
expression of Hsp90 with aging in the aorta.  Decreases in Hsp27 expression appeared to be highly 
correlated to increases in intima-medial thickness, and have also been found in the progression 
of atherosclerosis [396].  Rayner and colleagues also found that Hsp27 is regulated by estrogen 
and is atheroprotective [239, 240, 447].  Although Hsp90 functions to help in the degradation of 
damaged proteins, it also plays an important role in NO production. The association of Hsp90 with 
eNOS increases NO generation.  Conversely, the disassociation of Hsp90 from eNOS leads to the 
increased production of superoxide in aortic endothelial cells [393].  We found that aging was 
characterized by decreased Hsp90 expression in the female F344xBN aorta.  This decreased 
expression may be associated with a reduction in NO production and eNOS stability.  Although 
correlation analysis suggested a high correlation between eNOS and Hsp90 expression and age, 
additional study is needed to determine cause and effect as well as physiological significance.  
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FIGURE 6.2 
 
 
FIGURE 6.2:  AGE-ASSOCIATED ALTERATIONS IN AORTIC STRUCTURE, FUNCTION, AND 
SIGNALING IN THE FEMALE F344XBN.   
With age the following was observed in the female F344xBN aorta: differential regulation 
of Hsps, activation of inflammatory signaling, intima-medial thickening, as well as no alterations 
in eNOS activity or apoptosis.  Solid lines indicate age-altered aortic cellular processes.  Dotted 
lines indicate laboratory results.  ↓ and ↑ indicate decrease and increase respectively. 
 
 
 
 
 
 
  
  126 
 
TABLE 6.5:  COMPARISON OF AGE-ASSOCIATED ALTERATIONS IN THE FEMALE F344XBN HEART 
AND AORTA.  Age-associated comparisons of cardiac and aortic in morphology and signaling of 
female and male F344xBN rats.    Arrows indicate significant increase (↑) or decrease (↓) in 
parameters compared to 6-month values within gender.  N.A. -- not applicable.  N.C. – no 
change.  N.D. – not determined.     
 26m 
Heart 
30m 
Heart 
 26m 
Aorta 
30m 
Aorta 
      
Proliferation/Hypertrophy      
Intima-medial thickness N.A. N.A.  N.C. ↑ 
HW/BW N.C. N.C.  N.A. N.A. 
      
Akt Signaling      
Akt N.C. N.C.  N.C. N.C. 
p-Akt(473) N.C. N.C.  N.C. N.C. 
p-Akt(308) N.C. N.D.  N.C. N.C. 
p-Akt(473)/Akt ↑ ↑  N.C. N.C. 
      
Apoptosis Signaling      
Bax N.C. ↑  N.C. N.C. 
Bcl-2 ↓ N.C.  N.C. N.C. 
Bax/Bcl-2 N.C. ↑  N.C. N.C. 
      
Heat Shock Proteins      
Hsp27 N.C. N.C.  ↑ ↑ 
Hsp70 N.C. N.C.  N.C. N.C. 
Hsp90 N.C. N.C.  ↓ ↓ 
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CONCLUSION 
In conclusion, this study observed three aspects of cardiovascular aging in the female 
F344xBN rat: 1) age-associated increases in oxidative-nitrosative stress and evidence of 
mitochondrial-mediated apoptosis in the female F344xBN heart; 2) alterations in cardiac 
structure as well as Cx43 heterogeneity and spatial distribution that may contribute to age-
associated heart rhythm interval changes; and 3) that aortic aging in the female F344xBN is 
associated with increased activation of p44/42 MAPK and intima-medial thickness. 
Taken together, the data of the present study suggest that cardiovascular structure and 
function is, for the most part, remarkably conserved in the 30-month old female F344xBN rat. 
This finding is consistent with the notion that the female F344xBN rat model may be applicable 
for investigating the effects of increasing age in the absence of underlying pathology on the 
cardiovascular system.  Future research examining the potential effects of alterations in hormonal 
levels on cardiovascular structure and function may be warranted.  
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SUMMARY 
 
1.  Aging in the female F344xBN heart is associated with increases in posterior wall thickness 
and cardiomyocyte fiber CSA. 
2. Aging in the female F344xBN heart is characterized by increases in superoxide production, 
lipid peroxidation, and nitration of tyrosine residues. This age-associated increase of 
oxidative-nitrosative stress did not appear to be related to changes in antioxidant mRNA 
expression. 
3. Aging in the female F344xBN heart is characterized by increases in the number of TUNEL 
positive nuclei and activation of the mitochondrial-mediated pathway of apoptosis. 
4. Aging in the female F344xBN rat heart is associated with cardiac hypertrophy, diastolic 
dysfunction, and evidence of increased valvular dysfunction.    
5. Aging in the female F344xBN rat heart is associated with changes in the localization of 
Cx43 and alterations in heart rhythm intervals.     
6. Aortic intima-medial thickness was increased with age in the female F344xBN rat. 
7. Aging increased the activation of p44/42 MAPK in the female F344xBN aorta. 
8. Aging in the female F344xBN aorta did not appear to alter the expression or 
phosphorylation of eNOS and Akt. 
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FUTURE DIRECTIONS 
 
 The present study determined the age-associated alterations in cardiovascular structure, 
function, and signaling in the female F344xBN rat.  Future studies will investigate in detail the 
mechanisms of these findings with respect to the specific aims below.   
 
SPECIFIC AIMS 1 AND 2: NATURAL AGING VS. OVAARIECTOMIZED AGING IN FEMALE F344XBN 
RATS 
 
 Findings from the present study suggest that aging in the female F344xBN rat is associated 
with cardiac hypertrophy, diastolic dysfunction, and alterations in heart rhythm intervals.  The 
present study also suggests that aging is associated with increases in oxidative-nitrosative stress 
and apoptosis.  Future studies could investigate if the age-associated alterations occur in young, 
aged, and very aged ovariectomized female F344xBN rats to see whether the absence of estrogen 
has a role in the development of age-associated CVD in the female F344xBN rat.  It is anticipated 
that the results of such studies will provide insight as to how aging and the presence of hormones 
may play a role in cardiac dysfunction, oxidative stress, and apoptosis.     
 
SPECIFIC AIM 3:  AORTA AND OXIDATIVE STRESS 
 
 This investigation has shown that there is an increase in intima-medial thickness and 
p44/42 MAPK activation in the aging female F344xBN aorta.  Future studies will determine if 
these age-associated aortic alterations in young, aged, and very aged female F344xBN are due to 
increased oxidative stress. These results will provide valuable information regarding how aging 
and oxidative stress play a role in the regulation of VSMC proliferation and protein signaling.  
  130 
 
LIMITATIONS 
 
1.  Although the F344xBN rats are genetically identical to one another, they still have alleles from 
each of the parental strain.  Due to the presence of different strain alleles as well as regulation 
of the X chromosome allele expression, it is difficult to control which allele is expressed in 
each individual using this model.   
2.  Echocardiogram and electrocardiogram parameters were measured under anesthetization 
with ketamine/xylazine for restraint in aging female rodents.   
3.  Age-associated alterations in some indices of cardiovascular structure and function can only 
be measured upon the death of the animal which prevents pre- and post-aging measurements 
from the same animal.  
4.  Rat ventricles are assumed to have the shape of a normal ventricle or with a non-uniform wall 
contraction.  Volumes determined by ECHO are estimates from changes in dimensions. 
5.  Only the EKG leads I, II, and III were used due to the small size of the rat. 
 6.  The cumulative effects of aging on the rat when comparing young to old age groups. 
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